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Abstract 
The cardinal feature of bipolar disorder type I (BDI) is mania. Episodes of mania may lead to 
marked impairments in social and occupational functioning and impose a significant financial 
burden on both patient and health-care system. In order to alleviate this burden a more detailed 
understanding of the aetiology and pathogenesis of mania is important to direct development 
of improved treatments.  
Chapter 1 is an introduction to the psychopathology, course, antecedents, precipitants, 
treatment response and pathogenesis of mania in bipolar disorder type I. Understanding of the 
underlying pathophysiology of mania is limited. The thesis identifies a series of studies based 
on review methodologies that bring together four perspectives on the causes and processes 
involved in episodes of mania. These perspectives comprise:  
Comparison of mania with a reference condition, namely partial seizures arising from 
the temporal lobe (PS) as a strategy for identifying localising pathways in the brain based on 
precipitating factors in common between the two conditions;  
Comparison of cognitive deficits between illness episodes in BD and temporal lobe 
epilepsy (TLE), to cast light on the underlying neuropsychological substrates that may indicate 
vulnerability and brain pathology;  
Treatment response of mental disorders to an evidence-based therapy used in epilepsy, 
the ketogenic diet; and 
Examination of a subset of substance-induced mania, that was reported in association 
with the use of herbal medicines. 
The second part of chapter 1 is an introduction to temporal lobe epilepsy (note: the 
nomenclature temporal lobe epilepsy (TLE) is synonymous with partial seizures (PS) or focal 
seizures (FS) arising from the temporal lobe, the term used in this thesis depends on the most 
common usage in the literature being reviewed). The third part introduces the studies, presented 
as four papers published in refereed journals, which follow in chapters 2 to 5. 
Chapter 2 presents a published paper that considers precipitating factors of recurrent 
episodes of mania. It identifies common precipitating factors for mania and partial seizures in 
TLE (PS) as stress, sleep deprivation, antidepressant medication and, tentatively, emotion; for 
mania alone, goal-attainment events, spring and summer season, postpartum, and drugs 
including steroids and stimulants; for PS alone, winter season, menstruation and specific 
Thesis page 1
triggers in complex reflex epilepsies. The overlap of precipitating factors in mania and PS 
implies that common brain processes may contribute to both, consistent with findings from 
neuroscience research regarding mechanisms, which are discussed in detail. 
Chapter 3 presents a published paper comprising a systematic review and comparison 
of cognitive function in euthymic BD-I and pre-surgical TLE. It is important to consider inter-
episode BD in order to better understand the neurobiological substrates involved in the 
propensity to mania. This review concludes that both disorders exhibit deficits in executive 
function and verbal memory suggestive of both frontal and temporal lobe involvement.  
Chapter 4 presents a published paper regarding the status of the ketogenic diet as a 
treatment in mental disorders. There is a well-established overlap in medications for BD and 
epilepsy, particularly with mood stabilizers such as sodium valproate. An evidence-based 
treatment for epilepsy, the ketogenic diet (KD) has received limited attention in mental 
disorders. In BD, the mechanism by which KD may be effective is based on the hypothesis that 
acidosis achieved through ketosis reduces intra-cellular sodium, calcium, both of which are 
elevated in the disorder. Mood stabilizers reduce intra-cellular sodium in an activity-dependant 
manner within the context of KD, through acidification of the blood. The literature regarding 
KD in mental disorders was reviewed and included studies on anxiety, depression, bipolar 
disorder, schizophrenia, autism spectrum disorder and attention deficit hyperactivity disorder. 
This identified the need for carefully controlled research to resolve whether KD has therapeutic 
potential in mental disorders and the potential utility of direct ketone supplementation (as 
opposed to a restrictive diet inducing ketosis) as a treatment modality.  
Chapter 5 presents a published paper examining case reports of substance-induced 
mania specifically associated with use of herbal medicines (HM). All case reports (n=35) were 
associated with use rather than withdrawal of HM. Causal attributions are problematic given 
the paucity of reports, antidepressant co-prescribing in 12 cases, inclusion of 7 cases with a 
past diagnosis of mania, insufficient data regarding pattern and type of HM use, and lack of a 
reference frequency of spontaneous mania. Putative pathophysiological mechanisms for each 
reported HM inducing mania are discussed. These centre on HPA-axis activation and increased 
monoamine activity. 
Chapter 6 Discusses the findings of chapters 2 to 5, concluding that the use of multiple 
perspectives and the reference condition of TLE identifies leads that may enhance 
understanding of basic mechanisms involved in episodes of mania. Directions for future 
research arising from the results are outlined.  
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Chapter 1 
Introduction and Thesis Overview 
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This introductory chapter provides an overview of mania in bipolar disorder (BD) with respect 
to classification, rating scales, management, aetiological factors, pathways, brain activation 
and neural substrates. The aim of this thesis is to study the aetiology and pathogenesis of mania 
in BD which is important to direct developments for improved treatments in individuals with 
BD.  Aetiology may be defined as “the cause, set of causes, or manner of causation of a disease 
or condition (Oxford Dictionaries 2019)”. Aetiology is synonymous with causation and in this 
thesis the terms are used interchangeably. Pathogenesis may be defined as “the manner of 
development of a disease (Oxford Dictionaries 2019)”.  It is noted that aetiology may represent 
the composite effects of many risk factors and precipitants with complex interactions, 
potentially feeding into final common pathways. Furthermore, there are many nuances and 
uncertainties in the diagnostic process. This introductory chapter indicates the main 
aetiological factors that are currently recognised. 
Following this, a novel approach to investigating aetiology is proposed, namely the 
comparison of mania and temporal lobe epilepsy (TLE).  TLE has a localizing pathology and 
is introduced as a potentially informative reference condition for comparison with mania. An 
overview of TLE covers the temporal lobes, comparison of mania to TLE as a reference 
condition, psychiatric comorbidities in epilepsy, BD and epilepsy similarities, treatment 
overlaps and prevalence of BD in epilepsy. The third part of this chapter provides an 
introduction to the published papers which address precipitating factors, neurocognition, the 
ketogenic diet and herbal medicine associated manias.  
1.1.1 An overview of mania  
BD and mania have been recorded throughout history. Soranus of Ephesus (98-177AD) made 
the distinction between mania and melancholia and accorded them separate aetiologies in 
humoral theory (Marneros and Goodwin 2005). Falret, a French psychiatrist, categorized what 
we now know as BD as “folie circulaire” which included manic and melancholic episodes 
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punctuated by symptom-free intervals (Falret 1854). Baillarger used the term “folie à double 
forme” to describe manic-melancholic episodes (Baillarger 1880). Kraepelin (1921) 
differentiated schizophrenia and manic-depressive psychosis (MDP) on the basis of course of 
illness with MDP being characterized as episodic with interepisode recovery compared to a 
chronic deteriorating course in schizophrenia. The  “circular” nature of the illness formed the 
prototype of a larger group of periodic psychoses encompassing periodic mania, melancholia 
and cyclic disorders (Angst and Sellaro 2000). Hence the concept of BD has exhibited both 
commonalities and differing points of emphasis over time. With the advent of syndromal 
diagnosis in the official nomenclature of DSM-III, the conceptualization of BD has become 
reified as a matter of convention based on a mathematical model of weights and value 
judgements as to essential criteria. This does not do justice to concerns as to what represent the 
core features of the illness, for example whether mood or vegetative symptoms are the more 
essential features with respect to the biological underpinnings of the illness. This is further 
emphasised by the inter-rater reliability coefficients for diagnosis of the presence of BD. Field 
trials of the iterations of DSM over the past three decades typically quote Kappa coefficients 
for inter-rater agreement of 0.56 (de Dios 2014).  
The occurrence of at least one episode of mania is required for a diagnosis of BD. 
Commonly reported signs and symptoms of mania include mood elevation or dysphoria, 
irritability, grandiosity, motor activation, accelerated thought processes, pressured speech, 
decreased need for sleep, irritability, distractibility and mood lability (Cassidy, Forest et al. 
1998). In the acute manic phase, poor insight is a defining characteristic (Ghaemi, Stoll et al. 
1995). The diagnostic classification of BD includes: bipolar disorder type I (BDI), which 
requires at least one episode of mania; bipolar disorder type II (BDII), which requires at least 
one episode each of hypomania and depression; substance/medication-induced bipolar and 
related disorder; and secondary mania caused by drugs, infection, neoplasm, epilepsy, and 
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metabolic disturbances. Krauthammer and Klerman view mania as a syndrome with multiple 
causes, and that the notion of secondary mania casts doubt on any unitary or single-agent 
hypothesis of the aetiology of mania supporting the concept of a continuum of 
psychopathologic syndromes (Krauthammer and Klerman 1978). Whether primary or 
secondary in origin, episodes of mania may lead to impairments in social and occupational 
functioning and impose a significant financial burden.  
1.1.2 Diagnosis of mania and bipolar disorder 
The development and categorization of diagnostic criteria allow clinicians to delineate healthy 
and pathological mental processes and behaviours (Kaltenboeck, Winkler et al. 2016). 
Diagnoses may be classified using the Diagnostic and Statistical Manual of Mental Disorders 
5th Edition (DSM-5) or the International Classification of Diseases (ICD-10). 
DSM-5 diagnostic criteria for a manic episode 
To obtain a diagnosis of BD there must have been one or more episodes of mania with or 
without depression at another point in time. According to the DSM-5, episodes of mania consist 
of several specifiers including the following criteria: 
A: A distinct period of abnormally and persistently elevated, expansive, or irritable mood and 
abnormally and persistently increased activity or energy, lasting at least one week and present 
most of the day, nearly every day (or any duration if hospitalization is necessary).  
B: During the period of mood disturbance and increased energy or activity, three (or more) of 
the following symptoms (four if the mood is only irritable) are present to a significant degree 
and represent a noticeable change from usual behaviour:  
1. Inflated self-esteem or grandiosity
2. Decreased need for sleep (e.g., feels rested after only three hours of sleep)
3. More talkative than usual or pressure to keep talking
4. Flight of ideas or subjective experience that thoughts are racing
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5. Distractibility (i.e., attention too easily drawn to unimportant or irrelevant
external stimuli), as reported or observed 
6. Increase in goal-directed activity (either socially, at work or school, or
sexually) or psychomotor agitation (i.e., purposeless non-goal-directed activity) 
7. Excessive involvement in activities that have a high potential for painful
consequences (e.g., engaging in unrestrained buying sprees, sexual 
indiscretions, or foolish business investments)  
C: The mood disturbance is sufficiently severe to cause marked impairment in social or 
occupational functioning or to necessitate hospitalization to prevent harm to self or others, or 
there are psychotic features.  
D: The episode is not attributable to the physiological effects of a substance (e.g., a drug of 
abuse, a medication, other treatment) or to another medical condition (American Psychiatric 
Association 2013). 
DSM-5 diagnostic criteria for a hypomanic episode 
Criteria A through F constitute a hypomanic episode. Hypomanic episodes are common in 
bipolar I disorder but are not required for the diagnosis of bipolar I disorder. 
A. A distinct period of abnormally and persistently elevated, expansive, or irritable mood and
abnormally and persistently increased activity or energy, lasting at least four consecutive 
days and present most of the day, nearly every day.  
B. During the period of mood disturbance and increased energy and activity, three (or more)
of the following symptoms (four if the mood is only irritable) have persisted, represent a 
noticeable change from usual behaviour, and have been present to a significant degree: 
1) Inflated self-esteem or grandiosity.
2) Decreased need for sleep (e.g., feels rested after only three hours of sleep).
3) More talkative than usual or pressure to keep talking.
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4) Flight of ideas or subjective experience that thoughts are racing.  
5) Distractibility (i.e., attention too easily drawn to unimportant or irrelevant 
external stimuli), as reported or observed. 
6) Increase in goal-directed activity (either socially, at work or school, or 
sexually) or psychomotor agitation. 
7) Excessive involvement in activities that have a high potential for painful 
consequences (e.g., engaging in unrestrained buying sprees, sexual 
indiscretions, or foolish business investments). 
C. The episode is associated with an unequivocal change in functioning that is 
uncharacteristic of the individual when not symptomatic. 
D. The disturbance in mood and the change in functioning are observable by others. 
E. The episode is not severe enough to cause marked impairment in social or occupational 
functioning or to necessitate hospitalization. If there are psychotic features, the episode is, by 
definition, manic. 
F. The episode is not attributable to the physiological effects of a substance (e.g., a drug of 
abuse, a medication, or other treatment). 
NOTE: A full hypomanic episode that emerges during antidepressant treatment (e.g., 
medication, electroconvulsive therapy) but persists at a fully syndromal level beyond the 
physiological effect of that treatment is sufficient evidence for a hypomanic episode 
diagnosis. However, caution is indicated so that one or two symptoms (particularly increased 
irritability, edginess, or agitation following antidepressant use) are not taken as sufficient for 
a diagnosis of a hypomanic episode, nor necessarily indicative of a bipolar diathesis. 
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DSM-5 diagnostic criteria for substance/medication-induced bipolar and related disorder 
A. A prominent and persistent disturbance in mood that predominates in the clinical picture 
and is characterized by elevated, expansive, or irritable mood, with or without depressed 
mood, or markedly diminished interest or pleasure in all, or almost all, activities. 
B. There is evidence from the history, physical examination, or laboratory findings of both 
(1) and (2):  
1. The symptoms in Criterion A developed during or soon after substance 
intoxication or withdrawal or after exposure to a medication.  
2. The involved substance/medication is capable of producing the symptoms 
in Criterion A. 
C. The disturbance is not better explained by a bipolar or related disorder that is not 
substance/medication-induced. Such evidence of an independent bipolar or related disorder 
could include the following: 
The symptoms precede the onset of the substance/medication use; the symptoms 
persist for a substantial period of time (e.g., about 1 month) after the cessation of 
acute withdrawal or severe intoxication; or there is other evidence suggesting the 
existence of an independent non-substance/medication-induced bipolar and related 
disorder (e.g., a history of recurrent non-substance/medication-related episodes). 
D. The disturbance does not occur exclusively during the course of a delirium.  
E. The disturbance causes clinically significant distress or impairment in social, occupational, 
or other important areas of functioning. 
The World Health Organization’s International Classification of Diseases (ICD-10) provides 
the following descriptions and definitions: 
The ICD-10 Mood [affective] disorders  
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The category of mood [affective] disorders appears in sections F30-F39 and "contains disorders 
in which the fundamental disturbance is a change in affect or mood to depression (with or 
without associated anxiety) or to elation. The mood change is usually accompanied by a change 
in the overall level of activity; most of the other symptoms are either secondary to, or easily 
understood in the context of, the change in mood and activity. Most of these disorders tend to 
be recurrent and the onset of individual episodes can often be related to stressful events or 
situations.” In addition hypomanic or manic episodes in individuals who have had one or more 
previous affective episodes (depressive, hypomanic, manic, or mixed) should be coded as 
bipolar affective disorder (World Health Organization 1992). 
ICD-10 criteria for a manic episode 
All the subdivisions of this category should be used only for a single episode. Hypomanic or 
manic episodes in individuals who have had one or more previous affective episodes 
(depressive, hypomanic, manic, or mixed) should be coded as bipolar affective disorder. A 
manic episode is characterized by a persistent elevation of mood, increased energy and activity, 
and usually marked feelings of well-being and both physical and mental efficiency. Increased 
sociability, talkativeness, over-familiarity, increased sexual energy, and a decreased need for 
sleep are often present but not to the extent that they lead to severe disruption of work or result 
in social rejection. Irritability, conceit, and boorish behaviour may take the place of the more 
usual euphoric sociability. The disturbances of mood and behaviour are not accompanied by 
hallucinations or delusions.  
1.1.3 Prevalence, incidence and course of bipolar disorder 
Reported prevalence estimates from the 2007 United States National Comorbidity Survey 
Replication study (n = 9,282) were lifetime (and 12-month shown in parentheses) prevalence 
1.0% (0.6%) for bipolar type I disorder (BDI), 1.1% (0.8%) for bipolar type II disorder (BDII) 
and 2.4% (1.4%) for subthreshold BD (which refers to recurrent hypomania without a major 
Thesis page 10
depressive episode or with fewer symptoms than required for threshold hypomania) 
(Merikangas, Akiskal et al. 2007). In a population-based cohort study (n= 800,000), it was 
found that the overall incidence rates (IR) of BD was 0.70/10,000 person-years (95% CI 0.57-
0.83) the IR rate of BDI was 0.43/10,000 person-years (95% CI 0.34-0.55) and the IR of BDII 
was 0.19/10,000 (95% CI 0.13-0.55) (Kroon, Wohlfarth et al. 2013). 
BD is a chronic disorder with episodic manifestations of mania and depression. The 
frequency of episodes varies widely between cases with inter-episode euthymia or normal 
mood. The time points that have been used to determine age of onset include the following: 
age at first treatment, age of first hospitalization, or the first time that the diagnostic criteria are 
met (Saunders and Goodwin 2010). Childhood onset is recognized but is controversial. The 
peak onset of BDI is distributed across three age brackets including 17.4 years (SD = 2.3), 25.1 
years (SD = 6.2), and 40.4 years (SD = 11.3) (Bellivier 2003). A significant proportion of 
patients with BDI do not receive treatment for their first episode of either major depression, 
mania or a mixed state (Chengappa, Kupfer et al. 2003). The polarity at onset of first episode 
has been examined and depressive episodes were the most common followed by mixed or 
manic episodes (Perugi, Micheli et al. 2000).  
The longitudinal weekly symptomatic course of patients with BDI (n=146) was 
examined by Judd et al. (2002). According to self-report results participants were symptomatic 
47.3% of weeks throughout a mean of 12.8 years of follow-up. Depressive symptoms (31.9% 
of total follow-up weeks) predominated over manic/ hypomanic symptoms (8.9%) or 
cycling/mixed symptoms (5.9%)(Judd 2002). Mania is typically of abrupt onset and the mean 
duration is 13 weeks though this may vary widely (Solomon, Leon et al. 2010). In a small 
percentage of patients, illness may be confined to one episode of mania in a lifetime or be 
continuous over years. Frank et al. (1991) illustrated the course of BD in two figures including 
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remission, recovery, relapse, switch and recurrence in mania (Figure 1) and depression (Figure 
2).  
 
 
 
 
Figure 1. Diagram showing manic symptoms, remission and recovery (Frank 1991) 
 
 
Figure 2: Remission, recovery, relapse, switch, and recurrence in depressive episodes (Frank 
1991) 
 
The ability to chart fluctuations in the course of BD is reliant on the valid and accurate 
measurement of signs and symptoms of the presenting illness. The severity of a manic episode 
Thesis page 12
may be quantified by using the Young Mania Rating Scale (YMRS) which is the most 
frequently used rating scale to assess manic symptoms. It is an 11-item clinician-administered 
rating scale with high validity (Young, Biggs et al. 1978). This measure considers various 
aspects of the presentation of mania such as elevated mood, increased motor activity/ energy, 
sexual interest, sleep, irritability, speech (rate and amount), language/thought disorder, content, 
disruptive/aggressive behaviour, appearance and insight, which together provide a clinically 
relevant picture of mania (YMRS=12).  
The Altman Self-Rating Mania Scale (ASRM) is a self-reported diagnostic scale which 
consists of 5 items to assess the presence and severity of hypomanic or manic symptoms. The 
five areas assessed include: positive mood, self-confidence, sleep patterns, speech patterns and 
amount of motor activity. Each item is assessed on a 4-point Likert scale whereby 0 is normal 
and 4 is overtly manic. The measure has been shown to be valid and reliable, to have good test-
retest reliability in patients with mania or depression and is sensitive to change after treatment 
(Altman, Hedeker et al. 1997). It may be useful in wide scale studies. It is noted that self-report 
scales may be subject to the over-reporting or under-reporting of symptoms by patients or 
participants. According to Cassidy, the YMRS and the ASRM provide variable coverage of 
classic mania symptoms including sleep, psychosis and sexuality and poor coverage of 
dysphoric features. No standardized rating scale to measure the manic state has emerged by 
consensus in the field (Cassidy et al. 1998).  
A further aspect of the course of the illness is response to treatment which may involve 
the same pathways as are triggered in the aetiology of the illness. According to the Canadian 
Network for Mood and Anxiety Treatments (CANMAT) and the International Society for 
Bipolar Disorders (ISBD) guidelines for the management of patients with BD, treatments for 
manic and depressive phases differ. For acute mania, lithium, valproate, and several atypical 
antipsychotics continue to be first-line treatments. For the management of bipolar depression, 
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lithium, lamotrigine, and quetiapine monotherapy, olanzapine plus selective serotonin reuptake 
inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first-line options 
(Yatham, Kennedy et al. 2009). Lithium, lamotrigine, valproate, and olanzapine continue to be 
first-line options for maintenance treatment of BD. However, treatments have side effects and 
are not effective in all patients indicating heterogeneity of the condition. 
1.1.4 Aetiological factors in bipolar disorder 
Aetiology is commonly classified in terms of predisposing, precipitating and perpetuating 
factors, all of which are highly relevant to understanding the onset and course of a disorder. 
The precise pathogenesis of BD is unknown, though it is generally agreed that its development 
is influenced by genetic and environmental factors (Craddock and Jones 1999) and diagnosis 
is based on signs and symptoms as noted above in section 1.1.2. The variance in BD attributed 
to heritability is reported to be between 60-93%, more recent analyses tending to be at the 
higher range (Barnett and Smoller 2009). In addition, a range of other reported risk factors 
include inflammation and maternal or fetal infections (Avramopoulos 2015), cannabis use 
(Lagerberg, Sundet et al. 2011), obstetric complications (Kinney, Yurgelun-Todd et al. 1993), 
season of birth (Castrogiovanni, Iapichino et al. 1998) and childhood trauma (Etain, Henry et 
al. 2008). Together these account for less than 10 % of the variance in occurrence of BD 
(Marneros 2007).  
With respect to genetics, family studies have noted that first-degree relatives of BD 
patients have an excess risk of the disorder, while twin studies (combined with adoption studies) 
suggest that genes are largely responsible for this familial aggregation (Smoller 2003). 
McQueen et al. found genome-wide significant linkage to chromosomes 6q and 8q and 
suggestive linkage to chromosomes 9p and 20p (McQueen 2005). In a genome-wide 
association analysis in cases of BD (n=4,387) and controls (n=6,209) a region of strong 
association was identified in ANK3 (ankyrin G) and CACNA1C (alpha 1C subunit of the L-
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type voltage-gated calcium channel) suggesting that ion channelopathies may be involved in 
the pathogenesis of BD (Ferreira 2008). In a recent study by Charney et al. (2017) of BD 
patients (n=6447) relative to control participants (n=12639) eight genome-wide significant loci, 
including a novel locus on chromosome 10 were identified. Two coding genes, adducin 3 
(ADD3) and aminopeptidase P (XPNPEP1) and a non-coding RNA also annotated as an 
antisense ADD3 RNA are contained on the new locus. Evidence for genetic heterogeneity 
between clinical subtypes of BD that is BDI and BDII was also found.   
In linkage studies, Craddock and Jones (1999) identified regions of interest including 
4p16, 12q23-q24, 16p13, 21q22 and Xq24-q26. In a meta-analysis of whole-genome linkage 
scans of BD the strongest evidence of susceptibility loci was on 13q (Badner and Gershon 
2002). In a whole-genome linkage analysis in a multi-generational family (n=111) with mood 
disorder including BD Diniz et al. (2017) found that four regions on chromosomes 2p23.1-
p22.3, 3p25.3-p24.1, 11p15.4, and 12q24.22-q24.32 achieved genome-wide significance and 
four regions on chromosomes 1p22.2-p21.2, 1q21.1-q21.3, 12p13.32, and 22q11.21-q12.1 
achieved genome-wide suggestive of linkage.  
A meta-analysis of identification of pathways for BD was conducted by Nurnberger et 
al. (2014) who found that among 966 genes, 226 reached statistical significance among these 
9 differed in expression in the dorsolateral prefrontal cortex including CACNA1C, DTNA, 
FOXP1, GNG2, ITPR2, LSAMP, NPAS3, NCOA2, and NTRK3. It was identified that 
pathways involved in the genetic predisposition to BD include hormonal regulation, calcium 
channels, second messenger systems, and glutamate signalling. Gene expression studies also 
implicate neuronal development pathways (Nurnberger, Koller et al. 2014). Studies of the 
association of rare syndromes with the occurrence of BD have also been informative. Papolos 
et al. (1996) found a strong association between velo-cardio-facial syndrome and early-onset 
BD suggestive of a gene deleted at the 22q11 chromosomal locus may be involved in the 
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pathogenesis of the disorder. Darier’s disease, a rare autosomal genetic skin condition 
associated with BD has been linked to ATP2A2 mutations (Gordon-Smith et al. 2018). The 
implications of these genetic studies are not sufficiently advanced to form a rigorous 
understanding of the genetics of BD. The proposed pathways involved in mania derive from 
the mechanisms of actions of anti-manic agents and abnormalities seen in patients experiencing 
mania.  
1.1.5 Pathophysiology of mania 
A number of biological pathways have been implicated in the pathogenesis of mania and reflect 
our emerging understanding of the complexities of brain functioning. Current and emerging 
perspectives include the role of genetic mutations and deletions, the modulating effects of 
epigenetics on gene expression, the role of the microbiome and the role of neuroinflammation. 
These are generally hypothesised as underlying basic abnormalities or alterations of biology 
which may become manifest through their effects on brain systems such as neurotransmitters 
or brain repair mechanisms.  
The gene-environment interaction is involved in the pathogenesis of BD. This process 
includes interaction between the genome, environmental factors and epigenetic marks (Ludwig 
and Dwivedi 2016). Epigenetics refers to “modifications of the genome that do not alter DNA 
sequences and are potentially heritable and reversible thus allowing the single genome to adapt 
its transcriptional repertoire to changing environmental conditions and/ or to create different 
cell or tissue types in multicellular organisms” (Alam, Abdolmaleky et al. 2017). Changes in 
DNA methylation in monozygotic twins discordant for mental disorders is of interest as the 
twins share an almost identical genome even if their pre and post-natal environments differ 
(McGowan and Szyf 2010). In discordant identical twins with BD, Kuratomi et al (2007) found 
decreased methylation status of peptidylprolyl isomerase E-like (PPIEL) in the twin with BD. 
In addition, in female patients with BD compared with female controls, a region upstream of 
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the spermin synthase (SMS) gene on the X chromosome was significantly hypermethylated. 
This may affect the heritability of BD and warrants further examination. 
In recent years, several discoveries have increased our understanding of the aetiology 
and pathogenesis of mental disorders, one such factor being the role of the gut. Within the 
human gastrointestinal tract, there is a variety of microbes (bacteria, archaea, fungi, microbial 
eukaryotes and virus/phages), known as the microbiota, which are now thought to play pivotal 
roles in human health. Their genes and metabolic products are known as the microbiome 
(Allaband, McDonald et al. 2018). There is considerable interest in the microbiome (Allaband, 
McDonald et al. 2018), with disruptions in this ecosystem linked to several disorders in humans 
including, Clostridium difficile infection, inflammatory bowel disease, coeliac disease, obesity, 
colorectal cancer, autism spectrum disorder (Kho and Lal 2018) and BD (Evans, Bassis et al. 
2017). Evans et al. compared the stool microbiota of individuals with BD (n=115) relative to 
controls (n=64) and examined illness severity in those with the disorder (Evans, Bassis et al. 
2017). Levels of Faecalibacterium, a key butyrate-producing genus, were decreased relative to 
controls. Faecalibacterium concentrations were positively associated with better self-reported 
health outcomes based on the Short Form Health Survey, the Patient Health Questionnaire, the 
Pittsburgh Sleep Quality Index, the Generalized Anxiety Disorder scale, and the Altman Mania 
Rating Scale. This suggests that Faecalibacterium may protect against episodes of BD although 
the precise mechanism is unknown and replication is needed.  
Another factor that has increased our understanding of mental disorders is the role of 
neuroinflammatory and immunological abnormalities which have been found in patients with 
psychiatric disorders (Najjar and Pearlman 2015).  In a meta-analysis of studies comparing BD 
(n=761) relative to controls (n=919), BD is accompanied by dysregulation of the immune 
response system (Munkholm, Braüner et al. 2013). The relationship between BD and immune 
dysfunction has been attributed to a variety of pathophysiological mechanisms including 
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cytokine-induced monoamine changes, increased oxidative stress, pathological microglial 
overactivation and HPA axis overactivation (Rosenblat, Gregory et al. 2018). A recent review 
examined the effects of anti-inflammatory agents in the treatment of manic, depressive and 
euthymic phases (Rosenblat, Gregory et al. 2018). Promising results have been found in the 
treatment of depression in BD for anti-inflammatory agents as shown by moderate effect sizes 
and good tolerability whilst their effects during manic and euthymic phases remain uncertain 
(Rosenblat, Gregory et al. 2018).  
Dopamine was first reported to be involved in the pathophysiology of mania in the 
1970s and changes in dopaminergic neurotransmission have been reported to be consistent with 
abnormalities in BD (Berk, Dodd et al. 2007). Dopamine has been implicated in the 
pathophysiology of affective syndromes. The dopamine hypothesis suggests that decreased 
dopamine neurotransmission is involved in the pathogenesis of depression, while increased 
dopamine activity contributes to the symptoms of mania (Diehl and Gershon 1992). Abler et 
al. examined the reward activation system in mania and found evidence for abnormal function 
of the dopamine system during delivery or exclusion of expected rewards in BD. The authors 
postulated that these deficits in acute mania may aid in our understanding of symptoms of 
disinhibition and abnormal goal pursuit regulation (Abler, Greenhouse et al. 2008).   
Gould and Manji identify Glycogen Synthase Kinase-3 (GSK-3) as a potential 
molecular target for lithium (Gould and Manji 2005). Lithium inhibits glycogen synthase 
kinase 3β (GSK-3β) directly or indirectly via stimulation of the kinase Akt-1 (Prickaerts, 
Moechars et al. 2006). Evidence suggests that the protein kinase C (PKC) signalling cascade 
may be a similarity for the actions of anti-manic agents, and that excessive PKC activation can 
disrupt prefrontal cortical regulation of thought and behaviour(Szabo, Machado-Vieira et al. 
2009). In a recent review of the role of PKC, several mechanisms such as apoptotic, neoplastic, 
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inflammatory, energy homeostasis, synaptic neurotransmission, and oxidative balance were 
thought to be involved in the pathophysiology of BD (Saxena, Scaini et al. 2017). 
Others have hypothesised that BD is related to an imbalance between cholinergic and 
catecholaminergic neuronal activity, as centrally active cholinergic agonists had anti-manic 
properties (Müller-Oerlinghausen, Berghöfer et al. 2002). Several measures have been 
reviewed in relation to mania including cerebrospinal fluid, post mortem, platelet, 
neuroendocrine challenge, and tryptophan depletion studies and they provided some evidence 
to support the hypothesis that a 5-HT deficit is involved in mania (Shiah and Yatham 2000).  
Kynurenic acid (KYN) controls the neurotransmission of glutamine and dopamine and 
elevated brain KYN appears to be related to psychotic symptoms and cognitive impairment 
(Erhardt et al. 2017). Relative to controls, patients with BD have shown decreased 
neuroprotective kynurenine metabolites in the hippocampus and amygdala (Savitz et al. 2015). 
Whilst these all provide interesting hypotheses, there is as yet no definitive understanding of 
the chemical pathways involved in mania.  
1.1.6 Findings from brain activation and brain imaging  
In a word-generation task, decreased right rostral and orbital prefrontal cortex activation and 
decreased orbitofrontal activity during rest were associated with mania (Blumberg 1999). In a 
functional MRI (fMRI) study comparing manic patients (n=9) to healthy controls (HC) (n=9) 
on a facial recognition task it was found that manic patients had significantly increased 
activation in the left amygdala and reduced bilateral activation in the lateral orbitofrontal cortex 
relative to HC (Altshuler, Bookheimer et al. 2005). On the Go-NoGo task, mania was 
associated with significant reduction of task-related activation of right lateral orbitofrontal 
function, which may aid in explaining some disinhibition seen in mania. In addition, it was 
found that hippocampal and cingulate activation were decreased (Altshuler, Bookheimer et al. 
2005). Sigitova et al (2017) summarized recent fMRI evidence which showed that the affective 
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symptoms of BD may be associated with brain regions involved in emotional regulation. They 
elaborated that these findings were consistent with overactivation of the amygdala, striatum 
and thalamus. 
 MRI studies have been reviewed to identify neuroanatomical risk factors for BD. Hajek 
et al. found that possible candidates for risk factors for BD are volumetric abnormalities of the 
subgenual prefrontal cortex, striatum, white matter, and possibly the hippocampus and 
amygdala (Hajek, Carrey et al. 2005). Brambilla et al. found significantly larger left amygdala 
volumes in BD compared with HC (Brambilla 2003). Sub–cortical volume analysis revealed 
consistent volumetric reductions in BD in the hippocampus and thalamus and enlarged lateral 
ventricles. In addition, cortical grey matter was thinner in frontal, temporal and parietal regions 
of both brain hemispheres. BD had large general effects on mean grey matter thickness in both 
left and right brain hemispheres (Andreassen 2017). Lopez-Larson et al. found that patients 
with BDI have subregion-specific grey matter volume reductions in the prefrontal cortex when 
compared to HC (López-Larson, DelBello et al. 2002). Another review noted that in BD, 
abnormalities in the third ventricle, frontal lobe, cerebellum, and possibly the temporal lobe 
are present (Beyer and Krishnan 2002). It has also been shown that patients with BD have an 
enlargement of the amygdala and possibly the thalamus and globus pallidus (Strakowski, 
DelBello et al. 1999). 
 Phillips and Swartz (2014) conducted a critical appraisal of neuroimaging studies of 
BD and conceptualized the disorder in terms of neural circuitry as one of parallel dysfunction 
in prefrontal cortical hippocampal-amygdala emotion-processing and emotion-regulation 
circuit bilaterally, along with an overactive left-sided ventral striatal-ventrolateral and 
orbitofrontal cortical reward-processing. Strakowski, DelBello and Aldler (2005) reviewed the 
functional neuroanatomy of BD and stated that the disorder involves dysfunction within 
subcortical (striatal-thalamic)-prefrontal networks and the associated limbic modulating 
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regions (amygdala, midline cerebellum). The authors further posited that the resulting 
dysregulation of mood in the disorder may be suggestive of diminished prefrontal modulation 
of subcortical and medial temporal structures within the anterior limbic network (amygdala, 
anterior striatum and thalamus). The aforementioned results are considered to relate to 
behavioural abnormalities that are core features of BD including emotional lability and 
dysregulation, and heightened reward sensitivity. Accompanying these are gray matter 
reductions in the prefrontal and temporal cortices, amygdala and hippocampus (Phillips and 
Swartz 2014).  
Imaging studies of brain chemistry have reported that glutamine/glutamate ratio is 
significantly higher in the anterior cingulate cortex and parieto-occipital cortex in BD (Öngür, 
Jensen et al. 2008). Studies have consistently noted elevations in striatal choline concentration 
and reported decreased N-acetyl aspartate in prefrontal cortical regions of those with BD 
(Cerullo, Adler et al. 2009).   
1.1.7 Comparison of bipolar disorder with reference conditions 
One method to increase understanding of a disorder is to compare it with another disorder 
which shares similar features, for example schizophrenia (SZ). Flor-Henry proposed that 
manic-depressive and schizophrenia-like disturbances originated from the right and left 
temporal lobes respectively (Flor-Henry 1969). With advances in neuroimaging, some degree 
of laterality of BD and SZ has since been observed. Meta-analyses have shown that in BD, 
compared to healthy control (HC), a number of brain regions are affected including the medial 
temporal lobes (Yu, Cheung et al. 2010). In a meta-analysis of magnetic resonance imaging 
(MRI) studies in BD and SZ, BD was associated with smaller lateral ventricular volume and 
enlarged amygdala volume (Arnone, Cavanagh et al. 2009). Other smaller studies have found 
differing results. In an MRI study of temporal lobe structures in males with BD or SZ it was 
shown that hippocampal volumes were significantly smaller in the SZ group than in both BD 
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and HC. In addition, amygdala volumes were significantly larger in the BD group than in both 
SZ and HC participant groups (Altshuler, Bartzokis et al. 2000). In a different study of cerebral 
asymmetry in BD versus SZ, it was found that the left amygdala was smaller and the right 
anterior superior temporal gyrus was larger in BD but not SZ (Pearlson 1997). These show 
differing results affecting the temporal lobes in BD. 
BD has also been compared with major depressive disorder (MDD) on volumetric 
neuroimaging. It has been found that whole brain volumes of patients with mood disorders do 
not differ from those of HC. Regional deficits in the frontal lobe, particularly in the anterior 
cingulate and the orbitofrontal cortex, differentiate participants with MDD or BD from HC 
(Konarski, McIntyre et al. 2008). In a recent review comparing patterns of volume alteration 
in MDD and BD it was demonstrated that both disorders were associated with lower grey-
matter volume relative to HC in a number of areas. Conjunction analysis showed smaller 
volumes in both disorders in clusters in the dorsomedial and ventromedial prefrontal cortex, 
including the anterior cingulate cortex and bilateral insula. Group comparisons indicated that 
findings of smaller grey-matter volumes relative to HC in the right dorsolateral prefrontal 
cortex and left hippocampus, along with cerebellar, temporal and parietal regions were more 
substantial in MDD. These results suggest that MDD and BD are characterised by both 
common and distinct patterns of grey-matter volume changes (Wise 2017). 
1.2 Mania and temporal lobe epilepsy 
An alternative method to increase understanding of mania is to compare BD with another 
disorder which has localizing brain pathology, in this instance focal epilepsy arising from the 
temporal lobes (FS). The temporal lobes are one of the four major lobes in the mammalian 
brain along with the frontal, parietal and occipital lobes. The following overview of TLE builds 
the case for its use as a reference condition which is then taken up in the succeeding chapters 
2-5 based on published research papers investigating the extent of association between the two
Thesis page 22
conditions with respect to precipitants, cognition, treatment and substance use.  These papers 
are introduced in the final section, 1.3, of the present chapter. 
 Humans with amnesia and animal models of amnesia in the primate brain have allowed 
scientists to better understand the anatomical components of the brain for memory, that is the 
medial temporal lobe (Squire and Zola-Morgan 1991). The medial temporal lobe includes a 
system of structures that are crucial for declarative memory (conscious memory for facts and 
events). This consists of the hippocampal region (CA fields, dentate gyrus, and subicular 
complex) and the adjacent perirhinal, entorhinal, and parahippocampal cortices (Squire, Stark 
et al. 2004). One example of declarative memory is recognition which is the ability to judge a 
recently encountered item as having been previously presented (Squire, Wixted et al. 2007). 
Experiential phenomena may occur with spontaneous seizures or evoked by brain stimulation. 
Experiential phenomena most often encompass perceptual, mnemonic and affective features, 
in combination or in isolation, and commonly relate to the patient's individual past experience 
(Gloor 1990).   
1.2.1 Temporal lobe epilepsy and seizures 
Focal seizure (FS) includes both simple partial and complex partial seizures (PS). Where the 
focal seizure arises from the temporal lobe the term is synonymous with temporal lobe epilepsy 
(TLE) in the International League Against Epilepsy (ILAE) classification (Berg, Berkovic et 
al. 2010). In 2017, the ILAE published a position paper of the commission for classification 
and terminology and the following changes were made: (1) “partial” becomes “focal”; (2) 
awareness is used as a classifier of focal seizures; (3) the terms dyscognitive, simple partial, 
complex partial, psychic, and secondarily generalized are eliminated (Scheffer, Berkovic et al. 
2017). 
In this thesis, the change in nomenclature from PS to FS to TLE reflects the ever-
changing landscape that is used to describe epilepsy syndromes, and accordingly the term used, 
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depends on the most current usage in the literature being reviewed. The term epilepsy reflects 
a diagnostic umbrella encompassing a variety of neurological disorders. Fisher et al. and the 
ILAE put forth several definitions: “Epilepsy is characterised by an enduring predisposition to 
generate seizures and the neurological, cognitive, psychological and social consequences that 
ensue.”  The ILAE defined an epileptic seizure as: “A transient occurrence of signs and/or 
symptoms due to abnormal, excessive or synchronous neuronal activity in the brain.” 
The effects of seizures can include alterations in sensory, motor, autonomic function, 
consciousness, emotional state, memory, cognition or behaviour. Common symptoms include 
staring, unusual feelings, twitching, a loss of consciousness and jerking of the peripheral limbs 
(Fisher, Boas et al. 2005).  
Types of seizures include symptomatic seizures (identifiable brain disease), further 
classified as acute (resulting from active brain disease) or remote (which involve static brain 
insults). Generalised seizures (including absence, atonic, tonic-clonic, tonic, myoclonic), 
simple partial/focal seizures (where consciousness is maintained), complex partial seizures 
(where altered consciousness occurs), non-epileptic and status epilepticus (partial, complex 
partial or generalised) (Reddy, 2013). Diagnosis is based on neurological history and 
examination including obtaining eyewitness description of seizures, EEG, MRI and positron 
emissions tomography (PET) (Engel 2001).  
Medial/Mesial Temporal Lobe Epilepsy (MTLE) is the most common form of epilepsy 
in adults (Cohen-Gadol, Bradley et al. 2005). Epileptogenic regions of the brain include the 
hippocampus, amygdala, perihippocampal and entorhinal cortex (Bernasconi, Bernasconi et al. 
2003). Typically, the age of onset is in adolescence or early adulthood although a history of 
complicated febrile seizures, head trauma or infection within the first 4 or 5 years of life is 
usually present (Mathern, Pretorius et al. 1995). TLE typically originates from one medial 
Thesis page 24
temporal lobe (Travers 1991). Due to the localizing pathology of TLE we may better 
understand mania and BD (in Chapter 3 and 4) when comparing the two disorders. 
1.2.2 Similarities between bipolar disorder and epilepsy 
In patients with epilepsy, up to 30% will experience some sort of psychiatric 
comorbidity (Vuilleumier and Jallon 1998). These include mania, depression, anxiety, 
psychoses, cognitive disorders, suicidal ideation and attempts (Hermann, Seidenberg et al. 
2008). These can present during the prodromal, ictal (which refers to the actual seizure), post-
ictal or inter-ictal phases (Gaitatzis, Trimble et al. 2004). Behavioural manifestations of 
seizures and misinterpretations of symptoms can complicate psychiatric assessments in 
patients with epilepsy (Mula, Schmitz et al. 2008).  
Both BD and epilepsy constitute striking manifestations of brain disorders. Speculation 
has included the extent to which these two superficially very different disorders share common 
aetiology, pathogenesis and treatment responses. Similarities between BD and epilepsy include 
their episodic and often chronic clinical course, the observed efficacy of antiepileptic 
medications, and proposed involvement of kindling mechanisms (Mula, Marotta et al. 2010).   
Kindling was originally proposed as contributing to the pathogenesis of epilepsy based 
on research in animals whereby repeated administration of an electrical stimulus results in the 
culmination of a generalized seizure  (Girgis 1981). In BD, Post (1992) posited that external 
stressors and episodes may leave residual traces and vulnerabilities to further occurrences of 
affective illness. At the physiological level, permanent alterations in neuronal activity arise 
when long-term multiple central nervous system challenges occur following repeated episodes 
of affective illness (Berk et al. 2011). Shapero et al. (2017) examined early life adversity, 
proximal life events and the occurrence of affective episodes in BD (n=145). Early childhood 
adversity sensitised participants to the effects of recent stressors for depressive but not for 
hypomanic episodes. Stressful life events were associated with the initial rather than later 
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affective episodes in BD (n= 149) (Subramanian et al. 2017). In BDII (n=102) however the 
number of past episodes was not influenced by the relationship between life events and time 
onset of mood episodes (Weiss et al. 2015). A review of life stress and kindling in BD, found 
that 1 in 3 retrospective studies in humans supported the involvement of kindling 
mechanisms (Bender and Alloy 2011). 
1.2.3 Treatment overlaps between BD and epilepsy 
Antiepileptic drugs (AEDs) are used in both BD and epilepsy. Randomized controlled trials 
(RCT) have shown that carbamazepine, oxcarbazepine, lamotrigine and valproate are effective 
in BD (Muzina, El-Sayegh et al. 2002). The delayed clinical efficacy of AEDs in BD is 
indicative that the pathophysiological mechanisms may be distinct from those that are relevant 
to epilepsy, pain syndromes and neuromuscular disorders (Rogawski and Löscher 2004).  The 
mechanism of action of lithium in preventing recurrences of illness episodes is only partially 
understood (Alda 2016). One proposed mechanism of the efficacy of lithium is related to the 
depletion of inositol by inhibition of the enzymatic breakdown of inositol phosphates to free 
inositol. The resulting reduction of free intracellular inositol is thought to slow the recycling 
of inositol containing metabolites required for signal transduction. In some animal models, low 
doses serotonin and dopamine are protective against limbic seizures and in high concentrations 
exhibit proconvulsive properties (Amann and Grunze 2005). Similar to lithium, the mood-
stabilizing action of VPA and carbamazepine have been linked to inositol depletion (Berridge, 
Downes et al. 1989). It has been recognized that AEDS have a deleterious effect on mood, 
including depression which is reported in a number of patients taking drugs including 
barbiturates, vigabatrin and topiramate (Mula and Sander 2007). AEDS have been associated 
with mania with almost all drugs except valproate, lamotrigine, and levetiracetam (Mula and 
Monaco 2006). 
1.2.4 Prevalence ratio of BD in epilepsy 
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The similarities between the two extend to their episodic manifestations. Mania and TLE share 
psychopathological symptoms including sensory, perceptual, cognitive and affective changes 
(Silberman, Post et al. 1985). Not only do the two disorders share common features, they can 
also co-occur. The prevalence ratio for diagnosed BD in epilepsy is 2.11% (95% CI 1.82-2.45) 
(Ottman, Lipton et al. 2011). Mania is more common in patients with TLE than in the general 
population (Lyketsos, Stoline et al. 1993) and symptoms of BD are often found in patients with 
epilepsy (Lyketsos, Stoline et al. 1993, Ettinger, Reed et al. 2005). In a study on the prevalence 
of BD in epilepsy, it was shown that 11.8% of patients had the DSM-based diagnosis of BD, 
whereas only 1.4% of participants were thought to have ‘‘pure” BD. This was attributed to the 
observation that in all other cases BD symptoms were related to phenotype copies of BD such 
as inter-ictal dysphoric disorder of epilepsy, postictal manic or hypomanic states, and pre-ictal 
dysphoria (Mula, Schmitz et al. 2008).  
1.3 Research publications investigating similarities between mania and TLE 
This section introduces the series of four published review papers presented in chapters 2 to 5. 
The first paper investigates the extent of overlap between mania and TLE with respect to 
precipitating factors, the second paper compares inter-episode neuropsychological deficits in 
bipolar disorder and TLE. The third paper examines the clinical application in mental disorders 
of an evidence-based treatment used in refractory epilepsy treatment, the ketogenic diet. The 
fourth focusses on an aspect of the precipitants of mania, that of reported substance-induced 
mania secondary to the consumption of herbal medicines.  
1.3.1 Comparison of precipitating factors for mania and partial seizures 
Chapter 2 presents a published paper that reviews precipitating factors of recurrent episodes of 
mania and partial seizures. Bostock ECS, Kirkby KC, Garry MI & Taylor BVM (2015). A 
comparison of precipitating factors for mania and partial seizures: indicative of shared 
pathophysiology? Journal of Affective Disorders, 183, 57-67.  
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Comparing and contrasting precipitating factors between two disorders which share 
common features may be a fruitful line of research. Several studies have taken this approach 
in the fields of psychiatry and neurology. In the Iowa 500 study, the precipitating factors of 
schizophrenia and primary affective disorders (Clancy, Crowe et al. 1973) were compared to 
assist in delineating the two syndromes. Precipitating factors have also been reviewed as a 
component of a comparison between migraine and epilepsy (Haut, Bigal et al. 2006). The 
examination of precipitating factors that are temporally linked to illness episodes may inform 
research into underlying neurobiological mechanisms involved in the occurrence of episodes. 
Precipitating factors may enhance our understanding of the causes of mania.  
This paper addresses the following research questions:  
• What are the precipitating factors in bipolar disorder and partial seizures arising from 
the temporal lobes? 
• Are there common precipitating factors in the two disorders? 
• What brain mechanisms have been imputed to account for the action of these common 
precipitating factors? 
1.3.2 Cognitive function in euthymic BD-I and pre-surgical TLE 
Chapter 3 presents a published paper comprising a systematic review of cognitive function in 
euthymic BD-I and pre-surgical TLE: Bostock, ECS, Kirkby KC, Garry MI & Taylor BVM. 
(2017). Systematic review of cognitive function in euthymic bipolar disorder and pre-surgical 
temporal lobe epilepsy. Front. Psychiatry, doi: 10.3389/fpsyt.2017.00133. This paper 
compared the inter-episode deficits in order to better understand trait markers of both disorders. 
Further research involving a head-to-head comparison of the two disorders on a broad range of 
neuropsychological tests is needed to clarify the nature and extent of cognitive deficits and 
potential overlaps. 
This paper addresses the following research questions:  
Thesis page 28
• What neuropsychological deficits have been identified in bipolar disorder and temporal
lobe epilepsy?
• Are there common neuropsychological deficits in the two disorders?
• What brain mechanisms have been imputed to account for the action of these common
neuropsychological deficits?
1.3.3 The ketogenic diet (KD) as a treatment in mental disorders 
Chapter 4 presents a published paper regarding the status of the ketogenic diet (KD) as a 
treatment in mental disorders: Bostock ECS, Kirkby KC and Taylor BVM (2017) The Current 
Status of the Ketogenic Diet in Psychiatry. Front. Psychiatry 8:43. doi: 
10.3389/fpsyt.2017.00043. The aim of this review paper is to clarify the potential role of KD 
in a variety of psychiatric conditions including; anxiety, depression, bipolar disorder, 
schizophrenia, autism spectrum disorder and attention deficit hyperactivity disorder. The 
methodology consisted of a review of electronic databases which included PubMED, 
PsychINFO and Scopus.  
This paper addresses the following research questions:  
• To what extent has the ketogenic diet been used in psychiatric conditions or animal
analogues?
• What is the current evidence of the efficacy of the ketogenic diet in psychiatry?
1.3.4 Mania associated with herbal medicines  
Chapter 5 presents a published paper examining substance-induced mania, in this instance 
associated with use of herbal medicines (HM). Bostock ECS, Kirkby KC, Garry MI, Taylor BV 
and Hawrelak JA (2018) Mania associated with herbal medicines, other than cannabis: a 
systematic review and quality assessment of case reports. This systematic review examines 
published reports linking mania with the consumption of HM. A comprehensive search of the 
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electronic databases EMBASE, CINAHL, Health Source, PsychINFO and PubMed was 
conducted.  
This paper addresses the following research questions:  
• Which herbal medicines have been associated with mania? Does the association 
confirm causality? 
• What mechanisms have been imputed to explain the association? 
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A comparison of precipitating factors for mania and partial 
seizures: indicative of shared pathophysiology? 
 
 
 
This chapter contains the first of four publications in the thesis: 
Bostock ECS, Kirkby KC, Garry MI & Taylor BVM. (2015). A comparison of 
precipitating factors for mania and partial seizures: indicative of shared 
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Objectives: Mania in bipolar disorder (BD) and partial (focal) seizures (PS) arising from the temporal
lobes, have a number of similarities. Typically, a chronic course of the disorders is punctuated by acute
illness episodes. Common features of episodes may include sensory, perceptual, cognitive and affective
changes. Both respond to anticonvulsant treatment. Common mechanisms imputed include neurotrans-
mitters and kindling processes. Further investigation may improve understanding of the occurrence of
both mania and PS, casting light on the relevance of temporal lobe mediated processes and pathology.
One avenue of investigation is to compare aetiological factors and determine the extent of overlap which
may indicate shared brain localization or pathophysiology. Aetiology includes predisposing, precipitating
or perpetuating factors. This paper examines the literature on precipitating factors of mania, ﬁrst or
subsequent episode, and of PS in diagnosed epilepsy, which is the second or subsequent seizure, to
identify the extent and nature of their overlap.
Method: Narrative review based on a literature search of PubMed and Google Scholar.
Results: Precipitating factors for both mania and PS were stress, sleep deprivation, antidepressant
medication and, tentatively, emotion. For mania alone, goal-attainment events, spring and summer
season, postpartum, and drugs include steroids and stimulants. For PS alone, winter season, menstrua-
tion and speciﬁc triggers in complex reﬂex epilepsies. Those not substantiated include lunar phase and
menopause. A wide range of chemicals may provoke isolated seizures but by deﬁnition epilepsy requires
at least two seizures.
Conclusions: The overlap of precipitating factors in mania and PS imply that common brain processes
may contribute to both, consistent with ﬁndings from neuroscience research.
& 2015 Elsevier B.V. All rights reserved.
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1. Introduction
The precise pathogenesis of bipolar disorder (BD) is unknown,
though it is generally agreed that its development is inﬂuenced by
genetic and environmental factors (Craddock and Jones. 1999).
Currently there are no biological markers available for a deﬁnitive
diagnosis of BD, rather diagnosis is based on signs and symptoms.
The cardinal feature of BD type I (BDI) is mania, characterized by “a
distinct period of abnormally and persistently elevated, expansive,
or irritable mood, lasting at least 1 week (or any duration if
hospitalization is necessary)” (American Psychiatric Association,
2013). Episodes of mania may lead to marked impairments in
social and occupational functioning and impose a signiﬁcant
ﬁnancial burden on both patient and health care system. In order
to alleviate this burden a more detailed understanding of the
aetiology and pathogenesis of mania is important to direct devel-
opment of improved treatments.
Aetiology is commonly classiﬁed in terms of predisposing, pre-
cipitating and perpetuating factors, all of which are highly relevant to
understanding the onset and course of a disorder. This review
considers one of these dimensions, precipitating factors, which
consist of recurrences of episodes in established cases of illnesses
distinct from the cause of an initial episode. Two reviews have
focused on the precipitating factors of mania/ hypomania in young
adults (Proudfoot et al., 2012) and adults (Proudfoot et al., 2011). The
examination of precipitating factors that are temporally linked to
illness episodes may inform research into underlying neurobiological
mechanisms involved in the occurrence of episodes.
Further insights may be gained by comparing and contrasting
precipitating factors between two disorders which share common
features. Several studies have taken this approach in the ﬁelds of
psychiatry and neurology. In the Iowa 500 study, the precipitating
factors of schizophrenia and primary affective disorders (Clancy et
al., 1973) were compared to assist in delineating the two syn-
dromes. Precipitating factors have also been reviewed as a com-
ponent of a comparison between migraine and epilepsy (Haut et
al., 2006). Following this approach, a potential reference condition
for comparison with mania is partial seizures arising from the
temporal lobes. The term partial seizures (PS) includes both simple
partial and complex partial seizures and is synonymous with focal
seizures in the International League Against Epilepsy (ILAE)
classiﬁcation (Berg et al., 2010).
Both BD and epilepsy constitute striking manifestations of brain
disorders. Speculation has included the extent to which these two
superﬁcially very different disorders share common aetiology, patho-
genesis and treatment responses. The two disorders have long been
of interest to the medical profession. In particular, the unusual
behavioural disturbances rather than convulsions that may occur in
epilepsy have been of interest since ancient times, reaching a peak in
19th century medical literature (Schmitz and Trimble, 1992).
Renewed interest came with the advent of the electroencephalogram
(EEG) and the discovery of forced normalization, a process which
involves, in patients with epilepsy, the normalization of EEG record-
ings during psychotic states (Krishnamoorthy and Trimble, 1999). The
then presumed beneﬁcial relationship between epilepsy and psy-
chosis resulted in the introduction of convulsive therapy as a
treatment for psychosis (Sachdev, 1998).
Further, it was observed that the nature of the psychotic dis-
turbance bore some relationship to the laterality of the epileptic focus.
Flor-Henry (1969) proposed that manic-depressive and
schizophrenia-like disturbances originated from the right and left
temporal lobes respectively. With advances in neuroimaging, some
degree of laterality of BD and schizophrenia has since been observed.
Meta-analysis has shown that in patients with schizophrenia and
bipolar disorder, compared to neurotypical control participants, gray
matter volume is lower in the prefrontal cortex, thalamus, left caudate
and medial temporal lobe and right insula. Schizophrenia has been
associated with gray matter deﬁcits in the left insula and amygdala
(Yu et al., 2010). In epilepsy, PS typically originate from one medial
temporal lobe, although they may be propagated from other struc-
tures which project to limbic areas (Travers, 1991). PS may be lesional
or non-lesional and can be idiopathic or secondary, referring to the
predisposing aetiology; all of these are included in this review which
focuses on the precipitating factors for PS in established epilepsy.
Other similarities between BD and epilepsy include their episodic
and often chronic clinical course, proposed involvement of kindling
mechanisms and the observed efﬁcacy of antiepileptic medications
(Mula et al., 2010). In both disorders, kindling mechanisms may be
involved in perpetuating illness episodes. In order to understand
human limbic epilepsies, experimental kindling has been performed
in rodents. This involves the observation of progressive changes that
result from repeated electrical stimulation (Goddard et al., 1969). The
premise that seizures beget seizures has long been postulated and in
BD it has been hypothesised that stressors and relapses leave traces
and cause vulnerabilities for future recurrences (Post, 1992). Mazza
et al. (2007) provide a comprehensive explanation of the kindling
paradigm with respect to BD and epilepsy.
The similarities between the two extend to their episodic man-
ifestations. Mania and PS share psychopathological symptoms
including sensory, perceptual, cognitive and affective changes
(Silberman et al., 1985). Not only do the two disorders share common
features, they can also co-occur. The prevalence ratio for diagnosed
BD in epilepsy is 2.11% (95% CI 1.82–2.45) (Ottman et al., 2011). In a
recent study in a sub-Saharan African population it was demon-
strated that epilepsy occurs at a higher rate among ﬁrst-degree
relatives of patients with BD 15.2% than controls 2% and the rate of
BD among those with epilepsy 14.5% compared with controls 2.1%
(Jidda et al., 2014). In a population-based registry study, the propor-
tion of BD among people with epilepsy was twice as high relative to
individuals without epilepsy (Bakken et al., 2014). Mania is more
common in patients with TLE than in the general population
(Lyketsos et al., 1993) and symptoms of BD are often found in
patients with epilepsy (Ettinger et al., 2005).
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Seemingly unprovoked episodes may cause marked distress
and impairments in social, occupational and ﬁnancial wellbeing.
By contrast, an increased understanding of episode precipitating
factors can aid patients to have a sense of control over their illness
and practitioners to formulate individual treatment plans. Given
the similarities between BD and epilepsy, in particular PS arising
from the temporal lobes, it may be expected that the two share
precipitating factors. Precipitating factors refer to the catalyst for
an illness, symptom or episode, distinguishing it from the under-
lying cause of an illness (Mosby, 2012). Precipitating factors may
not be reliable predictors but are associated with an increased risk
of an episode and are not usually deterministic. Several procedures
may be used for provocation of epileptiform discharges, including
hyperventilation, sleep deprivation and photic stimulation (Flink
et al., 2002). In some instances, classiﬁcation of epilepsy syndrome
is based on precipitating factor, for example thinking, music and
reading epilepsies (Engel, 2001).
Given the degree of interest in the relationship between bipolar
disorder and epilepsy and the observed similarities between
mania and PS in illness course, symptomatology and treatment
response this review examines the precipitating factors in the two
conditions. The extent of overlap of precipitating factors in both
conditions is summarised as a pointer to potential shared localisa-
tion in the brain and pathogenesis. Suggestions are made for
future research following these leads.
2. Methods
A review of the literature was conducted in August 2014, based on
searches in PubMED and Google Scholar using the terms “bipolar
disorder”, “manic depression” “epilepsy”, “temporal lobe epilepsy”,
“precipn”, “precipitating factors”, “triggers”, “mania” “seizures” “com-
plex” “partial” and each of the precipitating factors examined
throughout the review. A hand-search of the reference lists of
published articles was also conducted. Publications were included
based on relevance and overall quality judged by the authors, with
no restriction on year of publication. An initial literature search was
conducted as per the search criteria listed above, abstracts of these
studies were reviewed by authors EB and KK and in cases where
their applicability to the subject area was questionable the full text
article was examined and articles not relevant to the subject were
discarded. For example, studies of precipitants in animal models and
epidemiological studies which mentioned precipitating factors in
passing but did not present data on the subject. All authors
commented on the relevance of the remaining citations in their area
of expertise.
For the purpose of reliability, similar to Proudfoot et al. (2011),
only precipitating factors that (1) result in mania or hypomania in
bipolar I or II disorder are included (2) secondary manias, due to
drugs other than antidepressants, metabolic disturbances, infections,
tumours and epilepsy are excluded although some other precipitat-
ing factors which are mentioned may be classed as secondary to drug
use. In addition, this review focuses on (3) PS arising from the
temporal lobes or (4) where data is unavailable, seizures of any type
in established cases of epilepsy. Consistent with the cited literature,
PS arising from the temporal lobes is referred to as temporal lobe
epilepsy (TLE) where this is the original term used.
3. Results
The search strategy identiﬁed 126 articles that discussed
precipitants of mania or temporal lobe epilepsy, that is factors
with a close temporal relationship to a recurrence of illness and 39
relevant to candidate mechanisms of precipitants and these were
included in the review.
3.1. Precipitating factors
This review compares precipitating factors for mania and
partial seizures. Those evaluated are stress, goal-attainment
events, emotion, sleep reduction, lunar phase, seasonal variations,
reproductive life cycle stages, antidepressant medication and other
precipitants.
3.2. Stress
The subjective deﬁnitions of stress and the use of ambiguous
concepts such as stressful life events can result in the confusion of
prodromal or episode symptoms in BD as well as in other
conditions (Johnson and Roberts, 1995). Proudfoot et al. (2011)
reviewed the impact of stressful life events on the onset of manic
episodes and identiﬁed several retrospective studies which sup-
ported their role as a precipitating factor (Kennedy et al., 1983;
Ambelas, 1987; Joffe et al., 1989). Major life events including death
or suicide of a family member, divorce, unemployment and/or
disability were associated with an increased risk of ﬁrst admission
with mania. Data were obtained from 17 years of hospital admis-
sions for a total of 1556 patients. An acknowledged shortcoming of
the study was that life events may have occurred as a consequence
of symptomatic BD rather than a cause of admission for mania
(Kessing et al., 2004).
A prospective study examined the effects of stressors on ﬁrst
episode and recurrent mania over three years (Gilman et al., 2014).
Relapses of mania were more likely in participants who had
experienced recent personal loss, interpersonal or economic difﬁcul-
ties, or past childhood maltreatment and abuse. In a two-year
prospective study of 62 patients with BD 19% of relapses occurred
after a signiﬁcant/stressful life event in the month prior (Hunt et al.,
1992). Following a common stressor, a hurricane in that instance, BD
patients attending a lithium clinic had signiﬁcantly increased depres-
sive and manic relapses, despite adequate lithium levels during and
subsequent to the event (Aronson and Shukla, 1987). The likelihood
of experiencing stress before the onset of mania decreases with the
age of the patient (Hlastala et al., 2000). Using prospective metho-
dology, 125 individuals with BDI were interviewed monthly for
approximately 3 years. Stressful life events preceded depressive but
not manic relapses (Johnson et al., 2008). Others have failed to ﬁnd
support for the role of stressful life events in recurrences of mania,
suggesting their importance applies more to the onset of the disorder
than relapses (McPherson et al., 1993). These results support stressful
life events as a precipitating factor in ﬁrst episode of mania.
Patients with epilepsy commonly report stress as a precipitating
factor for seizures (Frucht et al., 2000; Haut et al., 2003, 2007;
Nakken et al., 2005; Ferlisi and Shorvon, 2014; Wassenaar et al.,
2014) and stress is associated with increased seizure frequency
(Temkin and Davis, 1984; Neugebauer et al., 1994). In a tertiary-
care facility (n¼400), stress was the most widely (30%) identiﬁed
precipitating factor across different types of epilepsy, although
patients with TLE were the most affected (46%) (Frucht et al.,
2000). In children with temporal, frontal, occipital and parietal
epilepsies, 20–30% reported the effects of stress and no signiﬁcant
difference was found between epilepsy syndromes (Fang et al.,
2008). A strong relationship exists between severe stressors experi-
enced by a whole population (for example emergency evacuation
and war) and seizure frequency in both adults and children (Swinkels
et al., 1998; Bosnjak et al., 2002). These effects may possibly be due to
missed medications and social rhythm disruptions. These results
indicate that recurrences of episodes in both disorders are associated
with stress.
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3.3. Goal-attainment events
Individuals who hold higher life ambitions, as assessed by the
hypomanic personality scale, are vulnerable to episodes of mania
(Johnson and Carver, 2006). In a sample of university students
with BDII or cyclothymia, hypomanic symptoms were associated
with preparing for and completing exams (Nusslock et al., 2007). It
is believed that episodes of inﬂated conﬁdence and self-esteem
coupled with high ambitions lead to excessive goal pursuit which
can precipitate mania (Johnson, 2005). Actions that relate to goal
attainment (e.g., acceptance into graduate school, getting married,
getting a new job) have been proposed as a precipitating factor for
mania. A prospective study of 43 participants with BDI found that
goal-attainment events were associated with increased manic
symptoms (Johnson et al., 2000), a ﬁnding which was later
replicated in a larger sample (n¼125) (Johnson et al., 2008).
Individuals with BDI reported mania after achieving an important
success and avoiding rewarding activities to prevent mania (Edge
et al., 2013). This effect may be related to the regulation of the
behavioural activation system, a motivational system which reg-
ulates reward-mediated behaviours and emotional homeostasis
(Depue and Iacono, 1989). Goal-attainment events are a precipi-
tating factor for mania, however to our knowledge there is no
research examining goal-attainment events and seizure control in
those with PS.
3.4. Emotion
The key symptoms of mania, irritability, distractibility and emo-
tional lability appear to be associated with abnormalities in emotion
processing including the intensity and regulation of mood (Phillips
et al., 2003). Prospective research has been used to examine the
association between positive emotion and the subsequent clinical
course of BD. Feelings of joy and amusement increased and feelings of
compassion decreased in mania (Gruber et al., 2009). In young adults
with BD (n¼198) falling in love was rated by participants as a
precipitating factor for mania (Proudfoot et al., 2012). This may be
related to a dysregulation of the behavioural activation system. Not
only might intense emotion predict increased symptoms of mania but
emotional hyper-reactivity is demonstrated during mania, measured
by arousal and attribution of valence in response to images (M’Bailara
et al., 2012). Lability and a more severe course of BD are found in
patients whose relatives show high levels of expressed emotion.
Levels of mania and depression were predicted by subjective distress
to relatives’ criticisms and emotional over-involvement (Miklowitz
et al., 2005).
Jackson (1931), a forefather of epilepsy research, noted that
intense emotions may precipitate seizures in vulnerable individuals.
Excitement, worry, anger, feeling upset and anxiety are commonly
reported as seizure precipitants in young adults with epilepsy (Cull
et al., 1996). Patients with mesial TLE (n¼71) identiﬁed feelings of
nervousness, worry, anxiety and anger as seizure precipitants. This
group also reported utilizing the inhibitory methods of concentrat-
ing, deep-breathing and changing thoughts to avoid seizures
(Lunardi et al., 2011). This supports the use of behavioural interven-
tions to minimise excessive emotion in patients with epilepsy
(Boylan, 2001). Intense emotion is a tentative precipitant of mania
and this is an area that would beneﬁt from future research. It is a
widely reported precipitating factor in PS.
3.5. Sleep reduction
The relationship between BD and sleep is multifaceted. Changes
in sleep patterns serve as a marker for manic or depressive episodes.
It is an aetiological agent, a predictor for future episodes, a ther-
apeutic target and an indicator for treatment response (Plante and
Winkelman, 2008). Patients with BDI retrospectively identify altered
sleep patterns due to social rhythm disruption in recurrences of
manic episodes (Malkoff-Schwartz et al., 2000). The sleep-wake
cycles of 67 patients with BD was examined during a depressive
episode, 7 patients switched to mania or hypomania following 40 h
of sleep deprivation (Wehr et al., 1982). Other prospective studies
have provided support for the role of sleep deprivation and sleep
reduction and the onset of mania (Leibenluft et al., 1996; Colombo
et al., 1999; Bauer et al., 2006). Mania is also associated with travel
across time zones, more commonly in east-bound travellers, whilst
depression is more common in west-bound travellers, an effect
possibly mediated by the physiological “phase shift” changes that
affect body temperature, sleep and melatonin production (Jauhar and
Weller, 1982; Young, 1995).
Patients with TLE commonly report sleep reduction as a
precipitant to seizures (Frucht et al., 2000; Sperling et al., 2008;
Ferlisi and Shorvon, 2014; Wassenaar et al., 2014). Rajna and Veres
(1993) examined seizures diaries, sleep duration and PS in 14
patients with TLE for a period of 4995 days. It was demonstrated
that even decrements of 1.5 h from patients’ mean sleep time
resulted in an increase of seizures. Not only does sleep affect
seizures, seizures also affect rapid eye movement (REM) sleep. In
patients with PS of TLE, a reduction in the duration of REM sleep is
observed particularly when a seizure occurred in the day prior
(Bazil et al., 2000). Sleep reduction and experimental/therapeutic
sleep deprivation is a shared precipitating factor for both mania
and PS arising from the temporal lobes.
3.6. Lunar phase
Historically, the moon was relied upon as a primary source of
night-time light and throughout antiquity, the belief persisted that
changes in behaviour were more prevalent during the full moon
(Raison et al., 1999). This view was reportedly still held among
mental health professionals in the 1990s (Vance, 1995). Lunar phase
was correlated with bed-occupancy rate but not speciﬁc psychiatric
diagnosis in a 12-month hospitals admissions dataset (Tejedor et al.,
2010). In a meta-analysis of 37 studies, phase of the moon accounted
for less than 1% of variance in psychiatric hospital admissions,
psychiatric disturbances, crisis calls, homicides and other criminal
offences (Rotton and Kelly, 1985).
Lunar phase and seizures were unrelated in a prospective three-
year study although a possible effect was observed on non-epileptic
seizures (those that resemble seizures without supportive EEG
results) (Benbadis et al., 2004). During the full moon, there was an
increase in hospital admissions (Polychronopoulos et al., 2006) and a
peak in episodes of status epilepticus was observed 3 days after a
new moon (Rüegg et al., 2008). In healthy individuals, during a full
moon, average sleep time decreases by 20 min per night and
morning fatigue increases compared to other lunar phases (Roosli
et al., 2006). Taken together, these results suggest that the lunar
phase exerts minimal inﬂuence on behaviour and seizure frequency
mainly due to disruptions in sleep.
3.7. Seasonal variations
Seasonal variations have been widely examined as a precipitat-
ing factor for mania. Using hospital admissions data, increases
have been found in summer (Takei et al., 1992; Barbini et al., 1995),
and spring and summer (Mulder et al., 1990; Lee et al., 2002). By
contrast, data obtained from Brazil has shown that a peak in
instances of mania is observed during winter–spring months
which is associated with the dryer, colder, increased daylight
seasons (Volpe and Del Porto, 2006; Volpe et al., 2010). Some
have found no effect of seasonality and hospital admissions for
mania (Daniels et al., 2000).
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Seasonal variations have been cited as a precipitating factor for
seizures (Spatt et al., 1998). A study conducted over 2 years
examined changes in weather and twice-monthly EEG recordings
from 30 participants with epilepsy (Motta et al., 2011). Epilepti-
form discharges were more common in winter during unstable
weather conditions and seizures most frequently occurred during
spring, autumn and winter. Data obtained from seizure diaries has
suggested that seizures are more frequent in winter (Clemens et
al., 2013). This ﬁnding has been conﬁrmed from data obtained
from an inpatient facility where PS were less likely to occur on
bright sunny days (Baxendale, 2009). These results suggest that
instances of mania are related to seasonal effects with the
strongest mediation by an increase in light, a ﬁnding which is in
contrast to that of PS. It is worth noting that the effects of
seasonality on mania have received far more attention in the
empirical literature than in epilepsy with only one study cited
examining the effects on PS.
3.8. Puberty/menarche
The effects on menarche on the onset of BD have been
examined utilizing retrospective methodology. Fifty participants
with BD were surveyed and 32% related the onset of the disorder
to the period prior and 18% within one year of menarche whilst
20% reported the age of onset as 12 or younger and 6% later in life
(Freeman et al., 2002), consistent with the typical age of onset
between 15 and 25 years (Kessler et al., 2005).
The age of onset of mesial TLE is typically in adolescence or
early life (Desgent et al., 2012). Contradictory ﬁndings on the
effects of menarche on seizures have been observed. A long-
itudinal study spanning 7 years followed 39 patients with epilepsy
(24 female, 15 male) during puberty. Eighty-seven percent of
participants had the same number of seizures as in prepuberty.
In female participants, better seizure control was obtained follow-
ing menarche with a reduction of PS (Diamantopoulos and
Crumrine, 1986). Others have noticed a worsening of symptoms
at the time of puberty or menarche (Morrell et al., 1998). These
results suggest that puberty or menarche may be important in the
initial onset of BD but may have less of an effect in PS arising from
the temporal lobe.
3.9. Menstruation
A recent review has examined the effects of the menstrual cycle
on the course of BD, ﬁnding that it is likely affected with
depressive and manic relapses occurring (Teatero et al., 2014).
Interviews of women with BD have shown that two-thirds
reported menstrual cycle symptom ﬂuctuations, although the
direction of the change to depression or mania was unclear due
to retrospective methodology (Blehar et al., 1998; Rasgon et al.,
2003). Another study examined mood of patients with BD 7 days
prior to the onset of menses and 7 days after; mood changes were
found in 11 of 25 participants although no consistent pattern of
change was found (Leibenluft et al., 1999). This has also been
found in a larger sample (n¼41) (Shivakumar et al., 2008). A case
study reported two women who experienced recurrent hyperac-
tivity, a decreased need for sleep and irritability ﬁve days prior to
menses, each of which are key features of mania. Euthymia was
observed for the rest of their menstrual cycles and the women
were successfully treated with lithium (D’Mello et al., 1993).
Whilst these studies suggest that the menstrual cycle does affect
symptoms there is no clear evidence to suggest that it is a
precipitating factor in mania.
Seizure clusters that occur in relation to the menstrual cycle,
known as catamenial epilepsy, is observed in approximately 12% of
patients (Duncan et al., 1993). Patients with TLE are particularly
vulnerable to the effects of menstruation. One study examined
seizure precipitants across different types of epilepsy and found
that 28% of patients with TLE cited menstruation as a precipitating
factor, a proportion that was twice that of other epilepsy syn-
dromes (Frucht et al., 2000). In addition, patients with mesial TLE
also report the effects of menstruation on seizure exacerbations
(Lunardi et al., 2011). An association between laterality of epileptic
focus and catamenial epilepsy has been demonstrated. In a sample
of 100 womenwith epilepsy those with left-sided TLE had seizures
which peaked cyclically with the onset of menses (Quigg et al.,
2009). Menstruation is a known precipitating factor for PS but its
role in mania is still unclear.
3.10. Postpartum
Twenty-six percent (81 of 313 deliveries) of womenwith BDI or
schizoaffective disorder experience postpartum psychosis (mania
inclusive) (Jones and Craddock, 2001), which typically presents in
the ﬁrst two weeks following delivery of a child (Dean et al., 1989).
Postpartum psychosis is associated with a longer duration of
labour and night time delivery suggestive of the role of sleep in
its onset (Sharma, 2004). Some have associated the birth of a child
and mania in men (Davenport and Adland, 1982; Ambelas, 1987)
although others have not supported this ﬁnding (Hunt and
Silverstone, 1995).
The occurrence of seizures and/or coma during pregnancy or
the postpartum period is known as eclampsia (Kaplan, 1999). In a
sample of 26 presurgical patients with partial seizures and
hippocampal sclerosis, eclampsia was identiﬁed as a possible risk
factor for the development of the disorder and 30% related its
onset to an eclamptic pregnancy (Lawn et al., 2004). The post-
partum period is a precipitating factor for mania and is a possible
risk factor for the development of PS arising from the
temporal lobes.
3.11. Perimenopause/menopause
Freeman et al. interviewed 50 womenwith BD and according to
self-report, 9 were perimenopausal and 13 postmenopausal. Three
participants reported that the onset of BDI occurred during or after
perimenopause. Half of the participants reported mood worsening
associated with perimenopause, including irritability (n¼8), more
rapid cycling (n¼6) and hypomania or mania (n¼8) (Freeman
et al., 2002). The self-reported perimenopausal worsening of
symptoms including mania, hypomania and depression has been
replicated (Blackmore et al., 2008). Wehr et al. (1988) interviewed
participants with BD and demonstrated that of those whose illness
had a rapid cycling course (n¼47) almost 50% reported that their
illness became rapid cycling (n¼9) or persisted (n¼14) following
menopause. In another study of 56 postmenopausal women with
BDI, almost 20% of participants reported experiencing emotional
problems associated with menopause, including manic episodes,
anxiety, agitation and depression. One participant interviewed
received a diagnosis of BD at the time of menopause subsequent
to a manic episode (Blehar et al., 1998).
During the perimenopausal period, an increased risk for new
onset seizures or the worsening of seizures occurs. Conversely during
menopause, improvements were seen in patients whose seizures had
previously followed a catamenial pattern (Rościszewska, 1977). This
was also observed in patients with TLE (Harden et al., 1999).
Menopause may also constitute a risk factor for epilepsy with one
study ﬁnding that some women had new onset seizures during this
period (Abbasi et al., 1999). In contrast with Harden et al. these
authors found a lower seizure frequency in perimenopausal women
compared to the pre and post menopausal women, but they did not
differentiate epileptic focus. During the perimenopausal period, an
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elevation of the estrogen to progesterone ratio occurs (Santoro et al.,
1996) and even in healthy women this period is associated with
changes in mood, possibly mediated by disruptions in sleep (Baker
et al., 1997). In summary the effects of perimenopause and meno-
pause on mania and PS are uncertain due to methodological
limitations of research largely based on retrospective self-report
without hormone level veriﬁcation.
3.12. Antidepressant medication
The use of antidepressant medication carries the risk of switch
to mania. Antidepressant-associated mood switching has been
found in BD (Ghaemi et al., 2004; Schneck et al., 2008). The switch
has been found with the use of selective serotonin reuptake
inhibitors (SSRIs) (Burrai et al., 1991), bupropion (Aggarwal and
Sharma, 2011), monoamine oxidase inhibitors (MAOIs) (Stoll et al.,
1994) and tricyclic antidepressants (Wehr and Goodwin, 1979).
Mania has also been associated with the use of the herbal
supplements Yohimbine which acts as a mild MAOI (Price et al.,
1984) and St John’s wort, which is reported to have antidepressant
qualities and has SSRI activity (Moses and Mallinger, 2000). Wehr
et al. (1988) demonstrated that, in those with rapid cycling BD
(n¼51), 37% showed remission or a slowing of symptoms follow-
ing the discontinuation of antidepressant medication. The risk of
antidepressant-induced mania was increased (95% CI¼1.12, 7.19,
p¼0.028) when patients with BD received monotherapy relative
to those treated with an adjunct mood stabilizer. Data was
obtained from 3240 patients (Viktorin et al., 2014). Some have
cautioned against the use of antidepressants in BD reserving their
use for acute cases, given the signiﬁcant risk of mania and possible
worsening of the illness (Ghaemi et al., 2003).
Approximately 30% of patients with epilepsy will experience
some sort of psychiatric comorbidity with depressive disorders
affecting between 20 and 60% of patients (Vuilleumier and Jallon,
1998). Depression appears to be related to epilepsy with a left-
sided temporal lobe focus (Altshuler et al., 1990) and mesial
temporal sclerosis (Quiske et al., 2000). Tricyclic antidepressants,
buproprion (Peck et al., 1983), SSRIs (Prasher, 1993) Yohimbine and
St John’s wort have been associated with seizures in humans
(Tyagi and Delanty, 2003). Due to the lowering of the seizure
threshold and interactions with antiepileptic medication the use of
antidepressant medication requires caution in this patient popula-
tion. In sum, antidepressant medication is a precipitating factor in
both disorders.
3.13. Other
There are a large array of precipitating factors for mania and PS
and this review has included those that are more commonly
reported by patients or described by clinicians. Cognition-
induced epilepsy refers to a broad group of syndromes for which
seizures are precipitated by speciﬁc cognitive tasks (e.g., playing
chess or card games) (Ritaccio et al., 2002). These complex stimuli
may involve emotional, motivational or mnestic components
suggestive of the integration of complex stimuli within limbic
structures (Sturm et al., 2002). To our knowledge, there are no
such precipitants of mania. This may be due to the longer time
interval between precipitant and episode in BD than in triggered
epilepsies. Mania is not reported to be a reﬂex phenomenon to
cognitive tasks.
Steroids, levodopa and dopaminergic agents, sympathomimetic
amines, triazolobenzodiazepines, hallucinogens (Sultzer and
Cummings, 1989), DHEA (Markowitz et al., 1999), chloroquine
(Lovestone, 1991), metoclopramide (Ritchie and Preskorn, 1984),
lupron (Rachman et al., 1999), varenicline (Alhatem and Black,
2009), the antimicrobials clarithromycin, isoniazid, erythromycin
and amoxicillin (Ahmed et al., 2002), steroid nasal spray
(Goldstein and Preskorn, 1989), energy drinks (Machado-Vieira
et al., 2001) and caffeine (Ogawa and Ueki, 2003) have also been
cited as precipitating factors for mania although many are case
reports. There is a high prevalence of co-morbid alcohol misuse
and BD which is associated with increased mood lability, impul-
sivity, violence and polydrug use (Salloum et al., 2002). Alcohol
can precipitate seizures in patients with epilepsy (Heckmatt et al.,
1990; Frucht et al., 2000). This is more commonly associated with
chronic heavy use (Yamane and Katoh, 1981). The occurrence of
mania or PS precipitated by a pharmaceutical or chemical agent
reﬂects the interaction of underlying vulnerabilities and the drug
and is strongly dependent on the dosing of the substance involved.
4. Discussion
The evidence reviewed is primarily derived from clinical observa-
tional or questionnaire studies in humans, epidemiology and animal
studies. In particular sleep deprivation in rodents is used as an
explanatory paradigm for mania, epilepsy and stimulus precipitants
in animals, for example the use of electrical kindling as a model of
partial epilepsy. This review compared the range of precipitating
factors for mania and partial seizures arising from the temporal lobes.
These factors were stress, goal-attainment events, emotion, sleep
reduction and deprivation, lunar phase, seasonal variations, men-
struation, the postpartum period, perimenopause/menopause and
antidepressant medication. The precipitating factors common to
mania and PS include stress, sleep reduction and deprivation,
antidepressant medication and more tentatively emotion. Goal-
attainment events, spring and summer season and the postpartum
period were only associated with mania, whereas winter season and
menstruation were only associated with PS. The identiﬁcation of
precipitating factors common to mania and PS is suggestive of
overlaps in candidate mechanisms, in particular temporal lobe
involvement in the generation of episodes in both disorders. These
factors and postulated mechanisms of action are discussed in
turn below.
The mechanisms by which stress can alter susceptibility for mania
and PS are not well understood. They are believed to include many
neural and endocrine pathways and a balance between those that
promote seizures and those that protect against (Reddy and Rogawski,
2002). It is established that, early life stress and stress affect the medial
temporal lobe (Herman et al., 2003) and the hypothalamic–pituitary–
adrenal (HPA) axis (Phillips, 2007) and has been hypothesised to
inﬂuence the development and progression of limbic epilepsy (Koe
et al., 2009) and BD (Agid et al., 1999). HPA axis dysfunction has been
found in patients with epilepsy (Zobel et al., 2004) and BD (Watson
et al., 2004). It is likely that these deﬁcits or insults caused earlier in
life cause vulnerability for future episodes.
The effects of stress on mania and PS susceptibility may be
modulated by the endocrinological response to stress. During periods
of stress, the adrenal cortex releases corticotropin-releasing hormone
(CRH), adrenocorticotropic hormone (ACTH) and cortisol (corticoster-
one in rodents) (Joëls, 2009). In animals, the administration of cort-
icosteroids facilitates kindling in amygdala and the hippocampus
(Karst et al., 1999) and exposure to repeated stress accelerates limbic
epileptogensis (Jones et al., 2013). The administration of exogenous
corticosteroids has been implicated in the onset and recurrence of
mania (Pies, 1981; Panwar and Lassi, 2011). By contrast, in patients
with Cushing’s disease, marked by excessive endogenous secretion of
cortisol, symptoms of increased fatigue, irritability and depressed
mood are commonly reported (Starkman et al., 1981). Meta-analysis
has shown that morning cortisol level is increased in BD patients
relative to controls (N¼704, g¼0.269, 95% CI 0.084–0.453, p¼0.004)
(Girshkin et al., 2014).
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The adrenal medulla responds to stress by producing the
catecholamines epinephrine and norepinephrine. The effects of
these are simulated by the analogues of epinephrine, pseudoephe-
drine (found in some cold and ﬂu remedies) (Dalton, 1990; Stuer
and Claes, 2006) and ephedra (found in some weight-loss supple-
ments) which have been reported to precipitate mania (Lewis and
Smith, 1983; Capwell, 1995). The ﬁnding that stress is a precipitat-
ing factor in the two disorders is suggestive of shared pathophy-
siology involved in the generation of episodes. Stress is also a
precipitating factor in other neurological conditions characterized
by recurrent attacks affecting the central nervous system, for
example multiple sclerosis. Stress is often coupled with other
known precipitating factors such as sleep reduction.
This review has shown that intense emotion can precipitate PS
and more tentatively mania. Patients with mania show decreased
recognition of fear and disgust compared to faces expressing anger,
sadness, surprise and happiness (Lembke and Ketter, 2002). Patients
with early-onset right mesial TLE show impaired recognition parti-
cularly for fearful faces (Meletti et al., 2003). In addition, impairments
in matching facial emotional expressions are found in remitted
patients with BD (Bozikas et al., 2006). These results are suggestive
of the involvement of the limbic system in both disorders. Clarifying
the role of intense emotion as a precipitating factor of mania would
require careful attention to trait and state emotions as a feature of
the disorder itself.
As indicated in the results, sleep reduction and deprivation are
precipitating factors for mania and PS. In rats and mice, sleep
deprivation leads to symptoms akin to mania in humans including
insomnia, hyperactivity, irritability, aggressive behaviours and
hyper sexuality (Benedetti et al., 2008). The importance of sleep
reduction in the onset of mania has been acknowledged as a
potential ﬁnal common pathway. Mania is hypothesised to cause
insomnia and its development is self-reinforcing and potentially
autonomous after being initiated by precipitants such as psycho-
logical, environmental and interpersonal factors (Wehr et al.,
1987). Sleep deprivation can elicit paroxysmal EEG activity in
healthy individuals (Rodin et al., 1962) and is an important
predictor of interictal epileptiform discharges, implicated in the
onset of recurrent seizures (Mattson et al., 1965). A reduction in
the seizure threshold has been observed following sleep depriva-
tion in amygdala kindled cats (Shouse and Sterman, 1982). The
inﬂuence of the circadian rhythm system on seizure frequency has
been shown in animal models of limbic epilepsy and in humans
with partial epilepsy with a prevalence of seizures occurring in the
daytime with a peak in the afternoon (Quigg et al., 1998). Also
noteworthy is that at times, the terms sleep deprivation is used
synonymously with sleep reduction in particular in the epilepsy
literature. Research on sleep hygiene in both disorders may cast
further light on the mechanisms in the generation of episodes.
Sleep and the functioning of the circadian rhythm systems are
inﬂuenced by external cues including the Zeitgeber light, the
effects of which may be most prominent during seasonal varia-
tions or historically, with lunar phase. Humans are particularly
sensitive to light which, through entrainment, is aligned with
external time that allows a shift according to seasonal variation
and changes in time zone (Harvey, 2008). Seasonal variations are a
precipitating factor in both disorders although exacerbations of
mania and PS are seen at different times of the year. In BD, there is
a relationship between higher sunshine hours and increased
incidence of mania (Carney et al., 1988). Heightened sensitivity
to light has been proposed as a possible phenotype for BD (Lewy
et al., 1985). Additionally, a recent multinational study has found
an association between sunlight and age of onset and BD (Bauer et
al., 2014). The relationship between light and mood extends
beyond a precipitating factor to a treatment. Light therapy can
be used as a treatment for depression. Side effects may include
rapid mood swings (Meesters and Van Houwelingen, 1998) and
case reports of mania occurring 5–6 days later (Schwitzer et al.,
1990). Conversely, in a pilot study, enforced darkness (14 h, from
6 p.m to 8 p.m) for three consecutive days has been used as an
adjunct treatment for mania. It was demonstrated that, when the
duration of the current manic episode was shorter than two
weeks, dark therapy was correlated with a rapid reduction of
Young Mania Rating Scale scores (Barbini et al., 2005). These
results suggest an interesting relationship between light and mood
that may be mediated through the production and synthesis of
melatonin. Melatonin in animals and humans acts as a chrono-
biotic cue for day-length related seasonal functions (Arendt and
Skene, 2005). Patients with BD show reductions of melatonin in
manic, depressed and euthymic states (Kennedy et al., 1996).
Patients with TLE also have low melatonin which increases within
24 h following a PS (Bazil et al., 2000) and research involving
animals has found that melatonin has anticonvulsant properties
(Mevissen and Ebert, 1998).
Both PS and mania are inﬂuenced by hormonal variations.
However, menstruation is a precipitating factor for PS but not for
mania. This is surprising given that mood changes in the premenstr-
ual phase are common even in healthy women. This is an area that
warrants future research given that the rate of rapid cycling BD is
higher in women than in men suggesting some relationship to
hormonal ﬂuctuations. Catamenial epilepsy is believed to relate to
hormonal changes associated with the menstrual cycle. Speciﬁcally,
estrogen is proconvulsant whereas progesterone is anticonvulsant
(Reddy, 2009). The postpartum period is not a shared precipitating
factor in these disorders. The postpartum period is marked by abrupt
hormonal, psychological and social changes and is implicated in the
onset and recurrence of mania in both women and men. This
suggests environmental changes contribute to the development of
postpartum mania.
Antidepressant medication are a precipitating factor for mania and
PS. As mentioned previously, antidepressants may cause a lowering of
the seizure threshold but the mechanism by which they may cause
mood lability or mania are not well understood. This may be related to
shared neurochemical underpinnings in the two disorders. Implicated
in the pathogenesis of BD are dopamine, serotonin and possibly
glutamate each of which are also believed to modulated epileptic
activity (Amann and Grunze, 2005).
There are several limitations to the conclusions of this review.
First, information on precipitating factors is derived from a variety
of sources that typically examine individual factors from published
epidemiological or clinical data. These may be identiﬁed using
retrospective study methodology which includes asking partici-
pants to identify factors from a list, self-report, or by prospective
studies involving longitudinal design. Given that the majority of
evidence cited in this review is derived from retrospective
accounts it is important to consider the associated limitations.
These include the high potential for systematic bias of memories
coupled with the process of effort after meaning. This is where
patients place high valence on events that precipitated an episode
in order to account for symptom exacerbations. In addition,
patients may be asked to recall precipitating factors for past
episodes further impacting upon the reliability of memories. In
order to overcome these limitations prospective studies are
particularly valuable although they are subject to high rates of
attrition particularly when studying individuals with mania.
Of the 30 papers included in the review that provided informa-
tion on precipitating factors in epilepsy, 10 speciﬁed and presented
data on TLE patients as an identiﬁed subgroup. The remainder of
papers either did not assess location of seizure adequately or did
not analyze by subgroup. All these papers included information
on the three precipitating factors identiﬁed as overlapping. The
conclusions regarding the three overlapping precipitating factors
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need to be considered in the light of the limited literature based on
well-deﬁned samples of TLE, which in this review comprised 10
papers. Assessing the data in these papers alone the case for the
overlapping precipitating factors was not materially diminished.
However ﬁndings in this area will be strengthened by careful
attention to sample deﬁnition in future research.
Whilst beyond the scope of this review it is noteworthy that
many of the secondary manias that occur in neurologic disorders
(e.g., multiple sclerosis, traumatic brain injury, acquired immune
deﬁciency syndrome) are also associated with seizures. This further
strengthens the notion that the two disorders share underlying
neural networks that result in episodes.
In summary, there is signiﬁcant overlap between precipitating
factors in mania and partial seizures. This is indicative of some
common underlying pathways, which mediate the occurrence of
episodes in these illnesses. The pathways highlighted by the review
include those serving sleep, stress responses, antidepressant action
and the effects of season. An understanding of precipitating factors is
beneﬁcial for patients and practitioners in formulating individual
treatment plans and self-management of the conditions. In addition,
health locus of control may be improved if a sense of greater
predictability of episodes is perceived. Further research on precipitat-
ing factors common to both disorders may lead to reﬁnement of
clinical interventions targeting these, drawing on relevant ﬁndings
from BD and epilepsy research to mutual beneﬁt (Table 1).
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Systematic Review of Cognitive 
Function in euthymic Bipolar 
Disorder and Pre-Surgical  
Temporal Lobe epilepsy
Emmanuelle C. S. Bostock1*, Kenneth C. Kirkby 2, Michael I. Garry1 and Bruce V. M. Taylor 3
1 Psychology, School of Medicine, University of Tasmania, Hobart, TAS, Australia, 2 Psychiatry, School of Medicine, University 
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Background: Bipolar disorder (BD) and temporal lobe epilepsy (TLE) overlap in domains 
including epidemiology, treatment response, shared neurotransmitter involvement and 
temporal lobe pathology. Comparison of cognitive function in both disorders may indi-
cate temporal lobe mediated processes relevant to BD. This systematic review examines 
neuropsychological test profiles in euthymic bipolar disorder type I (BD-I) and pre-surgical 
TLE and compares experimental designs used.
Methods: A search of PubMed, PsychINFO, and Scopus using Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses guidelines was conducted. Inclusion 
criteria were comparison group or pre- to post-surgical patients; reported neuropsy-
chological tests; participants aged 18–60 years. Fifty six studies met criteria: 27 BD-I; 
29 TLE.
Results: Deficits in BD-I compared to healthy controls (HC) were in executive function, 
attention span and verbal memory. Deficits in TLE compared to HC were in executive 
function and memory. In the pre- to post-surgical comparisons, verbal memory in left 
temporal lobe (LTL) and, less consistently, visuospatial memory in right temporal lobe 
(RTL) epilepsy declined following surgery. BD-I studies used comprehensive test batteries 
in well-defined euthymic patients compared to matched HC groups. TLE studies used 
convenience samples pre- to post-surgery, comparing LTL and RTL subgroups, few 
included comparisons to HC (5 studies). TLE studies typically examined a narrow range 
of known temporal lobe-mediated neuropsychological functions, particularly verbal and 
visuospatial memory.
Conclusion: Both disorders exhibit deficits in executive function and verbal memory 
suggestive of both frontal and temporal lobe involvement. However, deficits in TLE 
are measured pre- to post-surgery and not controlled at baseline pre-surgery. Further 
research involving a head-to-head comparison of the two disorders on a broad range of 
neuropsychological tests is needed to clarify the nature and extent of cognitive deficits 
and potential overlaps.
Keywords: bipolar disorder, temporal lobe, focal seizures neuropsychology, cognition, epilepsy, systematic review
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iNTRODUCTiON
Bipolar disorder type I (BD-I) is typically characterized by epi-
sodes of mania and depression with inter-episode euthymia. A 
number of impairments have been noted in the euthymic phase 
of the illness including social, occupational functioning, and 
cognitive deficits (1, 2).
Most studies have examined cognitive deficits in euthymic 
patients with BD-I compared to healthy controls (HC). Five 
meta-analyses have reported impairments in cognitive domains 
of executive functioning (3–7), verbal memory (3, 5–7), visuos-
patial memory (7), and attention (4, 6). One meta-analysis found 
no impairment of verbal memory and executive function in BD-I 
compared to HC (8). An individual patient data meta-analysis by 
Bourne et al. (9) reported impaired verbal memory and attention 
in euthymic BD-I patients relative to HC (9). The absence of an 
association between cognitive impairment and medication dose 
in euthymic BD-I patients suggest the effects of medication do 
not fully account for the cognitive impairments observed (4). 
These meta-analyses support the assumption that cognitive 
impairments exhibited in the euthymic phase are trait markers 
of the disorder.
An alternate research design is to compare and contrast 
cognitive deficits in BD-I to a reference condition which shares 
common features. For example, a meta-analysis comparing BD-I 
and schizophrenia reported more pronounced cognitive deficits 
in schizophrenia on measures of verbal fluency, verbal memory, 
executive function, visuospatial memory, mental speed, IQ, and 
concept formation (10). Similarly a single study comparing BD-I, 
obsessive compulsive disorder reported impaired verbal and 
episodic memory compared to HC (11). The BD-I group had 
greater impairments in learning word lists and delayed recall. 
These results suggest the importance of the temporal lobes in 
both disorders in the consolidation and retrieval of memories.
A single study compared BD-I with complex partial seizure 
disorder (12). It is noted that the classification of epilepsy syn-
dromes has been subject to a number of iterations. In this review, 
we use the most commonly reported and widely understood term 
“temporal lobe epilepsy (TLE)” to incorporate the terms complex 
partial seizure disorder and focal seizures arising from the tem-
poral lobes. The Jones et al. study reported greater impairment 
of executive function, attention and delayed verbal recall in the 
TLE group. These results should be interpreted with caution given 
the small and unequal sample sizes (BD-I n = 26, TLE n = 9). 
A case can be made for further exploration of similarities and 
differences between the neuropsychological test profiles seen in 
euthymic BD-I and interictal TLE. This is particularly so given 
the localizing pathology of TLE, which allows inferences to be 
made regarding the contribution of temporal lobe processes to 
the range of cognitive deficits reported in BD-I.
There are a number of established similarities between BD-I 
and TLE. These typically include a chronic course punctuated by 
episodic manifestations of mania and seizures, respectively. Other 
similarities include: the proposed involvement of kindling mecha-
nisms (13); changes in neurotransmitters (excitatory amino acids, 
GABA, dopamine and serotonin), voltage-opened ion channels 
(sodium, calcium and potassium) and second messenger systems 
(G-proteins, phosphatidylinositol, protein kinase C, myristoylated 
alanine-rich C kinase substrate), and treatment response to antie-
pileptic medications in both disorders (14).
In addition, episodes in both disorders commonly feature 
sensory, perceptual, cognitive, and affective changes (15) includ-
ing depression (16). Epidemiological studies have shown that 
the proportion of BD-I among people with epilepsy is more than 
twice as high as in the general population (17) and that mania is 
more common in patients with TLE than in the general popula-
tion (18). BD-I is also associated with comorbid epilepsy but not 
parental epilepsy (19). Episodes of mania in BD-I and seizures in 
TLE share precipitating factors including stress, sleep reduction 
and antidepressant medications (20).
The temporal lobes have also been the subject of neuroimaging 
research in both disorders. In BD-I many studies have investigated 
correlates of the disorder to specific brain regions. Meta-analyses 
of magnetic resonance imaging (MRI) studies have reported that 
BD-I is associated with right lateral ventricular enlargement (21) 
and an enlarged left amygdala (22). However, studies of temporal 
lobe size are inconsistent; with reported increases (23), reductions 
(24) or no differences (25–28) likely reflecting the difficulties of
defining and measuring the volume of individual cerebral lobes
on MRI.
In TLE, MRI studies have reported structural brain abnormali-
ties in the hippocampus, entorhinal cortex (29), thalamus (30), 
and fornix (31). On voxel-based morphometry, TLE is associated 
with gray matter pathology in the hippocampus, cingulum, thala-
mus, and frontal lobes. White matter reductions ipsilateral to the 
seizure focus were also found in the temporopolar, entorhinal, 
and perirhinal areas (32). Typically, TLE originates unilaterally 
from the medial temporal lobe; they may, however, be propagated 
from other regions which project to limbic areas (33).
Given these potential diffuse structural abnormalities seen in 
patients with TLE, it could be expected that neuropsychologi-
cal deficits may not be limited to tasks involving temporal lobe 
function. Patients with TLE display deficits in memory, general 
intelligence, language, executive function, and motor speed 
relative to HC (34, 35). Deficits in verbal memory, language, 
and psychomotor speed may be affected by factors such as age 
of onset of epilepsy, general intelligence, the number and dose of 
antiepileptic medications used, and seizure frequency (35).
The literature describing clinical features, imaging findings, 
and neuropsychological test profiles is largely in a separate corpus 
for BD-I and for TLE with only one small study directly compar-
ing the two (12).
The current structured review brings these two bodies of 
work together in a comparison of the neurocognition literature 
findings of the two conditions side-by-side. The aim is to deter-
mine whether and to what extent the cognitive impairments 
seen in euthymic BD-I are mirrored by those attributed to a 
pathology primarily affecting the temporal lobes, that is TLE.
MeTHOD
This systematic review was conducted in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines (36).
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Meta-Analyses flow diagram of included studies.
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Inclusion criteria: (a) controlled comparison, (b) patients 
diagnosed with BD-I as assessed by a recognized criterion-based 
diagnostic system, (c) BD-I patients rated as euthymic, defined 
by their scores on a rating scale (<8 HamD, <8 YMRS); patients 
with unilateral TLE, from any cause, with diagnosis confirmed in 
a pre-surgical workup, (d) at least one neuropsychological test, 
(e) adult participants (18–60 years), (f) in the case of more than 
one article by the same authors results were not identified as being 
from the same sample, (f) articles published 1980 or later.
identification of Studies
A comprehensive search of the electronic databases PubMed, 
PsychINFO, and Scopus for peer-reviewed articles published 
in English was conducted in the last week of May 2016. Search 
terms were grouped as follows: bipolar, manic depress*, baseline, 
asympt*, remit*, stable (group 1); or epilep*, seizure, presurg*, 
temporal, focal, partial, complex, interictal (group 2) and WAIS, 
Wechsler, trail making, continuous performance, stroop, digit 
span, verbal learning, rey, working memory, benton, card sort*, 
verbal fluency, RAVLT, CAVLT, tower of London (group 3). These 
search terms were combined as follows: group 1 AND group 3 for 
BD-I and group 2 AND group 3 for TLE.
Data extraction
The abstracts located from the search strategy were entered into 
EndNoteX7. The PRISMA flowchart (Figure 1) sets out the steps 
in screening conducted by author EB. After the screening of titles 
and abstracts the remaining 139 studies were examined in full 
text, using a purpose built coding sheet to assess whether they 
met inclusion criteria. This process resulted in the study sample 
of 56, of which 27 related to BD-I and 29 to TLE.
ReSULTS
The search strategy identified an initial 3,307 articles of which 56 
met inclusion criteria, 27 related to BD-I and 29 to pre-surgical 
TLE. Studies of BD-I are summarized in Table 1 and of TLE in 
Table 2 detailing authors, sample sizes, medication (BD-I only as 
this was not recorded in the TLE samples), neuropsychological 
test parameters, and summary results.
As demonstrated in Table  1, 25 of 27 studies compared 
patients with BD-I (n = 1,398) to HC (n = 1,142). The remaining 
studies compared manic, euthymic, and depressed groups. The 
most commonly reported impairments in BD-I were in executive 
function, attention span, and verbal memory. No studies found 
enhanced neuropsychological function in euthymic BD-I.
As shown in Table 2, in the epilepsy literature, all of the TLE 
studies compared neuropsychological test performance pre- to 
post-surgery. Only 5 of the 29 studies compared pre-surgical 
TLE (n = 150) to HC (n = 111); these studies found significant 
impairments in TLE compared to HC on tests of memory and 
executive function.
In 26 of the TLE studies, the samples were divided by laterality 
of seizure focus with the primary pathology affecting the right 
temporal lobe (RTL n =  846) or the left temporal lobe (LTL 
n =  1,068). In pre-surgical TLE, the direct comparison of LTL 
and RTL groups indicated that the LTL group showed impaired 
verbal memory and the RTL group, less consistently, impaired 
visuospatial memory.
The most common impairment observed in TLE related to 
surgery was in verbal memory. This finding was also associated 
with laterality, 24 studies reporting decline in verbal memory 
from pre- to post-surgery in LTL patients, whereas in RTL there 
was a less consistent decline in visuospatial memory. No signifi-
cant differences in attention were found for laterality or pre- to 
post-surgery in TLE.
Table  3 shows the results of individual neuropsychological 
tests that were reported in more than one study, for BD-I and 
TLE. Of note, the total number of neuropsychological tests used 
across all studies differed between BD-I (27) and TLE (11); this 
was not evenly distributed across cognitive domains. The number 
of studies where any executive function instrument was admin-
istered in TLE was only 4 (2 WCST, 2 COWAT) of 29 compared 
to 21 of 27 in BD-I. One study compared RTL, LTL and HC and 
showed that all patients were impaired on the WCST relative 
to HC (87). The number of studies where any verbal memory 
instrument was administered was 26 of 29 in TLE compared to 
14 of 27 in BD-I. The comparable figures for visuospatial memory 
instruments were 25 of 29 in TLE and 11 of 27 in BD-I. Similarly, 
only 6 studies measured attention in TLE compared to 17 studies 
in BD-I. Thus, while both fields have seen sustained research 
activity in identifying neuropsychological deficits, the focus of 
inquiry in TLE has been on verbal and visuospatial memory and 
in BD-I executive function.
Notwithstanding the differences in the intensity and focus of 
neuropsychological testing in both conditions, consistent results 
emerging from this study emphasize deficits in verbal memory, 
which have been reported in the majority of studies that have 
examined this area in both BD-I and TLE.
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TaBLe 1 | Summary of included studies on euthymic bipolar disorder.
Reference n Medications bipolar 
sample
Neuropsychological test parameters Results
Altshuler et al. (37) BD 40 Li 25, AC 12, AD 4, AP 
6, BZD 3
WAIS-R block design, vocab; TMT, WCST, 
Stroop; VFT, CVLT; ROCFT; Star mirror 
tracing Task, PR
BD impaired verbal memory and executive 
functioningSZ 20
HC 22
Bas et al. (38) BD 60 Li 39, AP 37, LTG 9, 
VPA 21
Stroop, TMT A and B; WMS-R visual 
reproduction; RAVLT
BD impaired on RAVLT
HC 41
Bora et al. (39) BD 514 Li 63.2%, VPA 47.6%, 
AP 47.2%, AD 5.7%
Stroop. WCST Deficits exist in subgroups who have severe and 
global cognitive deficitsBD-II 42
HC 416
Chang et al. (40) BD 23 BD Li 13, AP 15, LTG 
7, VPA 9
WAIS-R block design and vocab; CVLT, 
VFT
All NS
BD-II 23
HC 23
Chou et al. (41) BD 23 AP 13, VPA 19 The Color Trails Test, WCST; WMS-III – 
Word Lists Test, Face Test; Go/No-GO, 
Test for Attentional Performance
BD impaired faces memory and WCST
HC 33
Deckersbach et al. (42) BD 25 Li 11, AC 9, AD 9, AP 3 ROCFT Immediate recall BD impaired, copy and recognition 
preservedHC 25
Deckersbach et al. (11) BD 30 Li 13, AC 11, AD 8, 
AP 4
CVLT CVLT BD impaired learning and delayed free recall
Obsessive 
compulsive 
disorder 30
HC 30
Dell’Osso et al. (43) BD 15 BD Mono 2, Poly 12 N-Back NS HC and BD
BD-II13
HC 27
Dittmann et al. (44) BD 65 BD Li 27, AD 10, AP 
33, CBZ 4, VPA 28
TMT; HAWIE-R; WAIS-III letter number 
sequencing; RBANS
Psychomotor speed, working and delayed memory, 
verbal learning, executive functioning BD impairedBD-II 38
HC 62
Dixon et al. (45) BD manic 15 dep 
15, eu 15, HC 30
Eu Li 15, AD 8, AP 10, 
AC 2
WAIS-R Vocab; Stroop; FAS; Hayling 
sentence completion test; Cognitive 
Estimates Test
VF total responses, Hayling response initiation 
latency, error score and using strategy, stroop EuBD 
impaired
Doganavs¸argil-Baysal 
et al. (46)
BD 60 Li 11, MS + AP 12, 
2MS 12, VPA 6
WCST, TMT, Stroop; RAVLT; Cancelation 
test
Significant differences on all measures between BD 
and HCHC 20
Doganavs¸argil-Baysal 
et al. (46)
BD 54 Li 10, MS + AP 27, 
2MS 11, VPA 5
WCST; RAVLT Both measures BD < HC
HC 18
Doruk et al. (47) Manic 20 Unknown Stroop; Serial Digit Learning Test; RAVLT; 
Cancelation Test
NS HC and EuBD
Dep10
Eu 21
Fistikci et al. (48) BD 25 Li 25 WCST; Montreal Cognitive Assessment NS HC and BD
HC 25
Frangou et al. (49) BD 10 Li 5, AC 3 WCST; Hayling sentence completion WCST BD and offspring made more errors
Un offspring 15
HC 43
Hsiao et al. (50) BD 30 VPA 29 WAIS-III digit symbol; TMT; WMS-III Verbal memory, working memory, psychomotor 
speed, executive function BD impairedBD-II 37
HC 22
Martino et al. (51) BD 48 AD 16, AP 28, BZD 23, 
MS 48
WAIS vocab, digit span; TMT, WCST, IGT; 
Memory battery of Signoret
Verbal memory, attention and executive functions 
impairedBD-II 37
HC 34
Muralidharan et al. (52) BD 72 AP 27, Li 34, VPA 38 TMT, Stroop; CANTAB; CVLT; WMS-III 
LNS
P on VPA more working memory deficits than Li 
or HCHC 40
Muralidharan et al. (53) BD 68 AP 51, Li 32, MS + AP 
50, VPA 32
TMT, Stroop; CANTAB; CVLT; WMS-III 
letter number sequencing 
Verbal and visuospatial memory, working memory 
and executive function BD impaired.HC 38
Normala et al. (54) BD 40 AP 6, MS 11, MS + AD 
1, MS + AP22
WAIS Digit span; TMT; Verbal Fluency Executive and attention functioning BD impaired
HC 40
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Reference n Medications bipolar 
sample
Neuropsychological test parameters Results
Pattanayak et al. (55) BD 30 AP 5, LTG 2, Li 21, 
VPA 11
VIQ; TMT, Stroop; N-Back; Postgraduate 
Institute Memory Scale
Attention, information processing speed, executive 
function, verbal memory BD impairedHC 20
Radwan (56) BD 30 Unknown WAIS; WCST; WMS; CPT All BD impaired
HC 30
Sepede et al. (57) BD 24 AD 10, AP 15, BZD 8, 
Li 3, MS 9
CPT Sustained attention impaired BD and rels
Unaffected rels 
33
HC 24
Trivedi et al. (58) BD 15 CBZ 1, Li 8, VPA 6 WCST; SWMT; CPT Executive function BD impaired
HC 15
Trivedi et al. (59) BD 15 Unknown WCST; SWMT; CPT Executive function BD impaired
SZ 15, HC 15
Yates et al. (60) BD dep 34 AD 9, AP 18, BZD 9, 
MS 29
WAIS-III Verbal measure BD impaired
BDEu 31, HC 34
Zubieta et al. (61) BD 15 AP 3, CBZ 2, Li 7, 
VPA 12
WAIS-R: digit span; WCST, Stroop; 
WMS-R; verbal fluency; test of variable 
attention
Verbal learning, executive function, motor 
coordination and sequential memory BD impaired. 
NS verbal fluency or attention
HC 15
BD, bipolar; BD-II, bipolar II; HC, healthy controls; SZ, Schizophrenia; Li, lithium; AC, anticonvulsant; AD, antidepressant; AP, antipsychotics; BZD, benzodiazepine; CBZ, 
carbamazepine; LTG, lamotrigine; MS, mood stabilizer; VPA, valproate; Mono, monotherapy; Poly, polytherapy; AMIPB, Adult Memory and Information Processing Battery; BVRT, 
Benton Visual Retention Test; VLMT, Verbaler Lern- und Merkfähigkeitstest; DCS-R, Diagnosticum für Cerebralschädigung – II; NAART, North American Adult Reading Test; WRAT, 
Wide Range Achievement Test; WAIS, Wechsler Adult Intelligence Scale; CPT, Continuous Performance Test; CVLT, California Verbal Learning Test; RAVLT, Rey Auditory Verbal 
Learning Test; WCST, Wisconsin Card Sorting Test.
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DiSCUSSiON
To our knowledge, this is the first systematic review directly 
comparing the literature on cognitive function in BD-I and TLE. 
Consistent with the meta-analyses of cognition in euthymic BD-I, 
our review showed impairments on a wide range of cognitive 
measures. In the individual studies reviewed, the most com-
monly reported impairments in BD-I were in executive function, 
attention span, and verbal memory. The impairments of executive 
function in patients with BD-I may be suggestive of an underlying 
dysfunction in the prefrontal cortex (3).
In TLE studies, a decline in pre- to post-surgery in verbal 
memory was commonly reported in patients with seizures 
originating from the LTL, and less consistently, in visuospatial 
memory in patients with RTL epilepsy. Functional MRI studies 
have revealed that the right hemisphere is associated with spatial 
memory (91). In our sample, executive function was not widely 
examined in patients with epilepsy; however, an impairment was 
found. For executive function, two instruments were employed 
across four studies, three of which showed a difference between 
pre- to post-surgery scores and one study found impaired perfor-
mance in TLE relative to HC participants.
In keeping with our results, meta-analyses of memory func-
tion pre- to post-surgery reported that, following a resection 
of the LTL, a clear decline in verbal memory is observed, an effect 
that is particularly salient for immediate verbal recall. However, 
the pattern of impairment following partial resection of the RTL 
showed a trend for improvement on tasks of non-verbal memory 
(92). This suggests that memory impairments are state markers 
affected by seizures and abnormalities in the temporal lobes. 
Other factors that affect cognitive performance in TLE are the 
chronicity of the condition, older age, lower intellect, and greater 
abnormalities shown on imaging (92). Another meta-analysis 
found that the evidence regarding post-surgery outcome on visu-
ospatial memory following right anterior temporal lobectomy 
was less clear (93).
In TLE, it is unclear whether frontal lobe impairments shown 
on executive function measures are a product of temporal lobe 
involvement or are a side effect of the propagation of epileptic 
activity from the epileptic zone (94). Other evidence has suggested 
that the prefrontal cortex, in particular the orbitofrontal cortex, 
is influenced by ictal discharges from the mesial temporal lobe 
(95). Some studies have shown that the temporal neocortex is 
implicated in executive function implying that a frontotemporal 
network is used for processing information (96).
This review emphasizes that prior research on cognitive 
impairments in the fields of BD-I and TLE has employed method-
ologies that reflect different research questions. The BD-I litera-
ture predominantly examines cognition as a characteristic of the 
disorder itself, on a par with symptoms and potentially amenable 
to therapeutic intervention. The TLE literature is concerned with 
the effects of ablative surgery that aims to remove seizure foci 
but may consequently also directly affect healthy brain tracts. 
It addresses whether cognitive function improves or declines 
subsequent to surgery and the moderating effects of laterality.
The majority of BD-I studies compare euthymic patients with 
HC, whereas in the epilepsy studies, patients act as their own con-
trols in relation to surgical intervention and laterality. In addition, 
given that the BD-I studies are interested in trait markers in the 
euthymic phase, they routinely report the quantitative differences 
between patients and HC, rendering the results suitable for incor-
poration in meta-analytic studies. The TLE literature has focused 
TaBLe 1 | Continued
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TaBLe 2 | Summary of included studies on pre-surgical temporal lobe epilepsy (TLE).
Reference n Neuropsychological test parameters Results
Baxendale and Thompson (62) Right temporal lobe 
(RTL) 133
WAIS PIQ, VIQ; AMIPB Verbal memory decline post-surg left temporal lobe 
(LTL)
LTL 157
Baxendale et al. (63) RTL 146
LTL 177
WAIS PIQ, VIQ; AMIPB; Birt Memory and Information 
Processing Battery
RTL and LTL at equal risk of post-surg decline
Berenbaum et al. (64) LTL 57 WAIS Digit Span; CVLT CVLT decline post-surg
Bjørnaes et al. (65) RTL 50 WAIS Digit Span; Benton Visual Retention Test (BVRT); 
Design Learning and Retention Test; Verbal List 
Learning and Retention; Tactual Performance Test
Improvement at 2-year follow up post-surg
LTL 41
Chelune et al. (66) RTL 19 WAIS-R VIQ, PIQ; WMS-R, RAVLT; COWAT, Halstead-
Wepman Aphasia Screening Exam, BNT, Speech 
Sounds Perception Test; Hooper Visual Organization 
Test, Seashore Rhythm Test
LTL decline post-surg
LTL 23
Chiaravalloti et al. (67) RTL 16 WMS-III Faces Subtest; Graduate Hospital Facial 
Memory Test
RTL < LTL both pre- and post-surg
LTL 10
Chiaravalloti (68) RTL 42 CVLT; Graduate Hospital Facial Memory Test Verbal memory post-surg decline LTL, RTL improved. 
Visuospatial memory post-surg decline RTL, LTL 
improvement
LTL 28
Fernandes et al. (69) RTL 23 WAIS-R Block design, Vocabulary; WMS-R; RAVLT Cognitive scores post-surg decline low pre-surg 
scores. Non-verbal memory post-surg RTL decline, 
verbal and visuospatial memory LTL decline
LTL 24
healthy controls 
(HC) 28
Giovagnoli et al. (70) RTL 12 Raven’s Colored Progressive Matrices; Attentive 
Matrices; Verbal Selective Reminding Procedure, Story 
Recall, Verbal Memory Distractor Test; Visual Selective 
Reminding Procedure, ROCFT, Visual Memory 
Distractor Test
Verbal memory pre- and post-surgery LTL impaired 
relative to HC. Visual deficits present in both groups 
relative to HC
LTL 12
HC 36
Gleissner et al. (71) RTL 63 VLMT; DCR-S Verbal memory LTL decline
LTL 52
Glosser et al. (72) RTL 13 Boston Naming Test; CVLT Benton Facial Recognition, 
Graduate Hospital Facial Memory
Recognition of familiar faces and learning new faces 
RTL impaired. Names of familiar faces LTL impairedLTL 8
HC 10
Helmstaedter et al. (73) LTL 47 Verbal Learning and Memory Test; RAVLT Delayed recall and recognition post-surg improvement
Hermann and Wyler (74) RTL 14 COWAT; Token Test Language tests pre-surg LTL deficit
LTL 15
Hermann et al. (75) RTL 31 CVLT Verbal memory post-surg RTL increased
LTL 26
Hermann et al. (76) RTL 26 WAIS-R Digit Span; Multilingual Aphasia Examination 
Visual Naming Test; CVLT
CVLT post-surg decline LTL
LTL 36
Köylü et al. (77) RTL 12 List learning task LTL post-surg decline
LTL 14
Lee et al. (78) LTL 38 RAVLT; ROCFT Memory post-surg decline
Loring et al. (79) RTL 13 Selective Reminding Test, Serial Digit Learning, ROCFT, 
Form Sequence Learning
Complex figure RTL impaired. Verbal memory decline 
LTLLTL 16
Malikova et al. (80) RTL 11 WAIS-R; WMS-R; Verbal Fluency Test FSIQ, global and verbal memory, attention, and 
working memory all improved post-surgLTL 26
Morino et al. (81) RTL 31 WMS-R; Miyake Verbal Retention Test; BVRT Memory RTL improved post-surg. Verbal memory LTL 
post-surg improvedLTL 31
Quigg et al. (82) RTL 16 TMT; BNT; CVLT; WMS-R Logical Memory Scale BNT and CVLT LTL decreased post-surgery. 
Language and verbal memory LTL increased. TMT 
increased
LTL 14
Seidenberg et al. (83) RTL 30 CVLT Free recall LTL decline post-surgery
LTL 46
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Reference n Neuropsychological test parameters Results
Selwa et al. (84) RTL 14 WAIS-R; WMS FSIQ, Logical Memory RTL improved post-surg. 
Verbal memory decline LTL post-surgLTL 17
Non-surgical TLE 28
Shamim et al. (85) RTL 14 WAIS-III; WMS-III Verbal memory deficit post-surg LTL
LTL 16
Stretton et al. (86) RTL 17 WAIS-III Digit Span; Gesture Span Task; Motor 
Sequences Task; Dot-Back Paradigm
Working memory pre-surg RTL and LTL worse than 
HC. WM improved post-surg LTLLTL 16
HC 15
Tisser et al. (87) RTL 10 WAIS-R; WCST WCST RTL and LTL impaired, improved post-surg
LTL 15
HC 22
Trenerry and Jack (88) RTL 34 WAIS-R; WCST The WCST is not useful for lateralizing seizure onset 
in TLELTL 34
Trenerry et al. (89) RTL 36 WAIS-R; WMS-R; RAVLT; Visual Spatial Learning Test Verbal and visual memory LTL improved post-surg
LTL 44
von Rhein et al. (90) RTL 20 VLMT; DCS-R; BNT; Token Test Verbal Memory impaired post-surgery. Naming decline 
post-surgery LTLLTL 32
Tests of executive function: WCST, FAS, TMT-B, Stroop, Hayling Sentence Completion Test, CANTAB: Intra Extra Dimensional Set Shifting, CANTAB: Stockings Problem; Tests of 
Verbal Memory—CVLT, RAVLT, WAIS Vocab, WMS-R: Logical Memory, WMS-R: Verbal Paired Associates, Token Test, VLMT: Verbaler Lern- und Merkfähigkeitstest; Tests of non-
verbal memory- ROCFT, WMS: Visual reproduction, WMS-R: Design Memory, WMS-R Visual Reproduction, WMS-III: Face Test, CANTAB: Spatial recognition memory, CANTAB: 
Pattern Recognition Memory, CANTAB: Paired Associates Learning; Attention span WAIS: Digit Span, Adult Memory and Information Processing Battery (AMIPB); sustained 
attention CPT; working memory SWMT, N-Back, WAIS: Letter Number Sequencing, WMS-III: Letter Number Sequencing, CANTAB: Spatial Working Memory.
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TaBLe 3 | Neuropsychological test findings summary table (for tests used more than once) in studies of bipolar disorder (BD) and temporal lobe epilepsy (TLE).
Measure BD                                TLe Pre- to 
post- 
surgical 
↑        ↓
Laterality 
effects
Use in studies, number of 
participants BD
BD < HC 
sig
Use in studies, number of 
participants TLe
sig
executive function
WCST 12 studies 11 2 studies 1 ↑1
BD n = 859, healthy controls (HC) 
n = 676
Right temporal lobe (RTL) n = 44, left 
temporal lobe (LTL) n = 49, HC n = 22
COWAT(FAS) 5 studies 2 2 studies 2 ↑1 Higher score 
LTL group 
pre- assoc. 
with greater 
impairment 
post-surg
RTL n = 33, LTL n = 38
BD n = 133, HC n = 130
TMT-B 9 studies 7
BD n = 513, HC = 339
Stroop 10 studies 7
BD n = 895, HC = 642
Hayling Sentence Completion Test 2 studies 2
BD n = 25, HC n = 73
CANTAB: Intra Extra Dimensional  
Set Shifting
2 studies 2
BD n = 140, HC n = 78
CANTAB: Stockings Problem 2 studies 2
BD n = 140, HC n = 78
verbal memory
CVLT 5 studies 3 7 studies 6 ↓6 Post-surg LTL 
decline 6
BD n = 233, HC n = 153 RTL n = 158, LTL n = 215, HC n = 10 RTL > LTL 1
(Continued)
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Measure BD                                TLe Pre- to 
post- 
surgical 
↑        ↓
Laterality 
effects
Use in studies, number of 
participants BD
BD < HC 
sig
Use in studies, number of 
participants TLe
sig
RAVLT 3 studies 2 5 studies 5 ↓5 Post-surg LTL 
decline 5BD n = 141, HC = 79 RTL n = 78, LTL n = 176, HC n = 28
Verbal comprehension: WAIS Vocab 4 studies 0
BD n = 187, HC n = 173
WMS-R: Logical Memory 6 studies 4 ↑3 ↓1 LTL < RTL 1
RTL n = 206, LTL n = 256, HC n = 28
WMS-R: Verbal Paired Associates 4 studies 4 ↑2 ↓1 LTL < RTL 1
RTL n = 119, LTL n = 151, HC n = 28
Token Test 2 studies 1 ↑1 Post-surg LTL 
improved 1RTL n = 34, LTL n = 47
VLMT: Verbaler Lern- und Merkfähigkeitstest 2 studies 2 ↓2
RTL n = 83, LTL n = 82
visuospatial memory
ROCFT 2 studies 0 3 studies 2 ↑1 LTL < RTL 1
BD n = 65, HC n = 47 RTL n = 25, LTL n = 62, HC n = 36
WMS: Visual reproduction 3 studies 0 2 studies 0
BD n = 105, HC n = 78 RTL n = 27, LTL n = 29
CANTAB: Spatial recognition memory 2 studies 2
BD n = 140, HC n = 78
CANTAB: Pattern Recognition Memory 2 studies 2
BD n = 140, HC n = 78
CANTAB: Paired Associates Learning 2 studies 2
BD n = 140, HC n = 78
WMS-R: Design Memory 4 studies 2 ↑1 ↓1 RTL decline 1
RTL n = 78, LTL n = 93, HC n = 28
WMS-R Visual Reproduction 5 studies 2 ↑1 ↓1 RTL decline 1
RTL n = 241, LTL n = 484, HC n = 28
WMS-III: Face Test 1 study 1 ↓1 RTL decline 1
RTL n = 16, LTL n = 10
Graduate Hospital Facial Memory 3 studies 3 ↑1 RTL < LTL 2
RTL n = 71, LTL n = 46, HC n = 10
Benton Visual Retention 2 studies 0
RTL n = 31, LTL n = 72
Diagnosticum für Cerebralschädigung 3 studies 2 ↓1
RTL n = 83, LTL n = 253
Spatial ability
WAIS: Block design 4 studies 0
BD n = 124, HC n = 109
attention span
WAIS: Digit Span 3 studies 2 4 studies 0
BD n = 103, HC n = 89 RTL n = 93, LTL n = 150, HC n = 15
TMT-A (also processing speed) 10 studies 8
BD n = 513, HC = 339
WAIS: Digit Symbol (also processing speed) 3 studies 3
BD n = 91, HC = 86
CANTAB: Rapid Visual Information 2 studies 2
BD n = 140, HC n = 78
(Continued)
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Measure BD                                TLe Pre- to 
post- 
surgical 
↑        ↓
Laterality 
effects
Use in studies, number of 
participants BD
BD < HC 
sig
Use in studies, number of 
participants TLe
sig
Adult Memory and Information Processing 
Battery (AMIPB)
2 studies 2 ↑1 ↓1
RTL n = 279, LTL n = 334
Sustained attention
CPT 4 studies 2
BD n = 84, HC n = 84
working memory
SWMT 2 studies 0
BD n = 30, HC n = 30
N-Back 2 studies 0
BD n = 45, HC n = 47
WAIS: Letter Number Sequencing 3 studies 3
BD n = 126, HC n = 126
WMS-III: Letter Number Sequencing 2 studies 3
BD n = 140, HC n = 78
CANTAB: Spatial Working Memory 2 studies 2
BD n = 140, HC n = 78
↑ refers to an increase, ↓ a decrease from pre- to post-surgery, sig refers to the number of studies with a significant result, laterality comments only significant main effects or 
interactions are discussed.
on statistically significant differences pre- to post-surgery and has 
not reported information in a form suitable for meta-analysis of 
pre-surgical cognitive functioning. Therefore, we have employed 
a systematic review methodology to examine and compare the 
profile of cognitive deficits in the two conditions. As indicated in 
the Section “Results,” the focus of inquiry of the neuropsychologi-
cal tests employed in the BD-I studies is predominantly on frontal 
lobe functions and in TLE on verbal and visuospatial memory.
There are significant differences in the experimental designs 
examining cognition in the two patient groups. In BD-I studies, 
cognition is tested broadly with a wide range of measures, with a 
HC comparison group and statistical control for medication use. 
This allows for observed deficits to be interpreted as trait markers 
of BD-I. This is further supported by familial studies that show 
similar patterns of impairments among family members and 
patients (89). By contrast, studies assessing cognitive performance 
in pre-surgical patients with epilepsy do so generally without HC. 
Only five studies included HC (n = 111), consequently the find-
ings have limited depth compared to those in the BD-I literature 
(n = 1,142). The pre-surgical neuropsychological workup consists 
mostly of tests of memory function, which is not surprising given 
that the surgery involves removing parts of or the whole temporal 
lobe.
In general, the studies on BD-I report the types of medications 
taken by patients at the time of testing (as shown in Table  1), 
which may have impacted the results. By contrast, in the epilepsy 
samples, it was typically not reported whether patients were receiv-
ing medication at the time of testing. A study that examined the 
effects of atypical antipsychotics on cognition in euthymic BD-I 
patients found that untreated patients showed better performance 
than those taking medication (93). Many patients with BD-I are 
treated with anticonvulsants that may worsen or enhance cogni-
tion (97). Of the total sample of 884 patients with BD-I included 
in the systematic review, 299 were taking lithium at the time of 
testing. A review of the effects of lithium on cognition found that 
impairments on tasks of psychomotor speed and verbal memory 
were present, whereas no effect was found on visuospatial ability 
or attention (97). Thus, cognitive performance may be impaired 
in various ways by different medications. A recent randomized 
crossover study examined the effects of methylene blue on cogni-
tion and mood-related symptoms in euthymic BD-I and BD-II. 
Neither low (15 mg) control doses nor high active doses (195 mg) 
had a significant effect on cognition (98). In rats, methylene blue 
prevents methylmalonate-induced seizures and oxidative damage 
in the striatum (99) providing interesting leads for future research 
into the overlaps between BD and epilepsy.
While this paper has provided an overview of the literature, 
it is subject to a number of limitations. One such factor is the 
differences of experimental designs in BD-I and TLE, which 
meant that a head-to-head meta-analytic comparison was not 
feasible. As discussed previously, the effect of medication was not 
uniformly controlled in BD-I and was either not reported or not 
systematically recorded in the epilepsy samples. In order to deter-
mine whether cognitive deficits are related to the illness and not 
undesirable side effect of medication, examination of otherwise 
stable drug-free patients would be of interest. The period of time 
between episodes (mania, depression, or seizures), time of test-
ing, hospitalizations, and the presence of psychotic features were 
not considered in this review. In BD-I patients, the presence of 
sub-clinical symptoms is common, even in those patients who are 
rated as euthymic at the time of testing and may have impacted 
performance overall (3).
TaBLe 3 | Continued
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The Current Status of the Ketogenic 
Diet in Psychiatry
Emmanuelle C. S. Bostock1*, Kenneth C. Kirkby2 and Bruce V. M. Taylor3
1 Psychology, School of Medicine, University of Tasmania, Hobart, TAS, Australia, 2 Psychiatry, School of Medicine, University 
of Tasmania, Hobart, TAS, Australia, 3 Menzies Institute for Medical Research, Tasmania, Hobart, TAS, Australia
Background: The ketogenic diet (KD) has been used in treatment-resistant epilepsy 
since the 1920s. It has been researched in a variety of neurological conditions in both 
animal models and human trials. The aim of this review is to clarify the potential role of 
KD in psychiatry.
Methods: Narrative review of electronic databases PubMED, PsychINFO, and Scopus.
Results: The search yielded 15 studies that related the use of KD in mental disorders 
including anxiety, depression, bipolar disorder, schizophrenia, autism spectrum disorder 
(ASD), and attention deficit hyperactivity disorder (ADHD). These studies comprised nine 
animal models, four case studies, and two open-label studies in humans. In anxiety, 
exogenous ketone supplementation reduced anxiety-related behaviors in a rat model. In 
depression, KD significantly reduced depression-like behaviors in rat and mice models in 
two controlled studies. In bipolar disorder, one case study reported a reduction in symp-
tomatology, while a second case study reported no improvement. In schizophrenia, an 
open-label study in female patients (n = 10) reported reduced symptoms after 2 weeks 
of KD, a single case study reported no improvement. In a brief report, 3 weeks of KD in a 
mouse model normalized pathological behaviors. In ASD, an open-label study in children 
(n = 30) reported no significant improvement; one case study reported a pronounced 
and sustained response to KD. In ASD, in four controlled animal studies, KD significantly 
reduced ASD-related behaviors in mice and rats. In ADHD, in one controlled trial of KD 
in dogs with comorbid epilepsy, both conditions significantly improved.
Conclusion: Despite its long history in neurology, the role of KD in mental disorders is 
unclear. Half of the published studies are based on animal models of mental disorders 
with limited generalizability to the analog conditions in humans. The review lists some 
major limitations including the lack of measuring ketone levels in four studies and the 
issue of compliance to the rigid diet in humans. Currently, there is insufficient evidence 
for the use of KD in mental disorders, and it is not a recommended treatment option. 
Future research should include long-term, prospective, randomized, placebo-controlled 
crossover dietary trials to examine the effect of KD in various mental disorders.
Keywords: ketogenic diet, psychiatry, mental disorders, ketones, epilepsy
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iNTRODUCTiON
The ketogenic diet (KD) has a long-standing place in neurology 
and has been used for treatment-resistant epilepsy since the 1920s 
(1). KD consists of a rigidly controlled high-fat, low-protein, and 
low-carbohydrate diet usually with a 4:1 lipid:non-lipid ratio (fat 
to protein and carbohydrate ratio) (2). Woodyatt noted that in a 
normal person in a state of starvation or eating a diet contain-
ing low carbohydrate and a high percentage of fat, the ketones 
acetone, acetoacetate, and beta-hydroxybutyric acid increase (3), 
and the absence of glucose serves as alternative fuels for the body. 
KD has been proven an effective treatment in difficult-to-control 
seizures with its use primarily in children with epilepsy (4, 5), 
particularly those with epileptic encephalopathies whereby epi-
leptic activity may contribute to severe neurological and cognitive 
impairments (6). The finding that KD is beneficial for epilepsy 
was supported by a systematic review (7), meta-analysis (8), and 
a Cochrane review (9). KD and related diets have been proven 
useful in pharmacoresistant childhood epilepsy (10).
The mechanism by which KD acts is not clearly understood. 
However, among the many hypotheses advanced, elevation of 
brain acetone may account for the efficacy of the diet in epilepsy 
as it has proven anticonvulsant effects (11). In a variation of the 
diet, the medium-chain triglyceride (MCT) KD increases plasma 
levels of decanoic acid, which in  vivo has been shown to be 
anticonvulsant; although the precise mechanism remains unclear 
(12). In young and adult rats, KD increases concentrations of 
kynurenic acid (KYNA) in the hippocampus and striatum but 
not the cortex (13). Elevated levels of KYNA in the cerebrospinal 
fluid have been demonstrated in patients with schizophrenia 
(14) and bipolar disorder (15). Pharmacological manipulation 
of kynurenines is a potential treatment strategy for psychiatric 
disorders (16).
Currently, there are no international protocols guiding the 
implementation of the diet, rather dietary recommendations are 
based on individual treating physician’s advice. Consequently, 
there exists a need for more standardized protocols for manage-
ment recommendations for clinical and research use (17). In 2006, 
a group of 26 pediatric epileptologists and dieticians was convened 
to create a consensus statement regarding the clinical management 
of KD. They specified the following absolute contraindications to 
commencing KD “carnitine deficiency (primary), carnitine pal-
mitoyltransferase (CPT) I or II deficiency, carnitine translocase 
deficiency, beta-oxidation deficiencies including medium-chain 
acyl dehydrogenase deficiency (MCAD), long-chain acyl dehy-
drogenase deficiency (LCAD), short-chain acyl dehydrogenase 
deficiency (SCAD), long-chain 3-hydroxyacl-CoA deficiency, 
medium-chain 3-hydroxyacl-CoA deficiency, pyruvate carboxy-
lase deficiency and porphyria. Relative contraindications of KD 
include the following: inability to maintain adequate nutrition, 
surgical focus identified by neuroimaging and video EEG 
monitoring, and parent or caregiver non-compliance” (18). The 
possible risks of KD must be weighted against its potential value 
for seizure control or its other benefits (19).
Ketogenic diet has been assessed in a variety of neurological 
conditions other than epilepsy in both animal models and human 
trials. In an animal model of amyotrophic lateral sclerosis, 
SOD1-G93A transgenic mice were fed KD. It was shown that 
KD led to significant alterations in the clinical manifestation 
of the disease, specifically a higher motor neuron count in the 
lumbar spinal cord and preserved motor function (20). KD has 
also been trialed in rats following controlled cortical impact 
injury, a model for brain trauma, showing that the diet improves 
both cognitive and motor functioning (21). In an animal model 
of multiple sclerosis, the effects of KD on memory impairments 
and inflammation expressed by experimental autoimmune 
encephalomyelitis were examined. In mice, it was demonstrated 
that brain inflammation was associated with impaired spatial 
learning and memory function, and the administration of KD 
exerted protective effects against these. The proposed mode of 
action was through attenuation of the immune response and 
increased oxidative stress observed in the mice (22).
In humans, KD has been trialed in a number of neurological 
conditions. In a randomized, double-blind, placebo-controlled, 
parallel group study in Alzheimer’s disease, an oral ketogenic 
compound AC-1202 was tested on 152 patients. Regular medi-
cations were continued throughout the study. Daily dosing of 
AC-1202 significantly elevated the levels of beta-hydroxybutyrate 
2 h after administration. After 45 and 90 days, patients treated 
with AC-1202 had significant improvements on the ADAS-Cog 
scale (23). In a small study of seven patients with Parkinson’s 
disease, five adhered to KD for 28  days (24). Scores on the 
Unified Parkinson’s Disease Rating Scale improved in all five 
as did symptoms such as resting tremor, freezing, balance, gait, 
mood, and energy levels. These results should be interpreted with 
caution due to the small sample size, subjective ratings, and the 
lack of a control group to exclude a placebo effect. The modified 
Atkins diet (a high-fat, low-carbohydrate diet), which creates a 
ketotic state was trialed in adolescent patients with chronic daily 
headaches (25). Due to difficulties adhering to the diet, the study 
was terminated prematurely. Three participants reported an 
improvement in headache severity and quality of life; however, 
they still required pharmacotherapy to manage their condition. 
In a comprehensive review of KD in diverse neurological condi-
tions, Stafstrom and Rho concluded that there are rich opportuni-
ties for further investigation of KD in both the laboratory and 
clinical practice (26).
The therapeutic advantage of KD has been replicated in animal 
models of neurological illnesses, and the purported underlying 
mechanisms include those which improve mitochondrial func-
tion (27). Molecular, biochemical, and physiological studies 
tend to support the assumption that cellular energy status is a 
determinant for multiple disorders (28). Aberrant energy pro-
duction has been associated with cancer (29), heart failure (30), 
aging (31), and neurological conditions such as epilepsy (32) and 
Alzheimer’s disease (33). The precise pathways by which energy 
disruption is related to these and other disorders are unknown. 
There are also strong indications of metabolic pathways involv-
ing energy production in the pathophysiology of some mental 
disorders including bipolar disorder, depression, schizophrenia 
(34) autism spectrum disorder (ASD) (35), and potentially atten-
tion deficit hyperactivity disorder (ADHD) (36). There is also a 
recognized comorbidity between epilepsy and mental disorders 
(37), which might indicate some commonality of mechanisms.
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Given the degree of interest in KD and neurological condi-
tions, the aim of this narrative review is to examine the effect of 
the diet in mental disorders. The literature searched in anxiety, 
depression, bipolar disorder, schizophrenia, ASD, and ADHD.
MeTHOD
A comprehensive search of the electronic databases PubMed, 
PsychINFO, and Scopus for peer-reviewed articles published in 
English was conducted in the last week of November 2016 and 
updated in January 2017. Search terms were “bipolar disorder” 
“manic depress*” “depress*” “schizophren*” “autism” “ASD” 
“attention deficit hyperactivity disorder” “ADHD” “obsessive 
compulsive disorder” “OCD” “anxiety” “anxi*” “psychiatry” 
“mental disorder*” (group 1) AND “ketogenic diet” “ketosis” 
“ketogenesis” “ketone bodies” “high fat low carbohydrate” “diet” 
“acetone” “acetoacetic acid” “beta-hydroxybutyric acid” “acetyl-
coA” “ketonemia” “ketonuria” “fatty acid metabolism” “hyper-
ketonemia” “fasting” “nutritional ketosis” “acidotic” (group 2). 
These terms were combined as follows: group 1 AND group 2. In 
addition, a hand-search of the reference lists of published articles 
was also conducted, and articles were assessed for their suitabil-
ity in the review. An initial search was conducted using all the 
search terms listed above, and abstracts were reviewed by author 
Emmanuelle C. S. Bostock. Full text publications were retrieved 
for those that addressed the subject matter.
ReSULTS
The results are discussed by mental disorders examining animal 
and human studies including case reports and studies of patient 
groups. The search yielded 15 studies that examined KD in men-
tal disorders, specifically anxiety, depression, bipolar disorder, 
schizophrenia, autism, and, ADHD. These studies included nine 
animal models, and in humans four case studies and two uncon-
trolled trials. A summary of results by animal models and human 
studies are presented in Tables 1 and 2, respectively.
Anxiety
Anxiety is a common mental disorder affecting 18.1% of the 
population in the United States (52). In humans, functional 
magnetic resonance imaging indicates that anxiety is associated 
with activation in the ventromedial prefrontal cortex and hip-
pocampal regions of the brain (53). Symptoms of anxiety and 
disorders are more frequent in patients with epilepsy with one 
recent study reporting a lifetime incidence of 22.8% as opposed 
to 11.2% in people without epilepsy (54).
In a recent animal model study of anxiety in male rats, two 
methods of administration of exogenous ketone supplement were 
applied (38). In the chronic administration condition, 48 male 
Sprague-Dawley (SPD) rats were fed for 83  days with either a 
standard diet (n =  9) or standard diet plus one of four ketone 
supplementation conditions. In the sub-chronic intragastric 
gavage bolus condition, 39 SPD rats were fed with standard diet 
and gavaged daily with water (control, n = 11) or 1 of 3 levels 
of ketone supplementation for 7  days; this was repeated with 
32 Wistar Albino Glaxo/Rijswijk rats receiving a half-dose of 
supplementation. In both modes of supplementation, beta-
hydroxybutyrate was significantly elevated indicating ketosis. All 
treatment conditions resulted in reduced anxiety as assessed by 
behavior on the elevated plus maze. The dependent variables of 
less entries and time spent in closed arms, more entries and time 
spent in open arms, more distance traveled in open arms, and 
delayed entry to closed arm were used as an analog of anxiety 
in humans. The authors hypothesized that the mode of action 
was through the glutamatergic and/or GABAergic and purinergic 
systems.
Depression
In a recent review, a number of studies suggested that depression 
is associated with an increased risk of epilepsy (55). The effec-
tiveness of conventional antidepressant therapies is frequently 
examined in animals. In rodents, to test current levels of depres-
sion, a methodology known as the Porsolt forced swim test is 
often employed (56) and has been used in testing the effectiveness 
of new antidepressant drugs (57). In the two-part swim test, 
animals are first placed in a container from which they cannot 
escape. When they then stop trying and immobility ensues, a state 
of behavioral despair is shown. Second, to assess the effects of 
antidepressants, the time spent immobile is used as a dependent 
variable, and reductions are interpreted for significance (56). 
To examine the antidepressant properties of KD, 20 Wistar rats 
given the diet (4:1 lipid:non-lipid ratio) were compared to 20 fed 
a standard diet (39). It was found that rats on KD spent less time 
immobile than control rats thus providing some evidence for 
potential antidepressant effects of the diet. The diet duration was 
7 days, and levels of beta-hydroxybutyrate were measured.
Brain morphology and behavior of CD-1 mice exposed 
to KD (4:1 lipid:non-lipid ratio) for 30 days in utero and fed a 
standard diet in postnatal life were examined (40). Adult mice 
that were fed the diet in utero showed reduced susceptibility to 
anxiety and depression and exhibited elevated physical activity 
when compared with control mice fed a standard diet in utero. 
Morphological differences included cerebellar volumetric 
enlargement by 4.8%, a hypothalamic reduction by 1.39%, and 
a corpus callosum reduction by 4.77%, as computed relative to 
total brain volume.
While animal models pave the way for future research in 
humans, the conclusions that may be made are limited. The 
mechanism by which KD acts in animal models of depression 
is unknown; however, in children with epilepsy, KD resulted 
in significant alterations in levels of serotonin and dopamine 
neurotransmitters (58), both of which are implicated in anxiety 
and depression. To the best of our knowledge, there are no studies 
examining the effects of KD in depressed humans.
Bipolar Disorder
A diagnosis of bipolar disorder type I requires an episode of 
mania, which consists of “a distinct period of abnormally and 
persistently elevated, expansive or irritable mood, lasting at least 
1  week (or any duration if hospitalization is necessary)” (59). 
A diagnosis of bipolar disorder type II requires at least one episode 
of hypomania. In a study of nutrition and exercise behavior, when 
compared to patients with schizophrenia or healthy controls, it 
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TABLe 2 | Summary of findings in human studies.
Reference Condition Subjects (n) Mode of administration of diet Duration of 
diet
Ketone* Result
(46) BD Human women 
(2)
Ratio not mentioned in first but in 
second (70% fat, 22% protein, and 
8% carbohydrate)
2 and 3 years ✓ Mood stabilization
(47) BD Human woman 
(1)
4:1 lipid:non-lipid ratio 1 month No urinary 
ketones 
detected
No clinical improvement
(48) SZ Human women 
(10)
Not listed 2 weeks Not listed Statistically significant decrease in symptomatology
(49) SZ Human woman 
(1)
Not listed 12 months Not listed No recurrence of auditory or visual hallucinations
(50) ASD Human children 
(30)
30% MCT, 30% fresh cream, 11% 
saturated fat, 19% carbohydrate, 
and 10% protein
6 months 
(intervals of 
4 weeks with 2 
diet-free weeks)
✓ 40% non-compliance. Two children showed 
significant improvements on Childhood Autism 
Rating Scale, while the rest showed mild-to-
moderate improvements
(51) ASD Human child (1) 1.5:1 lipid:non-lipid ratio Several years ✓ Score on the Childhood Autism Rating Scale 
decreased from 49 to 17 (severe autism to 
non-autistic)
DEP, depression; BD, bipolar disorder; SZ, schizophrenia; *, ketone levels reported; MCT, medium-chain triglyceride; ASD, autism spectrum disorder.
TABLe 1 | Summary of findings in animal models.
Reference Condition Subjects (n) Mode of administration of 
diet
Duration of 
diet
Ketone* Result
(38) ANX Sprague-
Dawley (48) and 
Wistar Albino 
Glaxo/Rijswijk 
rats (32)
Exogenous ketone supplement 83 or 7 days 
via oral 
gavage
✓ Reduced ANX-related behavior
(39) DEP Wistar rats (20) 4:1 lipid:non-lipid ratio 7 days ✓ Some evidence for potential antidepressant properties
(40) DEP CD-1 mice (20) 4:1 lipid:non-lipid ratio in utero 
and SD in postnatal life
30 days ✓ Those fed KD in utero showed reduced susceptibility to ANX 
and depression and increased hyperactivity
(41) SZ C57Bl/6 mice 
(?)
77.6% fat, 9.5% protein, and 
4.7% crude fiber, AD fiber 
4.7%
3 weeks ✓ Normalized pathological behaviors including psychomotor 
hyperactivity, stereotyped behavior, social withdrawal, and 
working memory deficits
(42) ASD Swiss mice (16) (Lard 690 g/kg, sunflower oil 
5 g/kg, protein 250 g/kg, fiber 
10 g/kg, ash 5 g/kg)
In utero 
exposure to 
KD (70 days)
– Statistically significant social deficits and stereotypies that are 
common behaviors in those with ASD
(43) ASD Wistar rats (6) 6:1 lipid:non-lipid ratio 10–14 days ✓ KD had a significant effect and was able to modify complex 
social behaviors in valproic acid and control rats
(44) ASD BTBR mice (?) 6.3:1 lipid:non-lipid ratio 14 days ✓ Temporal cortex and hippocampus brain regions showed 
improvements on autistic deficits associated with myelin 
formation and white matter development
(45) ASD EL mice (?) 3.0:1 or 6.6:1 lipid:non-lipid 
ratio
3–4 weeks ✓ Social novelty test—females fed higher KD ratio exhibited 
significant preference to the new mouse. Self-grooming 
significantly decreased in males
(36) ADHD Dogs (21) 10% moisture, 28% protein, 
15% fat, 6% ash, 2% crude 
fiber, and MCT oil
6 months ✓ Significant improvement in ADHD-related behaviors
ANX, anxiety; DEP, depression; BD, bipolar disorder; SZ, schizophrenia; *, ketone levels reported; ?, unknown sample size; MCT, medium-chain triglyceride; ASD, autism spectrum 
disorder; ADHD, attention deficit hyperactivity disorder; KD, ketogenic diet.
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was found that patients with bipolar disorder were more likely to 
report risk factors for poor nutrition including difficulty obtain-
ing or cooking food (60). Treatments for bipolar disorder typically 
include an antipsychotic and a mood stabilizer, and many patients 
are treated with adjunct anticonvulsants.
In a case study of two women with bipolar disorder type 
II, the patients maintained ketosis for an extended period of 2 
and 3 years, respectively. The women reported subjective mood 
stabilization, which exceeded that of medication as well as an 
overall improvement in their condition that they related to ketosis 
(measured in the urine). Both women tolerated the diet well with 
few or no side effects reported (46). The ratio of KD was not 
mentioned in the first case, but in the second it was estimated to 
be around 70% fat, 22% protein, and 8% carbohydrates.
In a separate case study, a woman with treatment-resistant 
bipolar disorder was placed on KD (4:1 lipid:non-lipid ratio) and 
showed no clinical improvement (47). It should be noted that no 
urinary ketones were detected, the type of bipolar disorder was 
not listed (type I or type II), and treatment duration limited to 
1 month.
These studies illustrate that careful attention should be paid 
to the intricacies of the diet (such as measuring ketones and 
calculating macronutrient ratios) to fully examine its efficacy 
in bipolar disorder, as well as the need for larger well-designed 
placebo-controlled studies in this area. The mechanism by 
which KD may be effective in bipolar disorder is based on the 
hypothesis that acidosis achieved through ketosis reduces intra-
cellular sodium and calcium, both of which are elevated in the 
disorder (47). Mood stabilizers reduce intracellular sodium in 
an activity-dependent manner within the context of KD; this is 
hypothesized as being achieved through the acidification of the 
blood (46).
Schizophrenia
Schizophrenia is associated with high levels of morbidity. The 
precise pathophysiology of the disorder is unknown, and current 
pharmacological treatment options are limited (61). Animal 
models of schizophrenia fit into four induction methods includ-
ing developmental, drug-induced, lesional, or genetic manipula-
tion (62). In a recent drug-induced (MK-801, dizocilpine) animal 
model of schizophrenia in C57BL/6 mice, it was demonstrated 
that 3 weeks of KD (77.6% fat, 9.5% protein, and 4.7% crude fiber, 
AD fiber 4.7%) normalized pathological behaviors (41). These 
included psychomotor hyperactivity, stereotyped behavior, social 
withdrawal, and working memory deficits, which reflect the posi-
tive, negative, and cognitive symptoms of the disorder. Weight 
loss was an observed side effect. Elevated levels of the ketone 
beta-hydroxybutyrate and decreased glucose levels indicated that 
metabolic adaptation had occurred.
In a 1965 study, the effect of KD was tested in 10 female 
patients with schizophrenia. All participants were reported to 
have a poor prognosis and were not treatment responsive at the 
time. Concurrent therapies remained throughout the duration 
of the diet including pharmacotherapy and electroconvulsive 
therapy. The Beckomberga Rating Scale was administered to 
patients three times during the diet period (2 days, 2 weeks, and 
1 week after discontinuation), there was a statistically significant 
decrease in symptomatology after 2  weeks of established KD 
(48). This was, however, a small, poorly controlled study, and in 
addition, the lipid:non-lipid ratios were not detailed, and it was 
not stated whether ketone levels were measured throughout the 
study. A further consideration is that the study was conducted 
in 1965 before the advent of atypical antipsychotics and their 
metabolic side effects.
In a case study of a 70-year-old overweight woman with a diag-
nosis of schizophrenia, KD was initiated by her treating physician 
(49). The patient remained on KD for 12 months and reportedly 
had no recurrences of auditory or visual hallucinations, and 
the patient lost weight. The patient reported eating mainly lean 
proteins and low-carbohydrate vegetables (the lipid:non-lipid 
ratio was not listed), ketosis was not confirmed and perhaps not 
established due to the lack of dietary fats listed; therefore, this case 
report is of indeterminate value.
Some studies suggest that abnormal glucose and energy 
metabolism may underlie the pathophysiology of schizophrenia, 
which may provide some potential pointers into the hypothesized 
mode of action of KD in the disorder (63, 64). Others have noted 
that abnormal glucose metabolism may occur secondary to antip-
sychotic medications alongside significant treatment side effects 
such as weight gain, hyperglycemia, and diabetes (65). The high 
metabolic risk associated with schizophrenia is due to genetic and 
environmental factors (66).
Autism Spectrum Disorder
Features of patients with ASD include compromised social inter-
action and communication (67). It is estimated that between 5 
and 40% of patients with autism will develop epilepsy (68), and 
while most patients will respond to pharmacotherapy, in one 
study, 34% of 170 patients had medically refractory epilepsy (69). 
The precise pathogenesis of ASD remains unknown, but genetic 
and environmental factors have been known to contribute to its 
onset. One such factor is exposure to valproic acid (VPA) in utero, 
which is associated with a 12% incidence of ASD in children (70) 
and is used as an animal model of induction of ASD (42).
Using the animal model of autism induced by prenatal expo-
sure to VPA in mice, the effects of KD were examined. Pregnant 
Swiss mice received a single intraperitoneal injection of 600 mg/
kg of VPA (n = 26) or saline (n = 18) on gestational day 11. At day 
21, 16 VPA treated and 16 control mice were used. Half of each 
group was fed KD (lard 690 g/kg, sunflower oil 5 g/kg, protein 
250 g/kg, fiber 10 g/kg, ash 5 g/kg), while the other received a 
standard diet. Ketone levels were not measured. After 70  days 
on KD, a statistically significant result was found in mice with 
VPA in behaviors such as social deficits and stereotypies that are 
common behaviors in those with ASD (42). It is also believed that 
mitochondrial dysfunction may play a role in the onset of ASD 
(35). Ahn et al. (43) aimed to determine if KD could reverse the 
social deficits and mitochondrial dysfunction seen in a prenatal 
VPA animal model of autism using Wistar rats. On postnatal day 
21, rats were placed on either KD (6:1 lipid:non-lipid ratio) or 
standard diet for 10–14  days. Beta-hydroxybutyrate was meas-
ured. KD had a significant effect and was able to modify complex 
social behaviors in VPA and control rats and mitochondrial 
respiration (43).
Thesis page 62
6Bostock et al. KD in Psychiatry
Frontiers in Psychiatry | www.frontiersin.org March 2017 | Volume 8 | Article 43
Another animal model of autism using the inbred BTBR 
mouse strain that exhibits three core features of autism, includ-
ing reduced sociability, communication, and increased repetitive 
behavior, was studied (71). In another study, 33 genes were 
differentially expressed in the temporal cortex and 48 in the 
hippocampus suggesting deficits in the stress response and in 
neuronal signaling and communication in BTBR mice. After 
14  days on KD (6.3:1 lipid:non-lipid ratio), both brain regions 
showed improvements on autistic deficits associated with myelin 
formation and white matter development (44). One study has 
found that in BTBR mice, KD reduces total gut microbial and 
compositional remodeling of the mouse microbiome providing a 
potential explanation as to its efficacy in this model (72).
In an animal model with behavioral characteristics of ASD 
and comorbid epilepsy in male and female EL mice, the effect of 
KD was assessed (45). Testing occurred at 8–9 weeks postpartum 
following 3–4 weeks of dietary treatment. Animals were fed either 
a standard diet or one of two KDs (3.0:1 or 6.6:1 lipid:non-lipid 
ratio). KD raised ketones in all groups, but the higher fat ratio 
deepened ketosis. Both KDs significantly increased sociabil-
ity, time spent in the chamber with another mouse, in females 
and males. Social novelty, preference for a newly introduced 
mouse was higher in females fed the higher KD ratio. The test of 
repetitive behavior (self-grooming) was significantly decreased 
in males but was non-significant in females. This study provides 
some intriguing results regarding the effects of sex and KD in a 
mouse model of ASD and idiopathic epilepsy.
The role of KD in ASD has been examined in a pilot study 
of 30 children (50). The diet (30% of energy as MCT oil, 30% 
fresh cream, 11% as saturated fat, 19% carbohydrates, and 10% as 
protein) was administered for 6 months with intervals of 4 weeks 
with 2 diet-free weeks. Of the total sample, 40% did not comply 
or did not tolerate the diet. Urinary ketones were measured. In the 
remaining sample, two children showed significant improvements 
on the Childhood Autism Rating Scale, while the rest showed 
mild-to-moderate improvements. As observed in patients with 
epilepsy, after the termination of KD the benefits persisted, which 
raise intriguing questions regarding the effects of plasticity.
In a case study of a child with autism and epilepsy, following 
standard treatment non-response, the individual was placed 
on KD (1.5:1 lipid:non-lipid ratio) with adjunct anticonvulsant 
therapy (51). The patient was in ketosis. After initiation of the 
diet several benefits ensued including the resolution of morbid 
obesity and the improvement of cognitive and behavioral features 
of the disorder. After several years on the diet, the patient’s score 
on the Childhood Autism Rating Scale decreased from 49 to 17, 
a change from a rating of severe autism to non-autistic, and IQ 
increased by 70 points. Fourteen months following the initiation 
of the diet the patient was also seizure free.
The suggested mechanisms of action of KD in ASD include 
that it may reduce pain sensitivity through the reduction 
of glucose and may have anti-inflammatory properties as it 
reduces swelling and plasma extravasation (42). In a systematic 
review of KD in ASD it was concluded that the limited number 
of reports of improvements after treatment with the diet is not 
sufficient to attest to the practicability of KD as a treatment for 
the disorder (73).
Attention Deficit Hyperactivity Disorder
Attention deficit hyperactivity disorder is characterized by a 
lack of behavioral inhibition and by neuropsychological deficits 
in four areas, including working memory, self-regulation of 
affect–motivation–arousal, internalization of speech, and behav-
ioral analysis and synthesis (74). ADHD is the most commonly 
occurring mental disorder in children and adolescents with 
epilepsy occurring in 16 (29.1%) of 78 patients (75). Children 
with ADHD have a high frequency of epileptiform discharges as 
observed by EEG (76). In a prospective study of children with 
epilepsy (n = 34) on KD it was found that after 1 year on the diet 
there was a statistically significant improvement of attention and 
social functioning (77).
There is little evidence examining ADHD and KD, but a 
6-month prospective, randomized, double-blinded, placebo-
controlled, crossover dietary trial compared the effects of 
KD (10% moisture, 28% protein, 15% fat, 6% ash, 2% crude 
fiber, and MCT oil) or a standard diet on behavior in 21 dogs 
with comorbid ADHD and idiopathic epilepsy (36). It was 
hypothesized that there were three specific behaviors related to 
ADHD in dogs including excitability, chasing, and trainability. 
ADHD in dogs is manifested as inattention and excitability/
impulsivity, which have been likened to the disorder in humans 
(78). When compared with the standard diet, KD resulted in 
a significant improvement in ADHD-related behaviors. Serum 
beta-hydroxybutyrate was measured. The mechanisms of behav-
ioral improvements during KD remain unknown. The authors 
postulated that alterations of energy metabolism in the brain 
may contribute to behavioral changes. Research into humans 
with ADHD and KD is lacking.
DiSCUSSiON
In neurology, KD is an established treatment option for 
treatment-resistant epilepsy with evidence from a range of 
studies including controlled trials. By contrast, KD research in 
humans with mental disorders, though extending over a 50-year 
period, has received little attention with few studies other than 
case reports, small sample size open studies, and no controlled 
trials. Animal studies have been more systematic, investigating 
mechanisms as well as outcomes on putative disease analogs in 
rodents and canines, the latter including randomized controlled 
trials of KD.
With respect to mechanisms, the pathophysiology of the 
mental disorders covered in this review is not clearly understood, 
though impaired metabolism due to mitochondrial dysfunc-
tion has been identified as an important substrate (34). This is 
congruent with findings in neurological conditions, Stafstrom 
and Rho concluding that energy metabolism changes induced 
by KD in neurological conditions suggest a final common 
pathway implicating mitochondrial function (26). KD may also 
influence neuronal plasticity by modifying neural circuits and 
cellular properties to normalize function (26). Mitochondrial 
dysfunction may be relevant in some mental disorders including 
schizophrenia, ASD, and ADHD, whereas the improvements 
seen in anxiety, depression, and bipolar disorder may be related 
to alterations of neurotransmitters.
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One other possible mediator of the beneficial effects of KD in 
mental disorders is the effect on sleep. In a study of 18 children 
with treatment-resistant epilepsy, after 3 months of KD sleep was 
reported to be enhanced with a pattern of significant reduction in 
total night sleep, preservation of slow-wave sleep, increased rapid 
eye movement (REM) sleep, and decrease in sleep stage 2 (79). 
The mechanisms by which KD affects sleep is unclear (80), and 
more studies are necessary to confirm reports that certain dietary 
patterns and foods improve sleep (81).
Sleep problems and mental disorders are codependent condi-
tions that exacerbate each other and lead to impaired quality 
of life and increased disability (82). Impairments of sleep are a 
widespread feature of mental disorders. Anxious patients have 
been found to have significantly less sleep period time, total 
sleep time, percentage stage REM and percent stage 4 sleep, 
shorter latency to stage REM, and greater percent stage 1 sleep 
than healthy controls (83). REM sleep abnormalities including 
shortening of REM latency, lengthening of the duration of the 
first REM period, and heightening of REM density are found 
in patients with depression (84). In patients with inter-episode 
bipolar disorder, shorter sleep onset latency and increased REM 
density has been observed (85). A decrease of REM sleep latency 
in schizophrenia has been described (86). Individuals with ASD 
have prolonged sleep latency, more frequent nocturnal awaken-
ings, lower sleep efficiency, increased duration of NREM stage 1 
sleep, and decreased deeper stages of NREM sleep (87). In ADHD, 
disturbed sleep architecture has been described including shorter 
REM latencies, reduced REM sleep, and increased delta sleep 
percentage (88). It should also be noted that sleep deprivation can 
precipitate mania in bipolar disorder and seizures in epilepsy (89) 
and can be used as a treatment for depression (90). The specific 
effects of KD on these mental disorder-related sleep symptoms 
has not been studied in detail, but interactions are likely and may 
be possible mediators of a therapeutic effect.
In epilepsy, KD acts differently to antiepileptic drugs (AED) 
in seizure prevention. While AED act directly on ion channels 
and synaptic processes, KD acts through intermediary metabolic 
pathways (91). Chang et al. showed that an MCT (palm oil and 
coconut oil) diet, a variation of KD, reduces seizures in children 
via inhibition on AMPA receptors (12, 92, 93). The questions 
posed by the literature indicate that the mechanism of action 
is still unknown, and there may be many potential pathways 
involved. The mechanism of action appears different from AED 
and therefore probably psychiatric drugs also, which opens 
potential avenues for treatment in a manner that may supplement 
conventional pharmacological treatment approaches. The exact 
mechanism of action of KD is unclear, and for detailed discussion, 
see Rogawski et al. (91). Thus, present knowledge indicates that 
KD exerts its effects on seizure control by mechanisms different 
from conventional AED and therefore, in psychiatry, this may 
also be the case although as yet unproven.
There are a number of reasons why the effectiveness of KD 
in mental disorders remains unproven. In addition to the low 
number of human studies, the quality of the studies has some 
significant limitations. Sample sizes are small, there is no control 
for placebo effects, and the establishment of ketosis is generally 
lacking with no confirmatory measurement of ketones in three 
human studies. There are also significant limitations associated 
with the diet itself including the detailed regimen, unpalatable 
food choices, side effects, and duration of diet required. There are 
also no enforced standards as to what constitutes KD in humans 
with variable lipid:non-lipid ratios reported. KD monotherapy is 
used in animal models of mental disorders but remains unexam-
ined in human studies. Ten adult patients with epilepsy followed 
KD monotherapy, and it was concluded that it may be feasible, 
well tolerated, and an effective long-term alternative (94).
To comply with KD, patients who may be acutely unwell are 
required to measure food portions to ensure that the macronutri-
ent targets associated with the diet are met, and they may find 
it difficult to adhere to such a demanding diet (47). This is par-
ticularly so for patients with mental disorders where symptoms 
such as impulsivity in mania, apathy, and reduced appetite in 
depression, food cravings, and binge eating associated with antip-
sychotic medications may variously interfere with compliance 
with KD (95). A mitigating factor to the outcomes in children 
with epilepsy may be that the diet is typically administered in a 
hospital setting initially and subsequently, by caregivers.
El-Mallakh and Paskitti have outlined the adverse conse-
quences of KD including constipation, menstrual irregularities, 
elevated serum cholesterol and triglycerides, hypoproteinemia, 
hemolytic anemia, elevated liver enzymes, and gall stones (96). 
Kidney stones have been noted to occur in 1 of 20 children on the 
diet (97). In a period of almost 2 years, prospective monitoring of 
52 children with pediatric epilepsy was conducted. Ten percent 
of children experienced serious adverse events associated with 
the diet 1 month after initiation (98). This included presacral and 
periorbital edema, developmental impairment, and unwanted 
weight loss in an infant, renal tubular acidosis, viral gastroen-
teritis, abnormal liver function, and thrombocytopenia. It should 
be noted that all patients were being treated with concomitant 
VPA. It was reported in a retrospective study of 158 children 
with intractable epilepsy that, in 80% emesis, food refusal and 
hypoglycemia occurred (99).
By definition, KD is confirmed by the production of ketones 
measured in the blood or urine. In the reviewed literature cover-
ing KD in mental disorders, four studies did not report ketone 
levels, which severely limit comparability across studies and the 
ability to invoke any consistent mechanism. One study compared 
whether measuring serum beta-hydroxybutyrate or urinary 
ketones was superior to monitor KD (100). In humans, it was 
found that beta-hydroxybutyrate correlated more strongly with 
a reduction in seizures than urinary ketones; therefore, future 
studies should measure ketones in the blood. Another issue is 
that the lipid:non-lipid ratios used were different (see Tables 1 
and 2). In a study that compared the efficacy and tolerability of 
the 3:1 versus the 4:1 lipid:non-lipid ratios, the latter was shown 
to have a higher seizure-free outcome (2).
One issue when interpreting the results is the levels of evi-
dence in the evidence-based hierarchy. Animal models of mental 
disorders are considered valuable preclinical tools to investigate 
the neurobiological basis of a disorder (62). While this may be 
true, they are nonetheless subject to a number of limitations. One 
such limitation is the issue of validity, and their use is based on the 
assumption that humans and animals share basic neurobiological 
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mechanisms associated with the complex behaviors that mimic 
mental disorders in animals (101).
Another difficulty posed to practitioners is that there are cur-
rently no international protocols guiding the administration of 
the diet; this is something that may be established from future 
research into KD. There was only one case study that detailed 
what the participant, diagnosed with schizophrenia, ate, and it 
was not established whether this individual was in ketosis. In the 
various studies in humans, outcomes were assessed following 
dietary durations that varied from 7 days to 2 years.
Further research into the neural correlates of KD is needed to 
help explain the mechanisms by which it acts. Some suggestions 
regarding methodologies, provided by Fusar-Poli are elaborated 
below. Changes in glucose metabolism seen in KD could be 
examined using positron emission tomography fluorodeoxy-
glucose. To observe the neural correlates of KD, a combination 
of electrophysiological measures including EEG and magne-
toencephalogram and fMRI/PET to combine the high temporal 
resolution of the former with the high spatial resolution of the 
latter may be used (102).
In the neurological literature, a single study, in Alzheimer’s 
disease, used a synthesized ketogenic compound AC-1202 rather 
than a KD. AC-1202 is an MCT composed of glycerine and 
caprylic acid (23). It is not yet clear what role ketogenic pharma-
cotherapy options might play alongside or as a substitute for KD.
While these animal studies are placing research into KD on a 
firm footing and identifying some promising leads, on balance 
the evidence in humans is insufficient to form an opinion as to the 
efficacy or lack thereof of this intervention in the mental disorders 
reported. Further basic research to clarify the specifics of dietary 
manipulation or supplementation required to produce optimum 
ketosis in specific models is an obvious intermediate step toward 
studying the effectiveness of the diet in human mental disorders 
using conventional phases of research including open-label stud-
ies and randomized controlled trials.
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Background: DSM-5 introduced the diagnostic category of
substance/medication-induced bipolar and related disorder. This systematic review
examines published reports linking mania with the consumption of herbal medicines
(HM), excluding cannabis. Putative pathophysiological mechanisms that may account
for the reported HM being associated with mania are discussed.
Methods: A systematic search of EMBASE, CINAHL, Health Source, PsychINFO, and
PubMed. The quality of case reports meeting inclusion criteria was assessed using the
modified Quality Assessment Scale by Agbabiaka.
Results: Nineteen single and seven multiple-case reports met inclusion criteria. These
yielded a study sample of 35 case reports, 28 of herbal medicine associated mania, 5 of
hypomania, and twomixed states, in 17 females [age in years M(SD)= 43.1(13.2)] and 18
males [40.7(18.1)]. A total of 11 herbal medicines were implicated. Case reports by herbal
medicine (number of reports) comprised: St John’s wort (Hypericum perforatum) (14);
Ginseng (Panax ginseng) (5); brindleberry (Garcinia cambogia) (4); ma-huang (Ephedra
sinica) (3); “herbal slimming pills” (2); Herbalife products (2); Hydroxycut (1); horny
goat weed (Epimedium grandiflorum) (1); “herbal body tonic” (1); celery root (Apium
graveolans) (1), and a “herbal mixture” (1). All case reports were associated with use
rather than withdrawal of herbal medicines. Only one case report was rated for probability
of association using a standardized algorithm. Laboratory assays to confirm composition
of the herbal preparation were reported in only one article describing two cases and
indicating admixture of a likely causal pharmaceutical in the herbal preparation.
Conclusions: Causal attributions are problematic given the limited number of reports,
antidepressant co-prescribing in 7 cases, insufficient data regarding pattern and type
of herbal medicine use, and lack of a reference frequency for spontaneous mania.The
quality assessment scores across the 26 papers (35 case reports) were as follows:
low quality (0), lower-medium quality (9), upper-medium quality (10) and high quality
(7). Putative pathophysiological mechanisms were postulated for nine of the 11 herbal
medicines and centered on HPA-axis activation and increased monoamine activity.
Thesis page 69
Bostock et al. Mania Associated With Herbal Medicines
Systematic study of the association between herbal medicines and the course of bipolar
disorder may contribute to defining targets for pathophysiological research.
Keywords: herbal medicine, case report, bipolar disorder, mania, phytotherapy
INTRODUCTION
DSM-5 introduced the diagnostic category of
“substance/medication-induced bipolar and related disorder.”
This diagnosis requires a temporal association between
occurrence of mania and the use or withdrawal of substances or
medications. The precipitating agents may include intoxicating
drugs such as cannabis or amphetamines, prescribedmedications
for mood disorders such as antidepressants, prescribed
medications for other illnesses such as steroids, and herbal
medicines (HM). DSM-5 sets a less restrictive standard for the
diagnosis of substance/medication-induced bipolar and related
disorder than for mania. Criterion A for mania, as required
for a diagnosis of bipolar disorder, is “A distinct period of
abnormally and persistently elevated, expansive, or irritable
mood and abnormally and persistently increased activity or
energy, lasting at least 1 week and present most of the day,
nearly every day (or any duration if hospitalization is necessary)”
(1). This compares with criterion A for substance/medication-
induced bipolar and related disorder “a prominent and persistant
disturbance in mood that predominates in the clinical picture
and is characterized by elevated, expansive or irritable mood.”
The concept of substance/medication-induced mania
antedates the DSM-5 classification, for example it was denoted
as bipolar disorder-III in Akiskal’s classification of bipolar
spectrum disorders (2). Mania associated with the antidepressant
medication imipramine was reported by Ball and Kiloh (3) and
mania has also been associated with lithium withdrawal (4).
The first reported association of mania with a HM was in 1984
by Price et al. who explored the relation of yohimbine, an α-2
adrenergic receptor antagonist, to mania under experimental
conditions (5). A number of substances have beneficial effects
in bipolar disorder and are prescribed medications in routine
treatment of mania for example lithium, sodium valproate and
atypical antipsychotics, and in bipolar depression for example
lithium, lamotrigine, atypical antipsychotics and selective
serotonin reuptake inhibitors (6). Their precise mechanism of
action is not fully understood, reflecting a lack of understanding
of the pathophysiology of mania and depression. The study
of substance/medication-induced bipolar and related disorder,
notwithstanding limitations of causal attributions, may further
our understanding of brain mechanisms relevant to the
occurrence and course of bipolar disorder. This is particularly so
for mania which has a strikingly unique set of clinical features, is
often of abrupt onset and has a relatively short duration with a
median of 13 weeks (7).
Many conventional drugs originate from plant sources (8).
HM or phytotherapy refers to the use of plant-based medicinal
preparations, a subset of complementary and alternative
medicines (CAM). In the United States, HM are regulated
as food products and therefore are not subject to the phases
of clinical testing that pharmaceuticals must undergo prior to
market release. Manufacturing standards are in keeping with
those applicable to other foods (9), the strength and composition
of HMmay therefore vary widely.
According to survey data, the use of CAM is prevalent and
increasing throughout many Western countries (10–12). CAM
usage is common in persons with psychiatric illness. In a survey
of CAMusage among psychiatric inpatients (n= 82) it was found
that 63% used at least one CAM modality within the previous
12 months, including 44% who used HM (13). This may be
attributed in part to factors such as side effects of conventional
medicines, ready access without prescription, a belief that HM
cause no harm, and in the case of bipolar illness, traits such as
novelty seeking in mania or hypomania (14, 15). In a survey
of 826 new patients presenting at a CAM clinic, 578 (70%)
had a mental disorder and reported lower quality of life and
greater levels of stress than those without a mental disorder.
Among patients with a mental disorder, the major reasons for
choosing complementary therapies were personal preference,
interest, or beliefs in complementary therapies (44.3%) including
as a treatment of last resort (30.7%) (16).
In a cross-sectional survey of 100 older (>55 years) inpatients
and outpatients with bipolar disorder (n = 50) or major
depression (n= 50), the use of herbal and nutritional compounds
(HNC) was examined to determine several factors including,
knowledge of products, perceived efficacy and safety, patterns
of use and discussion of use with health care providers.
Approximately 30% of respondents reported using oral HNC,
40% thought that they were Food and Drug Administration
regulated and 14–20% preferred to take HNC to psychotropic
medications (17).
A review of CAM therapies in the treatment of bipolar
disorder, noted that few rigorous clinical studies have been
conducted in this patient population (14). The herbal preparation
Free and EasyWanderer Plus has been examined as an adjunct to
carbamazepine (CBZ) in a double-blinded, randomized placebo-
controlled trial in patients with bipolar disorder in manic and
depressive phases (18). When compared to CBZ monotherapy,
at week 4 and 8 of the trial, the HM combined with CBZ
resulted in significant improvement in depression but not
mania.
Although cannabis has largely been seen as an illicit drug, it
is now entering into conventional medicine under the rubric of
“medicinal cannabis.” Cannabis has been extensively researched
in relation to its acute and chronic effects in psychosis. Discussion
of the role of cannabis in bipolar disorder is beyond the
scope of this article but is summarized in a systematic review
and meta-analysis by Gibbs et al. (19). This reported that, on
balance, in pre-existing bipolar disorder, cannabis may worsen
the occurrence of manic symptoms and may also act as a causal
risk factor in the incidence of manic symptoms.
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This paper presents a systematic review of single andmultiple-
case reports of mania associated with herbal medicines other
than cannabis. A more comprehensive understanding of what
precipitates mania in vulnerable individuals may potentially lead
to new understandings of the illness and the substrates that are
implicated in bipolar disorders.
METHOD
This review of reports of herbal medicine-associated mania was
conducted in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines
(20).
Inclusion Criteria: (a) published between 1980–2017 (b) in a
peer-reviewed journal (c) included adult participants (> 18 years)
(d) published in the English language. Exclusion criteria: (a)
psychosis in the absence of manic features (b) secondary manias
due to infection, neoplasm, epilepsy, and metabolic disturbances
(c) systematic reviews (d) relating to cannabis.
Identification of Studies
In the first week of September 2017, a search of the electronic
databases EMBASE, CINAHL, Health Source, PsychINFO and
PubMed was conducted to find published associations between
HM and mania. The search was commenced by identifying in
each database the controlled vocabulary terms/ subject terms
related to herbal medicines (group 1) and bipolar disorder
(group 2). All subject terms were exploded. Subject terms in the
respective databases for group 1 were herbal medicine (PubMed);
herbal medicine and medicinal herbs and plants (EMBASE and
PsychInfo); medicine and herbal medicine (CINAHL and Health
Source). Additionally, 182 free text terms that related to herbal
medicines, including botanical names, (see Appendix 1) were
combined with “OR.” Subject terms for group 2 were bipolar
disorder, cyclothymic disorder (PubMed); bipolar disorder,
cyclothymia (EMBASE and PsychInfo); and bipolar disorder
(CINAHL and Health Source). The free text terms bipolar
disorder, mania, cyclothymia, manic-depressive psychosis, manic
state, bipolar depression and manic disorder were searched for
and combined with “OR.” Finally, group 1 and group 2 were
combined with “AND.”
A purpose-built coding sheet was used to assess articles against
the inclusion criteria. To assess accuracy of initial screening KK
and EB separately rated 20 titles and abstracts, randomly selected
from the records screened using the RANDBETWEEN function
in Microsoft Excel version 15.23.2. Inter-rater agreement on
exclusion/inclusion was 100%.
Quality Assessment of Case Reports
Authors EB and KK individually assessed all included case
reports for quality, according to the following nine criteria:
classification on Quality Assessment Scale by Agbabiaka; use of
a validated instrument to assess for causality (Naranjo or WHO-
UMC score); botanical name of herbal medicine stated; herbal
material assessed for authentication; herbal material assessed for
adulteration; characteristics of herbal medicine detailed (e.g.,
plant part, extract type); product brand name and manufacturer
detailed; batch numbers; herbal dosage specified. The case report
Quality Assessment Scale by Agbabiaka (21) as modified by
Hung, Hillier and Ernst (22) has 21 questions rated as “yes,”
“unclear,” and “no,” each item scored between 0 and 2 points for
a total score out of 42 points. Each case report was classified as:
low quality (0-14 points), lower medium quality (15–21 points),
upper medium quality (22–28 points) or high quality (29–42
points) as recommended by Agbabiaka (21).
After each paper had been assessed EB and KK discussed
the results and came to a consensus score. Inter-rater reliability
on the Quality Assessment Scale by Agbabiaka was calculated
using several indices: raw agreement (number of agreements
for individual items divided by number of possible agreements),
kappa coefficient and intraclass correlation coefficient (ICC).
Raw agreement ranged from 52.4 to 95.2% for individual articles
with mean raw agreement 75.6% (95% CI [71.2%, 80.1%]).
Separate kappa coefficients were calculated between the two
raters for all items on each of the 26 articles. To obtain mean
kappa, the 26 kappa coefficients were first transformed using
Fisher’s transformation to achieve linearity. The mean and 95%
CIs were calculated, then back-transformed to original kappa
units. Individual kappa coefficients ranged from 0.16 to 0.92.
Mean kappa was 0.60 (95% CI [0.50, 0.68]). Applying the criteria
of Landis and Koch this represents a moderate-to-substantial
level of agreement (23). The ICC between the two raters was
calculated from the total score for each article using two-way
ANOVA (24). Each item on the scale was rated as 0, 1, or 2. With
21 items the maximum possible score for an article was 42. Rater
and article were treated as separate, random effects in the model.
For total scores the means were 24.5 (SD = 6.2) for EB and 24.7
(SD = 5.6) for KK. The inter-article correlation between raters
was 0.70 (95% CI [0.42, 0.85]). The ICC was 0.82 (95% CI [0.60,
0.92]) indicating a good-to-excellent level of agreement (25).
RESULTS
The results of the search strategy are summarized in the PRISMA
diagram (Figure 1). There were no randomized clinical trials
of HM in mania. The study sample comprised 35 case reports,
from 19 single and 7 multiple-case reports, of an association
between mania and use of HM. Details of each case report are
summarized in Table S1, including clinical and demographic
details, the composition of the HM, other medications, and
treatment outcomes.
In summary, the reports included 17 females [age in years
M(SD) = 43.1(13.2)] and 18 males [40.7(18.1)]. Case reports,
grouped by HM (number of reports) comprised: St John’s
wort (Hypericum perforatum) (14); Ginseng (Panax ginseng)
(5); brindleberry (Garcinia cambogia) (4); ma-huang (Ephedra
sinica) (3); “herbal slimming pills” (2); Herbalife products (2);
Hydroxycut (1); horny goat weed (Epimedium grandiflorum)
(1); “herbal body tonic” (1); celery root (Apium graveolans)
(1), and “herbal mixture” (1). Fourteen cases were taking
concurrent prescription medications, comprising antidepressant
(SSRI 3; SNRI 2; tricyclic 1; NDRI 1); lithium (1); antipsychotic
(2); atypical antipsychotic (1); anti-epileptic (2); statin (2);
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FIGURE 1 | Preferred reporting items for systematic reviews and meta-analysis flow diagram of included studies.
beta-blocker (1); NSAID (2); sildenafil (1) and a synthetic
glucocorticoid (1). A psychiatric history was noted in 24 of the
35 cases of HM-associated mania, diagnoses included depression
(n = 11) bipolar disorder type I (BDI) (n = 5), bipolar disorder
type II (BDII) (n = 2), post-traumatic symptoms (n = 1),
eating disorder (n = 2), past suicide attempt (n = 1) and
substance/medication-induced bipolar and related disorder (n=
1). For the whole sample the time to onset of manic symptoms
from commencing the HM was between 2 days and 2 years with
a median of 4 weeks.
St John’s Wort (Hypericum perforatum)
Fourteen case reports described mania, hypomania and two
mixed states associated with St John’s wort, in seven females [age
in years M(SD)=49.4(12.4)] and seven males [39.4 (17.8)]. Stated
reasons for taking St John’s wort were depression (12) (26–34),
to improve energy (1) (29) and to relieve symptoms of post-
traumatic stress (1) (29). The time of onset of manic symptoms
from commencing HM ranged from 3 days to 2 months. The
mental status on examination was consistent with mania and two
mixed state in the 14 cases. Three cases had a past psychiatric
history of bipolar disorder, and eight of unipolar depression of
whom four were concurrently taking antidepressants. In eight
cases, the dose of the St John’s wort preparation was not specified.
Ginseng (Panax ginseng)
There were five case reports of Ginseng-associated mania in
our study sample, two females [46(10) years] and three males
[42.7(25.7)]. Stated reasons for taking Ginseng were to boost
energy (2) (35, 36), fatigue (1) (37), erectile dysfunction (1) (34)
and one unknown (1) (38). The time to onset of symptoms
between taking Ginseng and mania ranged between 10 days and
2 months prior. Of these five cases, two had a prior history
of depression, one of substance-induced hypomania, two had
no past psychiatric history. The reported range of daily doses
of Ginseng in the case reports were 500–750mg of root or
300mg−20 g of extract, compared to a recommended short-term
dose range of 0.5–2 g of dry Ginseng root, equivalent to 200–
600mg of extract, and long-term dose of 1 g of dry root (39). In
two cases, the recommended long-term dose was far exceeded.
Brindleberry (Garcinia cambogia)
There were two case reports of mania and one each of
manic psychosis and hypomania, involving Garcinia cambogia,
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2 females [42.5(8.5) years] and 2 males [37.5(12.5)]. The stated
reason for taking the HM was weight loss (40, 41) and three
patients had a past history of bipolar disorder. In each case, the
dose of Garcinia cambogia was not specified. The time to onset
of manic symptoms from commencing the HM ranged from 2–6
weeks. Two cases were concurrently taking antidepressants and
mood stabilizers.
Ma-Huang (Ephedra sinica)
In three cases, ma-huang (in one case along with chromium
picolinate and caffeine) was associated with manic-like
symptoms in individuals without a history of bipolar illness, two
females [30.5(9.5) years] and one male [45 years]. Stated reasons
for taking the HM were weight loss (42, 43) and heightened
alertness and to prevent drowsiness (44). Past psychiatric history
included hospitalization for alcohol poisoning, and bulimia
without purging with a description of manic-like symptoms. The
family psychiatric history included possible bipolar disorder and
schizophrenia. The time to onset of manic symptoms ranged
between 5 days and 2 months. In each case the dose of the HM
was unknown, concurrent medication in one case comprised
thyroid hormone and recently discontinued antidepressant.
Herbalife Products
Two cases reported mania associated with the use of a Herbalife
product for the stated reason of weight loss (45, 46). Both were
male [32.5 (6.5)] and neither had a personal or family history
of bipolar disorder or were taking prescribed medication. In
one case, the patient became manic after taking “large amounts”
of the products both as tablets and tea. The time to onset of
manic symptoms ranged between 2 and 20 days. In a subsequent
published letter regarding the above case reports, by authors
affiliated with the Herbalife brand, (47), it was noted that the
case reports did not specify the precise product (as opposed to
the brand) and/or ingredients taken in these two cases.
Herbal Slimming Pills
In a multiple-case report by Chong, two cases of manic-like
psychosis were associated with the use of “Herbal slimming pills”
(48). An assay of the HM identified that it contained the anti-
depressant pharmaceutical sibutramine. The authors attributed
the occurrence of mania to this adulterant.
There were five single case reports that related an HM
(ingredients see Table S1) to mania, involving Hydroxycut (49),
Horny goat weed (Epimedium grandiflorum) (50), “herbal body
tonic,” prescribed for anger (51), celery root (Apium graveolans)
formenopausal symptoms (52) and a “herbal mixture” prescribed
for fatigue (53).
QUALITY ASSESSMENT OF CASE
REPORTS
In addition to the systematic review of HM associated mania, we
also assessed the quality of the individual case reports. The results
are shown in Table S2.
Applying Hung, Hillier and Ernst’s (22) modified version of
the Agbabiaka tool (54), the distribution of the quality assessment
scores across the 26 papers, covering 35 case reports, was
as follows: low quality (0), lower-medium quality (9), upper-
medium quality (10) and high quality (7). Only one single case
report used a validated instrument to assess causality, the Naranjo
scale. The botanical name was listed in 19 cases in 18 papers.
Only 1 paper presenting 2 case reports used a laboratory assay
to confirm the composition of the HM. The composition of the
HM, for example plant part used and extract type, was detailed in
only 1 case report. The brand name andmanufacturer were stated
in 3 case reports. The dosage of the HM was specified in only 18
of the case reports. Of the study sample, 2 case reports of 1 HM
were assessed for adulteration. The batch number was provided
in none of the case reports. Herbal dosage was detailed fully in 6
and partially in 3 cases.
DISCUSSION
This review examined case report evidence regarding
HM-associated mania. Those included were: St John’s
wort (Hypericum perforatum); Ginseng (Panax Ginseng);
Brindleberry (Garcinia cambogia); ma-huang (Ephedra sinica);
“herbal slimming pills”; Herbalife products; Hydroxycut;
horny goat weed (Epimedium grandiflorum); “herbal
body tonic”; celery root (Apium graveolans), and “herbal
mixture.” Where possible the candidate pathophysiological
mechanisms are discussed in turn, as are other factors
which may have contributed to the onset of mania in the
individuals included in the study. There is an inherent
difficulty in making attributions regarding the causality
of HM on mania as the course of bipolar disorder is
unpredictable.
Of the 35 case reports included in this review, 5 were isolated
reports of one HM and two cases (both “herbal slimming pills”)
were attributed to a contaminant. The remaining 28 cases were
accounted for by five HM, all of which were the subject of two
or more case reports of mania. Over a publication period of 38
years (1980–2017) this is a small yield of reported concurrence
of HM usage and mania. The small numbers and unreliability of
discerning and reporting a link between mania and HM preclude
any definitive statement as to whether any association is causal or
coincidental.
With respect to St John’s wort, there is a high specificity of
the stated reason for taking the HM to be for treatment of
depression (11 of 14 St John’s wort cases compared to 0 of 21
other HM). There was also greater morbidity in the psychiatric
history of the St John’s wort cases (13 of 14 cases compared
to 11 of 21 for other HM), in the family history of mood
disorder (6 of 14 compared to 2 of 21) and concurrent
antidepressant prescribing was more common (4 of 14 compared
to 4 of 21). Competing explanations for these patterns include
an increased diathesis toward bipolar disorder, fluctuations of
established affective illness, antidepressant-associated mania and
HM-associated mania. These factors are not mutually exclusive,
for instance according to Craddock and Sklar, a family history
of bipolar disorder is an important clinical predictor of a likely
bipolar course in a patient who presents with one or more
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episodes of depression even before their first personal episode of
mood elevation (55).
The mechanism by which St John’s wort may alter
susceptibility to mania is not well understood. As with
antidepressants, it is difficult to distinguish spontaneous episodes
of mania from St John’s wort-associated switching (56). Angst
et al. analyzed the time course and risk factors for a diagnostic
change from major depression to bipolar disorders over an
average of 20 years from onset. Diagnostic change from
depression to bipolar type I occurred in approximately 1% and
bipolar type II 0.5% of patients per year (57). In patients with
major depressive disorder treated with antidepressants, it has
been found that antidepressant-associated mania or hypomania
occurs at an average frequency of 3.42% of cases per year, but it is
unclear to what extent switching represents undiagnosed bipolar
disorder or a direct pharmacological effect of antidepressants
(58).
Depression is one of the most commonly cited reasons
for using CAM (59). The prevalence of depression in the
United States has been reported to have increased between
2005 and 2015 (60). For many patients with depression, HM
which are in many countries, predominantly available over-
the-counter, may be an attractive alternative to conventional
medicines. There is a substantial evidence base from randomized
controlled trials supporting the use of St John’s wort in mild-to-
moderate depression. In a systematic review and meta-analysis
comprising 23 randomized trials of St John’s wort in outpatients
with mild-to-moderate depression (N = 1757), it was found that
Hypericum perforatum extracts were significantly more effective
than placebo (61).
St John’s wort has a variety of actions that may contribute
to its therapeutic effects. In vitro, it acts on neurotransmitter
regulation, including beta adrenergic and glutamate receptors,
and ion channel conductance. Hypericin (an active constituent
of St John’s wort) inhibits serotonin reuptake, and 5-HT1A
and 5-HT1B receptor changes are associated with prolonged
use (62). According to Fahmi et al, in animals, hypericum
is effective in three major biochemical systems relevant for
antidepressant activity including inhibition of synaptic reuptake
of serotonin, noradrenaline and dopamine (26). In the human
case reported by Barbenel of concurrent prescribing of St John’s
wort and sertraline in a patient following surgery for crypto-
orchidism, alteration of testosterone and gonadotrophin levels
and interactions of antidepressant and St John’s wort were further
considerations.
With five case reports of Ginseng associated mania it was
the second most commonly reported HM after St John’s wort.
Based on the belief that it is a panacea and promotes longevity,
Ginseng root has been used for over 2000 years (63). There
are a number of plants that share the common name Ginseng
however only three of these are from the genus Panax (Panax
ginseng, P. notoginseng and P. quinquefolius). Other “ginsengs”
include Siberian (Eleutherococcus senticosus), Indian (Withania
somnifera), and Brazilian (Pfaffia paniculata) (64, 65). The most
important constituents of Panax ginseng are the ginsenosides, of
which 15 different types have been identified (35).
In a systematic review of RCTs examining the efficacy of
Panax ginseng root extracts for a number of indications, it
was concluded that there is contradictory evidence that Ginseng
improves physical performance and immunological measures. It
may have beneficial effects on psychomotor performance and
cognitive behavior. No trial has confirmed the alleged age-
delaying properties of Ginseng. Results suggesting a reduction of
blood glucose levels in type-II diabetic patients require further
investigation (64, 65). With Panax ginseng, two mechanisms
of action in depression have been advocated, firstly, an
activating effect of ginsenosides on the HPA-axis resulting in
elevated corticotropin and corticosteroid levels (33). Secondly,
monoamine signaling could also be affected by ginsenosides
(66, 67).
Thirteen of 35 case reports in our study sample involved
adverse psychiatric effects of weight loss products including
brindleberry (Garcinia cambogia), ma-huang (Ephedra sinica),
“herbal slimming pills,” Herbalife products and Hydroxycut.
The social stigma of obesity, a desire to lose weight without
making drastic lifestyle changes, and frustration at previous
failed attempts are commonly reported reasons for using dietary
supplements which are readily available and advertised as being
“natural” and safe (68).
In one 12-week randomized placebo-controlled trial,Garcinia
cambogia failed to produce significant weight loss and fat loss
beyond that observed with a placebo (69). In contrast, another
double-blind placebo RCT found thatGarcinia cambogia reduced
abdominal fat accumulation in participants (70). Other human
research has confirmed the potential of Garcinia cambogia/HCA
in stimulating fat oxidation, increasing serotonin release in
brain cortex and normalizing lipid profiles (71). The main
active ingredient of Garcinia cambogia is hydrocitric acid which
has serotonergic effects and has been implicated in serotonin
syndrome (38). Hydrocitric acid is the putative mediator of this
HM weight loss effect; it is thought to promote the release and
synaptic availability of serotonin thus influencing appetite (41).
The effects of Hydroxycut were attributed to the inclusion of
Garcinia cambogia in the preparation (49).
Partin and Pushkin, who reported a case of hypomania
associated with horny goat weed (Epimedium grandiflorum)
proposed that this may have been due to the addition of other
unidentified herbs and pharmaceuticals (50). However, these
were not explicitly tested for.
Ma-huang (Ephedra sinica) is native to China and Mongolia
and contains sympathomimetic compounds known as Ephedra
alkaloids. Traditionally used to treat asthma and hay fever
symptoms, more recently it has been combined with caffeine or
botanical sources of caffeine (for example Guarana) for weight
loss purposes (68). In a 6–month RCT of herbal Ephedra/
caffeine for weight loss, it was found that 90/192 mg/day of
herbal ephedra/caffeine promoted weight and body fat reduction
(72). In another randomized double-blind trial of a herbal
supplement containing ma-huang-guarana for weight loss, it was
found that the active treatment produced significant effects (73).
Ma-huang contains variable amounts of ephedrine congeners
which enhance norepinephrine release in central noradrenergic
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neurons. Ephedrine also has direct agonist activity at alpha and
beta-adrenergic receptors (44).
Sibutramine is an appetite-suppressing agent that is a
norepinephrine and serotonin reuptake inhibitor, initially
developed as an antidepressant (48) its use has been associated
with mania (74, 75) and hypomania (76). In a recent
analytical study of 447 weight loss products, 119 were found
to be adulterated with one or more weight loss compounds
including sibutramine, its metabolites benzyl sibutramine and
desmethyl sibutramine; phenolphthalein; bisacodyl; furosemide;
liothyronine (T3); and thyroxine (T4) (77). This demonstrates
the importance of having regulatory bodies oversee CAM
manufacturing practices and to regularly assess certain classes of
CAM products for adulterants (such as weight loss products).
These incidences of mania associated with HM weight-loss
products highlight the fact that they may be considered safe and
harmless by consumers when they have the propensity to trigger
adverse events in vulnerable individuals (78).
Khalid et al. reported a case of mania associated with celery
root (Apium graveolans), St John’s wort (Hypericum Perforatum)
and venlafaxine. Mania ensued shortly after the ingestion of
celery root, which belongs to a group of plants classified as
the umbelliferous family, which contain phytoestrogens that are
structurally similar to estrogen. In this case the patient developed
elevated serum venlafaxine levels after taking celery root for
menopausal symptoms, suggesting pharmacokinetic potentiation
of the venlafaxine level by the celery root as a likely mechanism
of induction of mania (52).
Thirteen of the patients were concurrently taking
conventional medicines (as shown in Table S1) as well as
HM which may have led to herb-drug interactions resulting
in mania. This might result from alterations of absorption,
distribution, metabolism or elimination of a conventional
drug by a herbal product, that is pharmacokinetic effects (79).
Alternatively, there may be synergistic effects of a HM and
a conventional medicine reflecting common mechanisms of
action such as neurotransmitter regulation. Drug dosage is
one important factor in such herb-drug interactions as well
as in interactions with underlying biological diatheses (80). In
approximately one third of the cases reviewed the dosage of
the HM was unknown. This limits the ability to make causal
inferences regarding the dose of the HM associated with a manic
switch in vulnerable individuals.
For the whole sample the time to onset of manic symptoms
from commencing the HM (treatment-emergence interval)
ranged between 2 days and 2 years with a median of 4 weeks.
None of the HM reported associated withmania diverged notably
from this median time to onset of manic symptoms. A treatment-
emergence interval of 8–12 weeks is deemed to implicate
causality; however, a much shorter interval may be necessary
to definitively link cause and effect (81). The manic episodes
reported in the cases were mostly treated with conventional anti-
manic agents, only two reports indicate the outcome of cessation
of the HM alone on the course of mania, one indicating remission
in 2 days, the other no improvement following a switch into
depression. Thus, no general statement can be made with respect
to mania resolution on ceasing the implicated HM.
In addition to the systematic review of HM-associated mania,
we also assessed the quality of reporting (Table S2) on the
modified Quality Assessment Scale by Agbabiaka, in each of
the 26 published case report papers. The case report quality
assessment score ratings were low quality (0), lower-medium
quality (9), upper-medium quality (10) and high quality (7).
There are two algorithm-based rating instruments to assign
the probability that an adverse event (in this case mania or
hypomania) is related to a given exogenous substance, the
Naranjo and the WHO-UMC. Of the cases reviewed only one
used the Naranjo scale, none used the WHO-UMC. One study
compared the two rating scales and found that the WHO-UMC
method was more simple and less time consuming compared to
the Naranjo probability scale (82). On the 7 additional quality
criteria, the quality of reporting was satisfactory only for the
inclusion of botanical name of HM (26 of 35 cases) and to a
lesser extent HM dosage (18 of 35 cases). On the remaining
5 criteria less than 10% of papers were compliant. It is noted
that many of the reports were published before the advent of
defined quality criteria ratings, for example 19 of the 26 papers
preceded the publication of the modified Quality Assessment
Scale by Agbabiaka in 2008. Future published case reports of
adverse events should adhere to such criteria in order to improve
their overall quality and inferences which may be made from
these articles.
The current review of case reports is subject to a number of
limitations. Substance/medication-induced bipolar and related
disorder may reflect a switch in a previously unexpressed bipolar
diathesis. It is possible that the reports in the scientific literature
are subject to a confirmation bias in that clinicians are looking
for links between mania and recent use of HM. There is also a
possible effect of researcher/ publication bias, which has led to
the publication of the included studies. Ethically, it is difficult
to replicate studies which suggest a potentially harmful effect of
various HM.
The compilation of case histories presents a different sample
to that commonly seen in a randomized controlled trial setting
where fixed inclusion and exclusion criteria apply. This sample
of putative HM induced mania includes a number of patients
(n = 7) with a stated past history of a diagnosis of BD and a
further 7 patients without a BD diagnosis taking antidepressants.
This increases the likelihood that the observedmanic episode was
attributable to extant bipolar disorder or antidepressant induced
switching rather than the HM per se, although interactions of
these variables cannot be excluded.
Despite these limitations, however, there are a number of
strengths associated with the inclusion of case reports including
that the patients, episodes ofmania, time course of symptoms and
aetiological factors are described in detail, as reflected in Table
S1. The authors are generally circumspect in their judgements
regarding causality, documenting an observed association,
summarizing knowledge regarding possible mechanisms of
action, and allowing for the multiplicity of explanations that
attend a disorder of unclear etiology and pathogenesis and with a
typically fluctuating course.
Concepts of exogenous and endogenous causation of
psychoses have been debated over the past century. In 1910,
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Bonhoeffer proposed that the brain only manifested a few
stereotyped mental reactions, whether from exogenous or
endogenous origins. He recognized delirium in particular as a
presentation that could follow diverse exogenous causes. The
typical features in delerium of clouding of consciousness and
disorientation form the rationale for categorizing it separately to
the psychoses (83). Similarly, in the concept of unitary psychosis,
as elaborated by Conrad in 1959, there is no fixed relationship
between symptom picture and exogenous factors, the latter
potentially triggering a range of symptom pictures (84). Relating
these propositions to the current study on case reports of mania
associated with herbal medicines, the results are inconclusive
because it is restricted to one diagnostic category, mania, and
one class of aetiological factors, herbal medicines. Comparisons
of reports of herbal medicines associated with the onset of a
variety of mental disorders would yield information as to whether
the relationship indicates specific aetiologies of a disease (e.g.,
mania) or a broader relationship whereby a diversity of diagnostic
categories (e.g., mania, psychotic depression and schizophrenia)
are attributable to a common aetiological factor, the unitarian
view.
In summary, the reported co-occurrence of HM usage
and mania, whilst inconclusive, provides a plausible signal
as to brain mechanisms relevant to the pathogenesis of
mania. With the increasing storage of health information
in electronic health records and evolving techniques of data
mining there are prospects for the widespread application
of case report level information to the elucidation of
associations and causal links between usage of HM and the
occurrence and varied course of mental disorders including
BD.
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APPENDIX
Search terms
1 Achillea
2 Adaptogen
3 Albizia
4 Anemone
5 Angelica
6 Asafoetida
7 Ashwagandha
8 Astragalus
9 Atropa
10 Avena
11 Bacopa
12 Ballota
13 Banxia-houpo-tang
14 Betony
15 Bitter orange
16 Borage
17 Borago
18 Botanicals
19 Californian poppy
20 Camellia
21 Cannabis
22 Catmint
23 Catnip
24 Centella
25 Chamomile
26 Chinese medicine
27 Citrus
28 Clove
29 Codonopsis
30 Cola
31 Convallaria
32 Corni fructus
33 Cornus officinalis
34 Corydalis
35 Cowslip
36 Cramp bark
37 Crocetin
38 Crocin
39 Crocus
40 Crocus sativus L.
41 Cyclothymia
42 Cypripedium
43 Damiana
44 Datura
45 Deadly nightshade
46 Dioscorea
47 Dong quai
48 Echium amoenum
49 Eleutherococcus
50 Ephedra sinica
51 Ephedrae herba
52 Eschscholzia
53 Ferula
54 Ganoderma
55 Gelsemium
56 Ginseng
57 Glycyrrhiza
58 Goldenrod
59 Gotu kola
60 Gou qi zi
61 Green tea
62 Guarana
63 Hange-koboku-to
64 Happiness bark
Search terms
65 Henbane
66 Herbal medicine
67 Herbs
68 Hoelen
69 Hops
70 Humulus
71 Hyoscyamus
72 Hypericum
73 Indian snakeroot
74 Jamaican dogwood
75 Jimson weed
76 Kampo
77 Kampo Medicine
78 Kanpo
79 Kanpo Medicine
80 Kava
81 Kava-Kava
82 Kola nut
83 korean ginseng
84 Koso-San
85 Lactuca
86 Lady’s slipper
87 Lavandula
88 Lavender
89 Lemon balm
90 Leonurus
91 Licorice
92 Lily
93 Linden
94 Lobelia
95 Lotus
96 Lycii Fructus
97 Lycium barbarum
98 Ma-Huang
99 Magnolia
100 Marrubium
101 Matricaria
102 Melissa
103 Mentha
104 Mistletoe
105 Mitchella
106 Motherwort
107 Mystica
108 Nelumbo
109 Nepeta
110 Nervine
111 Nutmeg
112 Nux vomica
113 Oat
114 Ocimum
115 Opium poppy
116 Panax
117 Papaver
118 Passiflora
119 Passion flower
120 Paullinia
121 Peppermint
122 Phytomedicine
123 Phytotherapy
124 Pinellia ternate
125 Pinelliae rhizome
126 Piper
127 Piper methysticum
128 Piscidia
Frontiers in Psychiatry | www.frontiersin.org 11 July 2018 | Volume 9 | Article 280
Thesis page 79
Bostock et al. Mania Associated With Herbal Medicines
Search terms
129 Plant extract
130 Plant preparation
131 Poria
132 Primula
133 Prunus
134 Pulsatilla
135 Rauvolfia
136 Rauwolfia
137 Rehmannia
138 Reishi
139 Rhodiola
140 Rhodiola rosea
141 Rosemary
142 Rosmarinus
143 Rosmarinus
144 Saffron
145 Safranal
146 Saffron extract
147 Saint John’s wort
148 Sceletium
149 Schisandra
150 Scutellaria
151 Shan zhu
152 Sheng ban xia
153 Siberian ginseng
154 skullcap
155 Solidago
156 Stachys
157 St John’s Wort
158 Sutherlandia
159 Syzygium
160 Thornapple
161 Thymoleptic
162 Tilia
163 Traditional Chinese medicine
164 Tulsi
165 Turnera
166 Valerian
167 Valeriana
168 Verbena
169 Vervain
170 Viburnum
171 Viscum
172 White horehound
173 Withania
174 Wild cherry
175 Wild lettuce
176 Wild yam
177 Xiang Su San
178 Yan hu suo
179 Yarrow
180 Yellow jasmine
181 Zizyphus
182 Free AND Easy Wanderer Plus
1. Bipolar depression
2. Bipolar disorder
3. Bipolar Disorder
4. Mania
5. Manic disorder
6. Manic state
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Chapter 6 
 
General Discussion 
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This thesis has examined a number of perspectives on causation and pathogenesis of 
mania in bipolar disorder (BD) in particular through a series of comparisons with a 
reference condition, temporal lobe epilepsy (TLE).  These studies have concluded that 
BD and TLE share some common features with respect to precipitants of mania and 
seizures (chapter 2), and cognitive impairments in euthymic BD and pre-surgical TLE 
(chapter 3). The possible application of an evidence-based treatment for refractory 
epilepsy, the ketogenic diet, as a treatment for mental disorders has been examined 
(chapter 4).  Finally, evidence that herbal medicine may precipitate manic episodes is 
summarised (chapter 5).  
The first section of this final chapter summarises the main results from the 
individual studies in chapters 2-5, with a particular focus on findings that shed some 
light on the pathophysiological mechanisms and neural substrates involved in the 
occurrence of manic episodes. The second section discusses limitations of these studies. 
The third section addresses directions for future research arising from the findings 
which may lead to development of improved treatments for individuals with bipolar 
disorder.  
 [Note: temporal lobe epilepsy (TLE) is also referred to as partial seizures (PS) and 
focal seizures (FS) arising from the temporal lobe reflecting changing nomenclature 
over time as discussed on page 23 of the thesis]  
6.1 Summary of results 
6.1.1 Precipitating factors for mania and partial seizures 
Chapter 2 reviewed precipitating factors in humans for both mania and partial seizures 
(PS). The precipitants common to both disorders included stress, sleep deprivation, 
antidepressant medication and more tentatively emotion. Precipitating factors for mania 
alone included goal-attainment events, spring and summer seasons, postpartum, and 
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drugs including steroids and stimulants. For PS alone precipitating factors included 
winter season, menstruation, and specific triggers in complex reflex epilepsy.  
The precipitants common to both - stress, sleep deprivation and antidepressant 
medications - are suggestive of shared pathophysiology between the two disorders.  
 The mechanisms by which stress can alter the susceptibility for mania or PS are 
not well understood but are thought to include both neurological (HPA axis 
dysfunction) (Phillips 2007) endocrinological pathways (adrenocorticotropic hormone 
and cortisol) (Joëls 2009) and the interaction between the two, as detailed in chapter 2. 
Stress is rarely experienced in isolation and is often present with other precipitating 
factors, for example sleep deprivation. 
 The effect of sleep deprivation/reduction is thought to be a final common 
pathway in the onset of mania whereby insomnia is also a feature of mania and may 
exacerbate mania, a self-reinforcing cycle, with or without initiation by other 
precipitants (e.g., stress) (Wehr, Sack et al. 1987). Changes in sleep patterns may act as 
a marker for manic or depressive episodes. In healthy individuals, sleep deprivation 
may elicit paroxysmal EEG activity (Rodin, Luby et al. 1962). In epilepsy a reduction 
of even 1.5 hours of sleep is correlated with an increase of seizures (Rajna and Veres 
1993). It is interesting to note that sleep deprivation has been used as a treatment for 
both bipolar and unipolar depression for many years (Svendsen 1976). The 
hypothesised mode of action of antidepressant effects of sleep-deprivation therapy is 
thought to be related to the clock genes and circadian rhythms. Sleep-deprivation 
therapy is thought to reset abnormal clock gene machinery. Relapse of depressive 
symptoms during recovery-night sleep reactivates abnormal clock genes and 
supplementary chronotherapies and medications can block relapse and stabilize 
circadian-related improvement (Bunney and Bunney 2013). 
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 Antidepressant medications are a shared precipitant in both disorders. 
Antidepressants lower the seizure threshold but the mechanisms by which they may 
cause mood elevation are not well understood.  It is hypothesized that in BD several 
neurobiological factors are associated with spontaneous and treatment-emergent mood 
episode switches, including abnormalities in catecholamine levels, upregulation of 
neurotrophic and neuroplastic factors, HPA-axis hyperactivity and circadian rhythms 
(Salvadore, Quiroz et al. 2010). A recent study assessed the risk of first-episode seizures 
in patients with depressive disorder and concluded that SSRI and SNRI antidepressants 
are associated with an increased risk of seizures (Blöchliger, Ceschi et al. 2015).  
6.1.2 Neurocognition 
It is unclear to what extent BD is best defined by acute signs and symptoms of illness 
episodes and to what extent BD may relate to inter episode brain vulnerabilities or 
damage secondary to illness episodes. This may be examined in terms of 
neurocognitive trait markers in euthymic BD and in TLE during seizure-free intervals. 
The findings in chapter 3 indicated that deficits in BD-I, compared to healthy controls, 
were in the three domains of executive function, attention span and verbal memory. 
Deficits specific to TLE compared to healthy controls included executive function and 
memory. Both disorders had deficits in executive function and verbal memory which 
implicated the frontal lobes and the temporal lobes.  
6.1.3 The ketogenic diet 
There is a well-established overlap in treatments for BD and epilepsy, particularly with 
mood stabilizer medications such as sodium valproate. The search for commonalities 
between BD and epilepsy led to a review of the application to mental disorders of an 
evidence-based treatment for epilepsy, the ketogenic diet (KD). The use of KD in 
mental disorders was presented in chapter 4. Fifteen studies (9 animal models, four 
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human case studies and two uncontrolled trials) examined the use of KD in anxiety, 
depression, bipolar disorder, schizophrenia, autism (ASD) and attention deficit 
hyperactivity disorder (ADHD). Whilst the pathophysiology of these mental disorders 
is not clearly understood and the literature is in a formative stage, a number of actions 
have been postulated for an effect of KD on mental disorders, including mitochondrial 
function, neurotransmitter changes and through the reduction of intra-cellular calcium. 
Mitochondrial dysfunction may be relevant in some mental disorders including 
schizophrenia, ASD, and ADHD, however there is no clear established link to BD. 
Improvements seen in anxiety, depression, and bipolar disorder may be related to 
alterations of neurotransmitters whilst patients are on the diet. In BD, a mechanism by 
which KD may be effective is based on the hypothesis that acidosis achieved through 
ketosis reduces intra-cellular sodium and calcium, both of which are elevated in this 
disorder. It is noted that mood stabilizers have a similar effect, reducing intra-cellular 
sodium in an activity-dependent manner, through acidification of the blood. A recent 
systematic review and meta-analysis of clinical studies of the kynurenine pathway in 
mood disorders reported that, contrary to previous reports, KYNA is decreased in major 
depression (Arnone et al., 2018). This opens the possibility that KD has a yet unproven 
anti-depressant effect mediated by increased KYNA.  
6.1.4 Mania associated with herbal medicine  
The aim of the research presented in Chapter 5 was to review published reports of mania 
associated with herbal medicine other than cannabis. This examined the diagnostic 
category of substance/medication-induced bipolar and related disorder to illustrate its 
potential use in understanding the varied pathophysiology of mania. There were no 
randomized controlled trials on this subject. The study sample consisted of 35 case 
reports published as 19 single and 7 multiple case reports. Putative pathophysiological 
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mechanisms were postulated for nine of the 11 herbal medicines reported and centred 
on HPA-axis activation and increased monoamine activity.  
6.2 Limitations 
Limitations discussed include the use of review methodologies, comparison with a 
reference condition, and specific limitations from the individual studies including 
retrospective accounts.  
6.2.1 Review methodologies: narrative review and systematic review 
Narrative review  
Narrative reviews are generally comprehensive and include a wide range of issues 
within a given topic but typically do not state or follow rules for the search of relevant 
evidence (Collins and Fauser 2005). The primary aim of a narrative review is to provide 
the reader with a comprehensive background for understanding current knowledge and 
highlighting the significance of new research (Cronin, Ryan et al. 2008). The studies 
on precipitating factors for mania and seizures (chapter 2) and the ketogenic diet in 
mental disorders (chapter 4) were completed using narrative review methodology as 
they sought to merge a broad body of research together in a cohesive format.  
 Unlike systematic reviews, narrative reviews are considered to be one of the 
weakest forms of evidence to use in clinical decision making as they often deal with a 
broader issue rather than focused clinical problems (Green, Johnson et al. 2006). 
However, they may be useful for the generation of hypotheses on a given topic. This 
thesis was not directed at clinical-decision making but rather the generation of leads in 
the understanding of the underlying causes and pathways of mania, including those 
drawn from the comparison with temporal lobe epilepsy.  
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Systematic review  
Systematic reviews are at the forefront of evidence-based medicine. They involve the 
process of systematically finding, appraising and using research findings as the basis of 
clinical-decision making (Rosenberg and Donald 1995). They constitute a rigorous and 
transparent form of literature review (Mallett, Hagen-Zanker et al. 2012) and involve 
the identification, synthesis and assessment of available information. In 2009, the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement was published (Moher, Liberati et al. 2009). This was devised to ensure that 
authors provided a transparent and complete reporting of this type of review. In this 
thesis, systematic review methodology has been applied in the studies on 
neurocognition (chapter 3) and mania associated with herbal medicine (chapter 5).  
 However systematic review methodology presents some disadvantages 
including publication bias whereby small or non-significant studies often fail to reach 
publication and are therefore not considered in the review process (Biondi-Zoccai, 
Lotrionte et al. 2011). Another limitation is that systematic reviews are often restricted 
to English language articles which may potentially lead to the omission of important 
findings in other languages. This may have been particularly problematic in  the 
systematic review of mania associated with herbal medicine (chapter 5) which excluded 
literature from studies written in languages other than English, whereas the use of 
herbal medicine is well established in different cultures and reported in various 
language sources.  
While systematic reviews are more appropriate for focused topics and 
traditional narrative reviews are better suited to comprehensive topics, either approach 
can be adapted to clinical or scientific avenues of enquiry (Collins and Fauser 2005).  
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6.2.2 Comparison with a reference condition  
The use of a reference condition to compare disorders which share some common 
features is a method that has been applied to conditions such as schizophrenia and TLE 
(Gold, Hermann et al. 1994) and migraine and epilepsy (Haut, Bigal et al. 2006). In this 
thesis, the basis for comparing BD and TLE was the recognition that there were a 
variety of features in common such that research findings in the two conditions might 
usefully be considered in framing hypotheses about pathogenesis and pathophysiology 
of either. This is particularly so with reference to the localizing pathology in TLE and 
the overlap in treatments targeting the central nervous system. However, as indicated 
throughout this thesis the relationship between the two disorders is complex. Similarity 
does not prove that underlying processes are identical. Thus, common surface features 
may derive from different underlying neuroanatomical pathways or neurophysiological 
processes. However, similarities, as with associations in general, are useful in framing 
hypotheses based on a presumption of shared mechanisms. 
6.2.3 Limitations of the individual studies 
Each of the four publications presented in chapters 2-5 includes a section on limitations 
specific to that study, the following comments are additional to these. In the study of 
precipitating factors (chapter 2) the literature relies heavily on retrospective accounts. 
These may be influenced by forgetting, remembering events as having occurred earlier 
than was the case and reinventing the past to suit their current needs and circumstances 
(Henry, Moffitt et al. 1994).  
 The overview of the literature on neuropsychology in BD-I and TLE (chapter 
3) is limited by the differences in experimental methodologies which prevented a meta-
analytical approach. Some medications may have a deleterious effect on cognition. This 
was not routinely reported or controlled in analyses in either BD or TLE. Other 
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extraneous variables that were not systematically considered in the literature included 
the time elapsed between mania or seizure episodes and neuropsychological testing, 
number of hospitalizations and the presence of psychotic symptoms. The experimental 
designs employed in the studies in BD-I and TLE reflected different lines of enquiry. 
The BD-I literature routinely included a healthy control group whereas the TLE 
controlled trials used patients as their own controls pre- and post-ablative surgery. This 
fundamental difference in design meant that the two conditions could not be directly 
compared using meta-analytic techniques.  
 In the review of KD studies (chapter 4), sample sizes were small (range 1-30) 
and there was no control for placebo effects. Confirmation of the establishment of 
ketosis (an important marker for the diet’s effect on metabolism) was not reported in 
three human studies. Adherence to the diet is limited by the need to follow a detailed 
regimen, often unpalatable food choices, gastrointestinal side effects and the duration 
of the diet required. In humans, what constitutes KD is varied with no uniform standards 
of lipid:non-lipid ratios.  
 It is difficult to establish whether the episodes of mania associated with herbal 
medicine (chapter 5) were causally linked or coincidental. The literature is insufficient 
in depth and case reports do not permit inferences regarding causality to be tested in 
depth. Case reports are also subject to confirmation bias, the tendency for authors to 
investigate a subject in conformity with existing beliefs as to causation.  
6.3 Directions for future research 
This thesis is primarily concerned with the aetiology of mania as a manifestation of 
bipolar disorder. The review papers aim to identify research findings from the published 
literature that may provide clues to directions in research that may yield an increased 
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understanding of the pathogenesis and pathophysiology of mania and potentially aid in 
the search for improved treatments.  
 The use of temporal lobe epilepsy as a reference condition has identified a 
number of overlaps with mania in clinical features, course, precipitants, cognitive 
deficits and treatment response. These lend themselves to further investigation in a 
number of ways, examples of which are presented below. These examples are based on 
head-to-head comparison of clinical samples of mania and TLE, comparing and 
contrasting the two conditions. Variables considered are precipitating factors including 
self-induction of manic and seizure episodes respectively, neurocognition, olfactory 
functioning and facial affect processing. In addition, potential further research on the 
ketogenic diet in BD is canvassed. Finally, the possibilities of population-wide 
screening for adverse reactions to herbal medicines in both mania and temporal lobe 
seizures are discussed with reference to the potential application of data mining using 
natural language processing techniques.  
Previous research has used different instruments and methodologies to 
investigate precipitating factors for mania in BD and seizures in TLE, examining each 
disorder in isolation. A direct comparison incorporating a questionnaire on precipitating 
factors developed for use in both conditions would yield higher quality comparative 
information. Further, given the unpredictable nature of episodes in both TLE and BD, 
a comparison of precipitating factors in the two disorders using prospective 
methodology involving seizure or mania diaries would strengthen the evidence as to 
what constitutes precipitants in common. An increased understanding of precipitating 
factors may lead to biological, psychological or social interventions to arrest episodes 
in the prodromal phase thus leading to a better quality of life for patients.  
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In epilepsy, self-induction of seizures is a well recognised phenomenon, for 
example waving a hand in front of the eyes to produce a flickering effect in 
photosensitive epilepsy. Typically, this involves an irresistible, compulsive attraction 
which precipitates seizure activity and interferes with social and occupational 
functioning (Rektor, Schachter et al. 2013). Patients report engaging in these forms of 
behaviour for a variety of motives including a pleasant feeling, a reduction in stress or 
to avoid obligations (Binnie 1987). Case-reports have been published on self-induction 
in various forms of reflex epilepsy (Binnie 1987), for example hand clapping (Van der 
Meij, Franssen et al. 1997) and listening to music (Klass 1989). There is a correlation 
between the pleasure that has been felt from a seizure and a person’s ability to induce 
seizures (Faught, Falgout et al. 1986). Patients with self-induced seizures are often 
resistant to traditional therapy; in these instances, seizures may be modifiable by 
behavioural or psychiatric intervention (Ng 2002). 
Self-induction of mania is a little explored aspect of the condition but may be a 
relevant form of precipitant. Participants in online consumer forums sometimes report 
using staying up late and consuming energy drinks as ways of bringing on highs. A 
case report described self-induction of mania using cough syrup (Mendez 1992). 
Another, often repeated, observation noted that “patients may discontinue the 
prophylactic use of lithium as they do not want to be deprived of their periodic 
hypomania” (Van Putten 1975). Survey data comparing patients with BD and TLE on 
both open-ended questions and questionnaire responses regarding self-induction 
methods may assist in delineating the phenomenon.  
With respect to neurocognition, head-to-head comparison of the 
neuropsychological deficits between the two disorders may improve understanding of 
the neural substrates of the two disorders. This would include individuals with a 
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diagnosis of: bipolar disorder type I (BD-I), left-sided temporal lobe epilepsy, right-
sided temporal lobe epilepsy and healthy matched control participants (HC). A targeted 
test battery would include tests of executive function, verbal memory and non-verbal 
memory coupled. Further information would be obtained by using functional magnetic 
resonance imaging to indicate areas of task relevant neural activation. 
Comparing BD and TLE on olfactory function could be a potentially fruitful 
line of research. In both humans and non-human animals, sense of smell represents an 
important arousal system that brings attention to environmental events, air quality and 
food (Engen 1983). The inferior frontal and temporal lobes are particularly implicated 
in human olfactory processing (Zatorre 1992). It may be expected that BD and TLE 
would have an effect on olfactory function. Eskenazi et al. (1986) found bilateral 
impairment in odour identification in patients with TLE (Eskenazi, Cain et al. 1986). 
Using the University of Pennsylvania Smell Identification Test (UPSIT) Kohler et al. 
compared olfactory dysfunction in schizophrenia and TLE (Kohler, Moberg et al. 
2001). The results showed that patients with schizophrenia and those with right TLE 
were impaired in smell recognition when compared to healthy participants. In a 
comparison of patients with left TLE and right TLE, the latter had difficulty matching 
smells to the stimulus (Hudry, Perrin et al. 2003). TLE patients were impaired on the 
UPSIT relative to HC; impairment was not related to laterality of seizure focus, duration 
of seizure, baseline seizure control or number of medications (Desai, Agadi et al. 2015).  
 There are relatively few studies on olfactory function in BD-I (Hardy 2012).  
Comparison of patients with BD-I to SZ, found UPSIT deficits in both groups with a 
larger effect size in SZ (Cumming, Matthews et al. 2011). Hardy et al. compared right 
and left nostril sensitivity for odour detection and smell identification in 20 patients 
with BD-I relative to 44 HC. Smell identification was normal in BD-I, symptoms of 
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depression were related to hyperacuity and symptoms of mania to hypoacuity of smells 
(Hardy 2012). In interepisode (euthymic) patients with BD-I, mood episodes triggered 
by emotional events were associated with heightened olfactory function relative to 
episodes without emotional triggers (Kruger, Frasnelli et al. 2006). These inconsistent 
findings in BD warrant future research into olfactory function.  
Facial affect processing is another point of comparison between BD and TLE. 
The recognition of emotion utilizes a distributed set of structures, including the 
occipitotemporal neocortex, amygdala, orbitofrontal and right frontoparietal cortices 
(Adolphs 2002). The processing of facial affect is important for socialization and social 
interaction (Corden, Critchley et al. 2006). One method to examine emotion perception 
is through studies of facial affect recognition.  
In epilepsy, psychosocial maladjustment is common (Hermann, Seidenberg et 
al. 2000). Childhood and early onset right TLE are associated with poor recognition of 
emotional facial expressions, in particular fear (Meletti, Benuzzi et al. 2003, Golouboff, 
Fiori et al. 2008). In another study, participants with TLE relative to HC were impaired 
in the recognition of all facial expressions except happiness (Meletti, Benuzzi et al. 
2009). A degree of laterality has been found. Patients with right TLE were more 
impaired that those with left TLE (Meletti, Benuzzi et al. 2009). 
In BD-I relative to HC participants, manic patients with BD-I, were impaired 
on a task of facial affect labelling (Getz, Shear et al. 2003). In another study, patients 
with BD-I showed worse recognition of facial affect than HC, in particular identifying 
fear and disgust (Lembke 2002). A direct comparison of BD and TLE would provide 
further information regarding the similarities and differences in deficits of emotion 
perception in the two disorders particularly in the euthymic and interictal phases of 
these disorders. 
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The ketogenic diet requires further research to clarify the specifics of dietary 
manipulation or ketone supplementation necessary to produce optimum ketosis using 
open-label studies and randomized controlled trials. Careful attention should be given 
to measuring ketone levels in either the urine or blood in both murine and human trials. 
Whilst adherence to KD can be confirmed by ketone levels, the diet is difficult to 
follow. The advent of an exogenous ketone supplement (AC-1202), taken on a standard 
diet, opens opportunities for more precise placebo-controlled research in humans to 
confirm or disconfirm its applicability. Research on exogenous ketone supplements is 
underway, for example the clinical trials register of the United States National Library 
of Medicine lists ‘a Study to Compare the Pharmacokinetics of AC-1202 and Two 
Doses of AC-SD-01 on Ketone Body Production’ was recently registered 
(NCT03063645, 24 February 2018).  
The systematic review of herbal medicine associated mania presented in chapter 
5 indicates that evidence is limited to case reports. Nevertheless, the findings suggest 
that herbal medicines may not be as innocuous as previously thought.  
New information technology techniques are emerging that assist in detecting 
associations between variables pertaining to medication use and mental disorders. 
Examples include the extraction of meaningful clinical summary information from 
electronic health records (EHRs) using natural language processing algorithms. In 
future, linked data might include purchases of herbal medicines, online searches on 
relevant health topics or reports of side effects or illness exacerbations in online forums. 
Further work is required to establish firm ethical protocols before such research can 
meet its potential. A full discussion of this area is outside the scope of this thesis, 
however recent studies in the mental health field indicate the applicability of such 
methods to studies of symptoms, substance use and mental health outcomes in large 
Thesis page 96
clinical populations. Examples using EHRs include a study of mood instability as a 
prognostic factor (Patel, Lloyd et al. 2015), ascertainment of tobacco use status (Hegde, 
Shimpi et al. 2018) and derivation of diagnostic phenotyping (Castro, Minnier et al. 
2015).  
The research presented in this thesis emphasizes the work of many thousands 
of researchers over decades, which in summary form provides some indication of ways 
forward in the quest to both understand and remedy the manifestations of bipolar 
disorder. With research proceeding on many broad fronts there is every reason to be 
confident that such an understanding can be reached through the application of insights, 
hypotheses and methodologies combined with careful and systematic investigation. 
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To ensure reliability of coding, articles should be classified using the “Coding Sheet 
Study ID: EB15” as per the following instructions: 
 
At the top right hand corner of each page a “Sheet ID number” should be allocated to each 
publication assessed. The first publication will be marked “15EB001”, the second 15EB002 
etc. This should be marked on the top right hand corner of each page. 
1. Article ID No: 
An article identification number should be included under “Article ID No.”. The ID is specified 
in BLOCK CAPITALS. It is comprised of: 
• the surname and the initials of the first author 
• the publication year 
• the surname of the second author (if no secondary author: xx) 
• the MEDLINE abbreviation of the journal (or in full if not available) in which it was 
published 
o e.g., BOSTOCK E C S  KIRKBY K C ET AL 2015 J AFFECT DIS  
o or BOSTOCK E C S 2014 XX J AFFECT DIS 
 
2. Bipolar Disorder/Focal seizures 
• Coder is to clearly indicate which disorder the article pertained to by circling, if both 
then circle one and complete two coding sheets.  
 
3. Title and abstract screening: 
Indicate by checking the box  for YES or NO under each criterion listed below: 
YES    NO  Published 1980 or later  
YES    NO  Included humans  
YES    NO  Adult participants (18 years or over) 
YES    NO  Examined at least one neuropsychological construct  
YES    NO  Full article in English 
 
4. Full text screening: 
YES    NO  Study included euthymic bipolar disorder participants  
YES    NO  Focal seizures arising from the temporal lobes 
YES    NO  Participants were judged as euthymic by a clinician 
YES    NO  Participants had a Young Mania Rating Scale below 8 
YES    NO  Participants had a Hamilton Depresssion Rating scale 
above 8 
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YES    NO  Participants had a brain lesion 
5. Actions arising:
Study will be included: This should be checked when the coder has decided that the inclusion
criteria have been met. 
Study will be excluded: A coding sheet must be created for any excluded study. However, it is 
sufficient to only fill in the first page of the coding sheet and the general publication 
information section.  
Multiple coding sheets: If both bipolar disorder and focal seizures are examined in a single 
publication, an individual coding sheet is filled out for each.  
Write to authors: This should be checked in situations where the manuscript did not contain 
sufficient information  
6. General Publication Information:
Coder: Enter the initials of the coder (e.g., Emmanuelle Bostock = EB)
Coding date: Day/ Month/ Year
Time of day: specify the start time in order to determine the total duration of coding.
Authors: Specify the last name of the first three authors. If more than three authors are
mentioned, all the other authors are abbreviated with et al. The publication year is four digits
(e.g., Bostock, Kirkby, Garry et al., 2015).
Title: Note the first six words from the title e.g., “Comparison of precipitating factors of mania
and partial seizures: Indicative of shared pathophysiology” becomes - “Comparison of
precipitating factors of mania”
Country of Origin - Author: of the first author is usually noted on the publication. If not, it
should be Googled and entered using the codes below. If the author has more than one
Country of Origin enter this as Other Origin.
Coding of Country of Origin: 
1 = USA 
2 = Canada 
3 = Germany 
4 = Great Britain  
5 = Netherlands 
6 = Scandinavia  
7 = Australia 
8 = Western Europe (excluding G, GB, N, S) 
9 = Eastern Europe (including Russia) 
99 = Other (Specify) 
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Discipline of the first author: This is usually noted on the publication. If not it should be 
Googled and entered using the codes below. If the author has more than one discipline listed, 
this should be entered under other discipline. 
Coding of Discipline: 
1 = Psychology 
2 = Psychiatry 
3 = Medicine 
4 = Sociology 
5 = Economy  
6 = Education 
99 = Other 
Publication found in: The source of the publication should be entered as follows 
1 = Scopus 
2 = Web of Science 
3 = PubMed 
4 = PsychINFO 
5 = Google Scholar 
6 = Manual search of journals 
7 = Hand search of reference lists 
8 = Contact with authors 
99 = Other source 
Note: Some publications may appear in more than one database. The code given will reflect 
the first place where the publication was found by the coder. 
Coding the type of publication: 
1 = Journal with peer review 
2 = Journal without peer review 
3 = Book/ book chapters 
4 = Dissertation (PhD) 
5 = Honours or Master’s thesis 
6 = Conference presentation/ Poster (Abstract or full paper) 
7 = Unpublished manuscript 
8 = Internet document 
99 = Other 
Citations: How many citations does the study have? 
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Impact: What is the impact factor of the journal?  
 
7. Description of the study: 
The experimental design (i.e., between groups, within groups or mixed designs) or the 
publication type (i.e.,literature review, narrative review or meta-analysis) should be clearly 
indicated by ticking the box next to the study design.  
 
8. Sample Information: 
Sample size: refers to the total amount of participants in the study. 
Illness: Should be clearly indicated whether the study examined BD or FS even though there 
is a separate coding sheet for each. 
Illness Phase: Can refer to mania, depression, euthymia. Interictal, periictal or postictal 
phases.  
YMRS Mean Score and HamD Mean Score: 
Bipolar illness phases has been adopted from  Arts, Jabben, Krabbendam and van Os 
(2008) who conducted a meta-analysis of euthymic patients. Studies should be coded as per 
the categories below: 
Euthymia is defined as: 
• judged as euthymic by a clinician  
• >8 on the Hamilton Depression Rating Scale 
• <8 on the Young Mania Rating Scale 
• and/or a score on mood rating scales below this point 
Duration of illness years: Should be recorded as a mean for the whole sample 
Age at Onset of illness: If indicated in the study, record information here regarding at what 
age participants were diagnosed with either BD or FS if known (in months).  
Whereby: 
M: Mean value.  
SD: Standard deviation. 
Males: the mean number of males in the sample Females: the mean number of females in the 
sample 
Age: The mean, standard deviation and Range: Specify a minimum and maximum Age at the 
time of testing 
Education in years: should be recorded as a mean of the total sample 
Coding of Ethnicity: Ethnicity is specified only if the proportion of this ethnic group makes up a 
minimum of 50% of the sample.  
1 = White (Caucasian, Anglo-American, European) 
2 = Black 
3 = Hispanic 
4 = Indigenous People 
5 = Asian 
6 = Mixed (when two ethnic groups are represented with 50% each) 
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99 = Other (specify) 
 
Coding of Country of Origin 
Specify in which Country the study was conducted. 
1 = USA 
2 = Canada 
3 = Germany 
4 = Great Britain 
5 = Netherlands 
6 = Scandinavia 
7 = Australia 
8 = Western Europe (excluding G, GB, N, Scandinavia) 
9 = Eastern Europe (including Russia) 
99 = Other (Specify) 
Medications: should be listed in the section provided. 
Seizure frequency: The mean number of seizures prior to assessment should be recorded as 
means and standard deviations. 
Surgical Procedure: 
Focal seizures arising from the temporal lobes: Also known as temporal lobe epilepsy and 
partial seizures arising from the temporal lobes: 
• participants’ cognitive abilities were assessed prior to selective  
o amygdalahippocampectomy or  
o anterior temporal lobectomy 
 
Decimal Places 
All sample values should be a maximum of two decimal places (rounded).  
All statistical values should be a maximum of three decimal places.  
 
9. Dependent Variables 
The dependent variable/s examined should be listed under the category.  
 
If the publication examined several dependent variables (including separate subscales) (e.g. 
WAIS, RAVLT), each dependent variable is listed.  
 
10. Concluding Information 
At the end of coding an article, the time needed for encoding should be noted.  
In addition, there is space for problems and comments. If information is missing, the missing 
information should be listed here. 
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Finally, include a brief interpretation of the study in this box. This can be transcribed or taken 
directly from the publication abstract. 
Appendix 1: Neuropsychological Measures used by other meta-analyses on euthymic BD 
Neuropsychological Measures Assessed: Kurtz & Gerraty (2009) 
Test 
Attention 
   Continuous Performance Test 
   Digits Forward 
   Trails A 
Working Memory 
   Digits Backward 
Verbal Memory 
   Rey Auditory/California Verbal Learning Test – Total recalled, long-delay 
     Free recall 
   Wechsler Memory Scale-logical Memory (WMS-LM) 
Nonverbal Memory 
   Rey Complete Figure Test (RCFT) – Immediate and delayed recall 
   Wechsler Memory Scale-Visual Reproduction (WMS-VR) 
Visuospatial function 
   Block design 
   Rey Complex Figure Test (RCFT)-copy 
Language 
   Controlled Oral Work Association Test (COWA-FAS) 
   Animal Naming (AN) 
Psychomotor speed 
   Digit Symbol Substitution Test (DSST) 
Executive –function 
   Wisconsin Card Sorting Test (WCST) – Categories achieved and 
     Perseverative errors 
   Stroop Color Word Test (SCWT) 
   Trails B 
Congintive Battery Mann-Worbel & Carreno (2011) 
Cognitive domain 
Processing speed 
Digit Symbol 
Trails A 
Stroop Word 
Stroop Color 
Haylings A (sec) 
Average effect size 
Executive functioning 
WCST categories 
WCST perseverative errors 
Trails B 
Stroop interference 
Haylings B (sec) 
Haylings B (errors) 
Average effect size 
Thesis page 171
 
Working Memory 
Digit Span-forward 
Digit Span-backward 
Digit Span-total 
Visual Span-backward 
Average effect size 
 
Perceptual/problem solving 
Block design 
Figure Copy 
Average effect size 
 
Intellectual/verbal 
Vocabulary 
Word Reading 
Average effect size 
 
Neuropsychological Battery: Robinson, Thompson et al. (2006) 
 
Test 
Intelligence and education 
IQ 
Years of education 
 
Executive measures 
Category Fluency 
Reverse Digit Span 
Trail Making Test B 
WCST perseverations 
Verbal Fluency (FAS) 
 
Verbal learning and memory measures 
A/CVLT total recall trails 1-5 
A/CVLT short delay free recall 
A/CVLT long delay free recall 
Forward digit span 
 
Attention and psychomotor speed 
Sustained attn: latency 
DSST 
Trail Making Test A 
Sustained attn: sensitivity 
 
 
 
Neuropsychological battery: Torres, Boudreau et al., (2007) 
 
Table1. Most frequently employed tasks in studies of euthymic bipolar patients 
Task by cognitive domain 
Premorbid intellectual 
   Single-work reading score from NAART, WRAT 
   WAIS vocabulary subset score 
   Attention/processing speed 
      Trail making Test A: completion time 
      Digit Symbol or Symbol Digit Modalities Test score 
      CPT* or variant: accuracy (hits) 
      CPT*  or variant reaction time 
Memory 
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      Learning (recall trails 1-5) from CVLT, RAVLT 
      Short delayed recall from CVLT, RAVLT 
 Long delayed recall from CVLT, RAVLT 
 Recognition hits from CVLT, RAVLT  
Executive/working memory 
 Digit span backward or total forward and backward 
 Trail making Test B: completion time 
 WCST: Total Categories score 
 Verbal Letter Fluency (3 trails): number correct 
 Stroop interference trail, number correct, or interference score 
NAART, North America Adult Reading Test; WRAT, Wide Range Achievement Test; WAIS, 
Wechsler Adult Intelligence Scale; CPT, Continuous Performance Test; WCST, Wisconsin 
Card Sorting Test. 
*When multiple CPT tasks were used within a given study, the simplest, non-working memory 
versions was employed.  
 
Neuropsychological Test battery: Arts, Jabben., (2008) 
 
Test  
Digit Backward 
Trail B 
WCST perseverative errors  
Fluency categories 
CVLT delayed recall 
DSST 
CVLT immediate recall 
Stroop Correct 
Rey figure recall 
FAS 
CPT correct 
WCST categories 
Digit forward 
Rey copy 
IQ 
 
Neuropsychological Test Battery: Bora, Yucel (2009) 
 
Table 3 
Mean weighted effect sizes for individual tasks and education for patient-control differences 
Test 
TMT-B 
Verbal learning 
 CPT omission 
Delayed recall 
Stroop  
DSST 
Digit span backwards  
Immediate recall 
WCST per 
TMT-A 
WCST Cat 
FAS 
Visual memory recall 
Verbal recognition  
Current IQ 
Digit span Forward 
CPT commission 
Visual copy 
IQ premorbid 
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Appendix B 
Coding Sheet 
Systematic Review of Cognitive Function in Euthymic Bipolar Disorder and Pre-
Surgical Temporal Lobe Epilepsy 
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Coding Sheet Study ID: EB15 
 
Systematic Review of Cognitive Function in Euthymic Bipolar Disorder 
and Pre-Surgical Temporal Lobe Epilepsy 
 
 
1. Article ID No: 
______________________________________________________________ 
 
2. (circle)       Bipolar Disorder                                                Focal seizures 
______________________________________________________________ 
 
3. Title and abstract screening: 
 
YES    NO  Published 1980 or later  
YES    NO  Included humans  
YES    NO  Adult participants (18 years or over) 
YES    NO  Examined at least one neuropsychological construct  
YES    NO  Used a quantitative design 
YES    NO  Full article in English 
4. Full text screening: 
YES  NO  Study included euthymic bipolar disorder type I 
participants  
YES    NO  Focal seizures arising from the temporal lobes 
YES    NO  Participants were judged as euthymic by a clinician 
YES    NO  Participants had a Young Mania Rating Scale below 8 
YES    NO  Participants had a Hamilton Depresssion Rating scale 
above 8 
YES    NO  Participants had a brain lesion 
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5. Actions arising: 
 Study will be included                                 Write to authors 
 Study will be excluded                         Multiple coding sheet
 
6. General Publication Information: 
 
Coder: ___________ Coding Date ___ / ___ / _______ Time of Day: ___________________ 
Authors: ___________________________________________________________________ 
Publication Year:  ____________________________________________________________ 
Title (first six words): _________________________________________________________ 
Country of Origin - Author: _____________________________________________________ 
Other Origin: _______________________________________________________________ 
Discipline of the First Author: ___________________________________________________ 
Other Discipline:_____________________________________________________________ 
Publication Found In: _________________________________________________________ 
Other Place Publication Found: _________________________________________________ 
Type of Publication: __________________________________________________________ 
Other Publication: ___________________________________________________________ 
Citations: __________________________________________________________________ 
Impact:  ___________________________________________________________________ 
 
7. Description of the Study 
 
Experimental: 
 Between groups 
 Within Groups 
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 Mixed 
 Literature review 
 Narrative review 
 Meta-analysis 
 
8. Sample Information: 
 
Sample Size ________________________________________________________________ 
Illness  (Circle)                  Bipolar Disorder                     Focal Seizures                          Other  
Illness Phase: ______________________________________________________________ 
YMRS Mean Score___________________________________________________________ 
HamD Mean Score: __________________________________________________________ 
Clinician rated as euthymic: ____________________________________________________ 
Duration of illness years:______________________________________________________ 
Age at Onset of illness : M = _______________SD= ________________________________ 
Males N=__________________________Females N=_____________________________ 
Age:  M = __________ SD = __________ Range from __________ to __________________ 
Education (years):____________________________________________________________ 
Ethnicity: ____  Other Ethnicity: ____  Country of Origin: ____  Other Country of Origin:  
Medication : ________________________________________________________________ 
Seizure frequency: ___________________________________________________________ 
Surgical Procedure: __________________________________________________________ 
 
9. Dependent variables 
 
DV1: _________________________________________________________ 
DV2:__________________________________________________________ 
DV3:__________________________________________________________ 
DV4:__________________________________________________________ 
DV5:__________________________________________________________ 
DV6:__________________________________________________________ 
DV7:__________________________________________________________ 
DV8:__________________________________________________________ 
DV9:__________________________________________________________ 
DV10:_________________________________________________________ 
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10. Concluding Information 
 
 
Time for Coding: _________ Minutes: ____________________________________________ 
Problems/Comments: ________________________________________________________ 
Study Interpretation: _________________________________________________________ 
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Appendix C 
Coding Manual 
Mania associated with herbal medicines, other than cannabis: a systematic 
review and quality assessment of case reports 
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Coding Manual: Herbal medicines, other than cannabis, associated 
mania: A systematic review 
 
Authors: Emmanuelle C. S. Bostock, Kenneth C. Kirkby, Michael I. Garry, Bruce V. M. Taylor 
& Jason, A. Hawrelak 
2017 
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Article ID No: 
At the top of each page of the coding sheet fill in the sheet ID number and also number the 
printed article (e.g., article 1, article 2). 
An article identification number should be included under “Article ID No.”. 
The 7-digit ID is specified in BLOCK CAPITALS. It is composed of: 
• the first three letters of the surname of the first author
• If the first author’s last name is two letters long a lower case z will be inserted after
the first two letters (e.g., Author HO becomes HOz)
• the last two digits of the publication year (e.g., 2017 becomes 17)
• the first two letters of the surname of the second author (if no secondary author: xx)
• e.g., Qureshi, N. A., & Al-Bedah, A. M. (2013). Mood disorders and
complementary   and alternative medicines: a literature review.
Neuropsychiatric Disease and    Treatment, 9, 639-658.
• Is coded as the following: QUR13AL
Title and Abstract Screening: 
Tick “YES” or “NO” for each of the inclusion criteria (e.g., inclusion criterion (a) is that articles 
must be published after 1980, therefore if an article has been published on the topic of 
interest in 1979 it is excluded thus leading the reviewer to select “NO”) 
Exclusion Criteria 
If one of the following criteria apply, the study must be excluded: 
1. Published prior to 1980
2. Included children (<18 years old) due to the generally agreed upon age of informed
consent
3. Was not peer-reviewed
4. Was in a language other than English, as this is the scientific language
5. Did not include a diagnosis of bipolar disorder or related disorder
For excluded studies it is sufficient to only fill in the general publication information section. 
In addition, the “Excluded” box should be ticked and reasons should be provided in the 
comments box on the last page. 
NOTE: CLARIFY: This should be checked in situations where the manuscript did not contain 
sufficient information. 
The type of bipolar disorder should be specified either bipolar type I, bipolar type II, 
Substance/medication-induced bipolar and related disorder, cyclothymia, mixed 
sample of BD,  animal analogue of BD 
Thesis page 181
General Publication Information: 
Coder: Enter the initials of the coder (e.g., Emmanuelle Bostock = EB) 
Coding date: Day/ Month/ Year 
Time of day: specify the starting time in order to determine the total duration of coding.  
Authors: Specify the last name of the first three authors. If more than three authors are 
mentioned, all the other authors are abbreviated with et al. The publication year is four digits 
(e.g., Bostock, Kirkby, Garry et al., 2015). 
Publication Year: Specify the date the article was published (e.g., 2015). 
Title: Note the first six words from the title (e.g., “Comparison of precipitating factors of mania 
and partial seizures: Indicative of shared pathophysiology” becomes - “Comparison of 
precipitating factors of mania”) 
Country of Origin: of the first author is usually noted on the publication. If not, it should be 
Googled and entered using the codes below. If the author has more than one Country of 
Origin enter this as Other Origin. 
 
Coding of Country of Origin: 
1 = USA 
2 = Canada 
3 = Germany 
4 = Great Britain  
5 = Netherlands 
6 = Scandinavia  
7 = Australia 
8 = Western Europe (excluding G, GB, N, S) 
9 = Eastern Europe (including Russia) 
99 = Other (Specify) 
 
Discipline of first author: This is usually noted on the publication. If not it should be Googled 
and entered using the codes below. If the author has more than one discipline listed, this 
should be entered under other discipline. 
 
Coding of Discipline: 
1 = Psychology 
2 = Psychiatry 
3 = Medicine 
4 = Allied Health 
99 = Other 
Publication found in: The coding of where the publication was found should be entered as 
follows: 
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1 = PubMED 
2 = EMBASE 
3 = CINAHL 
4 = Health Source 
5 = PsychInfo 
6 = Hand search of reference lists 
7 = Contact with authors 
99 = Other source 
 
Note: Some publications may appear in more than one database. The code given will reflect 
the database that has remained after duplicates have been removed. 
 
Coding the type of publication: 
1 = Journal with peer review 
2 = Journal without peer review 
3 = Book/ book chapters 
4 = Dissertation (PhD) 
5 = Honours or Master’s thesis 
6 = Conference presentation/ Poster (Abstract or full paper) 
7 = Unpublished manuscript 
8 = Internet document 
99 = Other 
 
Description of the study: 
If experimental the design should be marked (i.e., between groups, within groups, mixed 
designs, case study, case series) or if the publication is a literature review, narrative review or 
meta-analysis that should be clearly indicated.  
 
Sample Information: 
Sample size: Record the sample size listed in publication  
Illness: Should be clearly indicated whether the study examined BD or another illness, please 
note that mania that has occurred secondary to infection, neoplasm, epilepsy and metabolic 
disturbances are excluded. However mania that has arisen from a CAM intervention is 
included. 
Coding of Illness Phase: Are the participants in the study (a) hypomanic (b) manic (c) 
depressed or (d) euthymic. 
• NOTE: Given that we are interested in the bipolar spectrum in any phase of the 
disorder we are not applying strict criteria for euthymia as we have done in other 
papers as some of the participants are self-reported as having bipolar disorder. 
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Duration of illness years: List if specified 
• M: Mean value.
• SD: Standard deviation.
• Range: Specify a minimum and maximum.
Age at Onset of illness: Record information here regarding at which age participants were 
diagnosed with BD  
Males and Females: Should be filled in. 
Age: at time of testing. 
Education: Should be recorded in years 
Coding of Ethnicity 
1 = White (Caucasian, Anglo-American, European) 
2 = Black 
3 = Hispanic 
4 = Indigenous People 
5 = Asian 
6 = Mixed (when two ethnic groups are represented with 50% each) 
99 = Other (specify) 
Coding of Country of Origin 
Specify in which Country the study was conducted. 
1 = USA 
2 = Canada 
3 = Germany 
4 = Great Britain 
5 = Netherlands 
6 = Scandinavia 
7 = Australia 
8 = Western Europe (excluding G, GB, N, Scandinavia) 
9 = Eastern Europe (including Russia) 
99 = Other (Specify) 
Medication: List current medication of participants if known. 
Concluding Information: 
At the end of coding an article, the time taken should be noted. 
In addition, there is space for problems and comments.  
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Finally, include a brief interpretation of the study. This can be transcribed or taken directly 
from the publication abstract. 
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Appendix D 
Coding Sheet 
 Mania associated with herbal medicines, other than cannabis: A systematic 
review of case reports  
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Coding Sheet Study ID: EB17REV 
Mania associated with herbal medicines, other than cannabis: 
A systematic review of case reports  
 
Article ID No:  
Title and abstract screening: 
 
1. YES    NO  Published 1980 or later  
2. YES    NO  Only adult participants (18 years or over) 
3. YES    NO  Peer-reviewed 
4. YES    NO  Full article in English 
5. YES  NO  CLARIFY  Diagnosis of bipolar disorder or related 
disorder. 
 
6. YES  NO  Review article 
 
7. YES  NO  on cannabis  
 
 
Actions arising: 
Include all five YES                                  
Excluded any NO      
CLARIFY Write to authors  
Specify type of bipolar disorder: 
 
    bipolar type I, OR 
    bipolar type II, OR 
 Substance/medication-induced bipolar and related 
disorder  
    cyclothymia 
    mixed sample of BD 
    animal analogue of BD 
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General Publication Information: 
Coder: ___________ Coding Date ___ / ___ / _______ Time of Day: ___________________ 
Authors: ___________________________________________________________________ 
Publication Year:  ____________________________________________________________ 
Title (first six words): _________________________________________________________ 
Country of Origin - Author: _____________________________________________________ 
Other Origin: _______________________________________________________________ 
Discipline of the First Author: ___________________________________________________ 
Other Discipline:_____________________________________________________________ 
Publication Found In: _________________________________________________________ 
Type of Publication: __________________________________________________________ 
Description of the Study 
Experimental: 
 Between groups
Within Groups
 Mixed
 Case study
 Case series
 Literature review
 Narrative review
 Meta-analysis
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Sample Information: 
 
Sample Size ________________________________________________________________ 
Illness  (Circle)                  Bipolar Disorder                   Other  
Illness Phase: ______________________________________________________________ 
CAM Modality used (if several list all):____________________________________________ 
Duration of illness years:______________________________________________________ 
Age at Onset of illness : M =_________SD=_____________Range=___________________ 
Males N=__________________________Females N=_______________________________ 
Age:  M = __________ SD = __________ Range from __________ to __________________ 
Education (years):____________________________________________________________ 
Ethnicity: ____  Other Ethnicity: ____  Country of Origin: ____  Other Country of Origin:  
Medication : ________________________________________________________________ 
Concluding Information 
 
 
Time for Coding: ___________________________________________________________ 
Problems/Comments: ________________________________________________________ 
Study Interpretation: _________________________________________________________ 
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Appendix E 
Quality Assessment Scale by Agbabiaka 
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Appendix A. Quality Assessment Scale by Agbabiaka 
Category/questions Rating (please tick one box) Item score 
Question Yes Unclear No 
I – Information about the medicinal product and treatment 
A – Drug information: 
Are the following details reported? 
1. Drug name (i.e. International Nonproprietary Name INN or generic name)
2. Brand name and/or manufacturer
B – Therapeutic regimen
Are the following details reported?
3. Daily dose and dosing regimen
4. Route of administration (i.e. oral, subcutaneous, . . .)
5. Length of treatment period (dates and duration of treatment)
II – Patient history, diagnosis, medical condition(s) and medications
A – Patient history
Are the following details reported?
6. Age
7. Sex
B – Diagnosis
8. Is the diagnosis for which the suspected drug was administered stated?
C – Concurrent diseases and/or medical conditions:
9. Are concurrent diseases and/or medical conditions reported (including and
allergies)? (If explicitly stated that there
were none, give 2 points)
10. Are concurrent diseases analysed/considered with regards to their relevance to the
AE?
(Give 2 points if considered in respect to AE Or explicitly stated there are no
concurrent diseases, give 1 point if mentioned
but not adequately discussed and 0 point if not reported at all)
D – Concomitant medications
11. Are concomitant medications documented? (if it is explicitly stated that there were
none, give 2 points. 1 point if
inadequately reported or unclear and 0 point if no mention of concomitant
medications)
12. Are doses, therapeutic regimes and treatment duration reported for concomitant
medication? (all the information
is required to score 2 points or if explicitly stated there were no concomitant
medications, give 1 point if one or two of the
information is reported otherwise give 0 point)
13. Is the involvement of concomitant medications with AE considered/discussed in
the report? (give 2 points if
reported and discussed or stated there were no concomitant medications, 1 point if
mentioned but not adequately
discussed, 0 point if not reported)
III – Adverse event/drug interaction information
14. Is the AE/interaction described?
15. Is it reported how the AE (or drug interaction) was diagnosed using appropriate
diagnostic tests (including lab
tests)?
Does the report state that the procedures listed below were carried out or explicitly
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state that they were not? 
16. Dechallenge or dose manipulation (give 2 points if either is reported and patients
response discussed or explicitly
stated that there was no dechallenge and 0 point if not reported at all)
17. Rechallenge (give 2 points if dose, name of drug or class of drug for rechallenge
is reported and adequately discussed or
if stated that rechallenge was unacceptable, dangerous or unethical, 0 point if not
reported at all)
18. Is there a description of the Algorithm/instrument/scale used for causality
assessment (i.e. WHO classification, any
other published scale, or authors own clinical judgment)
Herbal preparation information:
Are the following details reported?
1. Full taxonomic name of the plant
2. Plant source (i.e. folium, radix, rhizome, . . .)
3. Extract name and/or manufacturer or brand name (all the information is required to
score 2 points, give 1 point if one
or two of the information is reported otherwise give 0 point)
Total Score /38
Scoring instructions
Give a score of 2 points for each “yes” or 1 point for each “unclear” and 0 point for
each “no”.
Some questions have additional scoring instructions.
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